MD_ID,ID_stats,number_arm,Trial_Reg_No,Prospective_Registr,Full_text_link,name_study,First_author,Journal_abbrv,Year,Type_publication,Pub_date_online,Blinding,Start_date,Center,Funding,Fund_Source,Research_question,Countries,Treatment_control,stats_name,n_Randomized,n_Analyzed_,All_cause_mortality_events_D28,mortality_d28_N,mort_D28_TP,Definition_of_clinical_improvement,Clinical_improvement_D28_n,clinic_imp_d28_N,clin_imp_D28_TP,SCORE_7_and_above_D28,score7_d28_N,score7_D28_TP,Total_AE,Serious_AE,safety_N,Safety_timepoint,ROB_6_for_website,Blind,Fund,Sample_size,HIC_LIC,Comment_HIC_LIC,CAF_mort,CAF_CI,CAF_WHO7,CAF_AE,CAF_SAE,Same_analysis,What_changed,new_outcome,del_outcome,unchanged,change_events,Status
1_preprint,1,2,ChiCTR2000030254,No,https://doi.org/10.1101/2020.03.17.20037432 ,*,Chen C,medRxiv,2020,preprint,4/15/2020,Unblinded,2/20/2020,Multicenter,Public/non profit,National Key Research and Development Program of China (2020YFC0844400) ,Moderate to critical,China,Treatment,Favipiravir,120,116,0,*,*,*,*,*,*,*,*,*,37,0,*,*,Some concerns,unblinded,Other,240,LIC_MIC,,,,,,,,,,,,,consistent
1_preprint,1,2,ChiCTR2000030254,No,https://doi.org/10.1101/2020.03.17.20037432 ,*,Chen C,medRxiv,2020,preprint,4/15/2020,Unblinded,2/20/2020,Multicenter,Public/non profit,National Key Research and Development Program of China (2020YFC0844400) ,Moderate to critical,China,Control,Umifenovir,120,120,0,*,*,*,*,*,*,*,*,*,28,0,*,*,Some concerns,unblinded,Other,240,LIC_MIC,,,,,,,,,,,,,consistent
1_pub,1,1,ChiCTR2000030254,No,https://www.frontiersin.org/articles/10.3389/fphar.2021.683296/full#h12 https://doi.org/10.1101/2020.03.17.20037432 ,*,Chen C,Front Pharmacol,2021,published paper,9/2/2021,Unblinded,2/20/2020,Multicenter,Public/non profit,National Key Research and Development Program of China,Moderate to critical,China,Treatment,Favipiravir,120,116,0,*,*,*,*,*,*,*,*,*,37,0,*,17,Some concerns,unblinded,Other,240,LIC_MIC,,,,,,,,,,,,,consistent
1_pub,1,2,ChiCTR2000030254,No,https://www.frontiersin.org/articles/10.3389/fphar.2021.683296/full#h12 https://doi.org/10.1101/2020.03.17.20037432 ,*,Chen C,Front Pharmacol,2021,published paper,9/2/2021,Unblinded,2/20/2020,Multicenter,Public/non profit,National Key Research and Development Program of China,Moderate to critical,China,Control,Umifenovir,120,120,0,*,*,*,*,*,*,*,*,*,28,0,*,17,Some concerns,unblinded,Other,240,LIC_MIC,,,,,,,,,,,,,consistent
3_preprint,3,3,NCT04252885,Yes,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2,*,Yueping L,medRxiv,2020,preprint,3/23/2020,Single blinded,2/1/2020,Single,Public/non profit ,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/moderate,China,Treatment,Lopinavir-Ritonavir,21,21,*,*,*,*,*,*,*,*,*,*,5,1,*,*,Some concerns,blinded,Other,44,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
3_preprint,3,3,NCT04252885,Yes,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2,*,Yueping L,medRxiv,2020,preprint,3/23/2020,Single blinded,2/1/2020,Single,Public/non profit ,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/moderate,China,Treatment,Umifenovir,16,16,*,*,*,*,*,*,*,*,*,*,0,0,*,*,Some concerns,blinded,Other,44,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
3_preprint,3,3,NCT04252885,Yes,https://www.medrxiv.org/content/10.1101/2020.03.19.20038984v2,*,Yueping L,medRxiv,2020,preprint,3/23/2020,Single blinded,2/1/2020,Single,Public/non profit ,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/moderate,China,Control,Standard care,7,7,*,*,*,*,*,*,*,*,*,*,0,0,*,*,Some concerns,blinded,Other,44,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
3_pub,3,3,NCT04252885,Yes,https://www.cell.com/pb-assets/products/coronavirus/MEDJ1.pdf,*,Yueping L,CellPress,2020,published paper,4/15/2020,Participants,2/1/2020,Single,Public/non profit,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/Moderate,China,Treatment,Lopinavir-Ritonavir,34,34,0,*,21,*,*,*,*,2,*,7,12,1,*,21,Some concerns,blinded,Other,86,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
3_pub,3,3,NCT04252885,Yes,https://www.cell.com/pb-assets/products/coronavirus/MEDJ1.pdf,*,Yueping L,CellPress,2020,published paper,4/15/2020,Participants,2/1/2020,Single,Public/non profit,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/Moderate,China,Treatment,Umifenovir,35,35,0,*,21,*,*,*,*,0,*,7,5,0,*,21,Some concerns,blinded,Other,86,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
3_pub,3,3,NCT04252885,Yes,https://www.cell.com/pb-assets/products/coronavirus/MEDJ1.pdf,*,Yueping L,CellPress,2020,published paper,4/15/2020,Participants,2/1/2020,Single,Public/non profit,"Project 2018ZX10302103-002, 2017ZX10202102-003-004 and Infectious Disease Specialty of Guangzhou High-level Clinical Key Specialty (2019-2021) ",Mild/Moderate,China,Control,Standard care,17,17,0,*,21,*,*,*,*,0,*,7,0,0,*,21,Some concerns,blinded,Other,86,LIC_MIC,,,,,,,N,sample size,"mort, WHO7",N,SAE,AE,exclude_diffanalysis
9_preprint,9,2,NCT04323527,No,https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2,*,Borba MGS,medRxiv,2020,preprint,4/16/2020,Double blinded,3/23/2020,Single,Public/non profit ,"Government of the Amazonas State, Farmanguinhos (Fiocruz), Superintende?ncia da Zona Franca de Manaus, Coordination for the Improvement of Higher Education Personnel, Fundac?a?o de Amparo a? Pesquisa do Estado do Amazonas, and federal funds facilitat",Severe/Critical,Brazil,Treatment,Chloroquine 450mg,40,40,6,*,*,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,81,LIC_MIC,,,,,,,,,,,,,consistent
9_preprint,9,2,NCT04323527,No,https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2,*,Borba MGS,medRxiv,2020,preprint,4/16/2020,Double blinded,3/23/2020,Single,Public/non profit ,"Government of the Amazonas State, Farmanguinhos (Fiocruz), Superintende?ncia da Zona Franca de Manaus, Coordination for the Improvement of Higher Education Personnel, Fundac?a?o de Amparo a? Pesquisa do Estado do Amazonas, and federal funds facilitat",Severe/Critical,Brazil,Control,Chloroquine 600mg,41,41,16,*,*,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,81,LIC_MIC,,,,,,,,,,,,,consistent
9_pub,9,2,NCT04323527,No,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765270,*,Borba MGS,JAMA Netw Open,2020,published paper,4/24/2020,Participants and health care provider,3/23/2020,Single,Public/non profit,"Government of the Amazonas State, Farmanguinhos (Fiocruz), Superintendencia da Zona Franca de Manaus, Coordination for the Improvement of Higher Education Personnel, Fundacao de Amparo a Pesquisa do Estado do Amazonas, and federal funds",Severe/Critical,Brazil,Treatment,Chloroquine 450mg,40,40,6,*,13,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,81,LIC_MIC,,,,,,,,,,,,,consistent
9_pub,9,1,NCT04323527,No,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2765270,*,Borba MGS,JAMA Netw Open,2020,published paper,4/24/2020,Participants and health care provider,3/23/2020,Single,Public/non profit,"Government of the Amazonas State, Farmanguinhos (Fiocruz), Superintendencia da Zona Franca de Manaus, Coordination for the Improvement of Higher Education Personnel, Fundacao de Amparo a Pesquisa do Estado do Amazonas, and federal funds",Severe/Critical,Brazil,Control,Chloroquine 600mg,41,41,16,*,13,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,81,LIC_MIC,,,,,,,,,,,,,consistent
11_preprint,11,2,ChiCTR2000029868,No,https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1,*,Tang W,medRxiv,2020,preprint,4/14/2020,Unblinded,2/11/2020,Multicenter,Mixed,"Funding: This work was supported by the Emergent Projects of
National Science and Technology (2020YFC0844500), National
Natural Science Foundation of China (81970020, 81770025),
National Key Research and Development Program of China
(2016YFC0901104),",Mild to severe,China,Treatment,Hydroxychloroquine,75,75,*,*,*,*,*,*,*,*,*,*,21,2,*,*,Some concerns,unblinded,Industry_Mixed,150,LIC_MIC,,Y,,Y,,,,,,,,,add_delete
11_preprint,11,2,ChiCTR2000029868,No,https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1,*,Tang W,medRxiv,2020,preprint,4/14/2020,Unblinded,2/11/2020,Multicenter,Mixed,"Funding: This work was supported by the Emergent Projects of
National Science and Technology (2020YFC0844500), National
Natural Science Foundation of China (81970020, 81770025),
National Key Research and Development Program of China
(2016YFC0901104),",Mild to severe,China,Control,Standard care,75,75,*,*,*,*,*,*,*,*,*,*,7,0,*,*,Some concerns,unblinded,Industry_Mixed,150,LIC_MIC,,Y,,Y,,,,,,,,,add_delete
11_pub,11,1,ChiCTR2000029868,No,https://www.bmj.com/content/369/bmj.m1849,*,Tang W,BMJ,2020,published paper,5/14/2020,Unblinded,2/11/2020,Multicenter,Mixed,Emergent Projects of National Science and Technology; National Natural Science Foundation of China; National Key Research and Development Program of China; Shanghai Municipal Key Clinical Specialty; National Innovative Research Team of High-level Loc,Mild to severe,China,Treatment,Hydroxychloroquine,75,75,0,*,28,*,*,*,*,0,*,28,21,2,*,33,Some concerns,unblinded,Industry_Mixed,150,LIC_MIC,,Y,,Y,,,,,,,,,add_delete
11_pub,11,2,ChiCTR2000029868,No,https://www.bmj.com/content/369/bmj.m1849,*,Tang W,BMJ,2020,published paper,5/14/2020,Unblinded,2/11/2020,Multicenter,Mixed,Emergent Projects of National Science and Technology; National Natural Science Foundation of China; National Key Research and Development Program of China; Shanghai Municipal Key Clinical Specialty; National Innovative Research Team of High-level Loc,Mild to severe,China,Control,Standard care,75,75,0,*,28,*,*,*,*,0,*,28,7,0,*,33,Some concerns,unblinded,Industry_Mixed,150,LIC_MIC,,Y,,Y,,,,,,,,,add_delete
13_preprint,13,3,ChiCTR2000029496,No,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,*,Zheng F,medRxiv,2020,preprint,4/29/2020,Unblinded,2/1/2020,Single,Public/non profit ,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/severe,China,Treatment,Novaferon+LPV/r,30,30,0,*,*,*,*,*,*,0,*,*,*,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
13_preprint,13,3,ChiCTR2000029496,No,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,*,Zheng F,medRxiv,2020,preprint,4/29/2020,Unblinded,2/1/2020,Single,Public/non profit ,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/severe,China,Treatment,Novaferon,30,30,0,*,*,*,*,*,*,0,*,*,*,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
13_preprint,13,3,ChiCTR2000029496,No,https://www.medrxiv.org/content/10.1101/2020.04.24.20077735v1,*,Zheng F,medRxiv,2020,preprint,4/29/2020,Unblinded,2/1/2020,Single,Public/non profit ,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/severe,China,Control,Lopinavir-Ritonavir,29,29,0,*,*,*,*,*,*,0,*,*,*,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
13_pub,13,3,ChiCTR2000029496,No,https://www.ijidonline.com/article/S1201-9712(20)30597-X/fulltext,*,Zheng F,Int J Infect Dis,2020,published paper,8/2/2020,Unblinded,2/1/2020,Single,Public/non profit,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/Severe,China,Treatment,Novaferon+LPV/r,30,30,0,*,9,*,*,*,*,0,*,9,25,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
13_pub,13,3,ChiCTR2000029496,No,https://www.ijidonline.com/article/S1201-9712(20)30597-X/fulltext,*,Zheng F,Int J Infect Dis,2020,published paper,8/2/2020,Unblinded,2/1/2020,Single,Public/non profit,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/Severe,China,Treatment,Novaferon,30,30,0,*,9,*,*,*,*,0,*,9,25,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
13_pub,13,3,ChiCTR2000029496,No,https://www.ijidonline.com/article/S1201-9712(20)30597-X/fulltext,*,Zheng F,Int J Infect Dis,2020,published paper,8/2/2020,Unblinded,2/1/2020,Single,Public/non profit,"National Science and Technology Major Project (2017ZX10202201, 2017ZX10202203), the National Key Research and Development Program of China (Nos. 2016YFD0500301), and Specialized Science and Technology Project of Hunan Province (2020SK3013)",Moderate/Severe,China,Control,Lopinavir-Ritonavir,29,29,0,*,9,*,*,*,*,0,*,9,26,0,*,*,Some concerns,unblinded,Other,89,LIC_MIC,,,,,,,,,,,,,add_delete
15_preprint,15,3,ChiCTR2000029544,Yes,https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1,*,Lou Y,medRxiv,2020,preprint,5/5/2020,Unblinded,2/3/2020,Single,Public/non profit ,supported by Zhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8),Unclear severity,China,Treatment,Favipiravir,10,9,0,*,*,"""Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital
discharge. The seven-category ordinal scale consisted of the following categories: 1. not hospitalized with ",5,*,*,0,*,*,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
15_preprint,15,3,ChiCTR2000029544,Yes,https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1,*,Lou Y,medRxiv,2020,preprint,5/5/2020,Unblinded,2/3/2020,Single,Public/non profit ,supported by Zhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8),Unclear severity,China,Treatment,Baloxavir marboxil,10,10,0,*,*,"""Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital
discharge. The seven-category ordinal scale consisted of the following categories: 1. not hospitalized with ",6,*,*,1,*,*,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
15_preprint,15,3,ChiCTR2000029544,Yes,https://www.medrxiv.org/content/10.1101/2020.04.29.20085761v1,*,Lou Y,medRxiv,2020,preprint,5/5/2020,Unblinded,2/3/2020,Single,Public/non profit ,supported by Zhejiang Provincial Science and technology department key R & D plan emergency project (No. 2020c03123-8),Unclear severity,China,Control,Standard care,10,10,0,*,*,"""Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital
discharge. The seven-category ordinal scale consisted of the following categories: 1. not hospitalized with ",5,*,*,0,*,*,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
15_pub,15,3,ChiCTR2000029544,Yes,https://www.sciencedirect.com/science/article/pii/S092809872030419X?via%3Dihub,*,Lou Y,Eur J Pharm Sci,2020,published paper,10/25/2020,Unblinded,2/3/2020,Single,Public/non profit,Zhejiang Provincial Science and technology department key R & D plan emergency project,Unclear severity,China,Treatment,Favipiravir,10,9,0,*,14,Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital discharge,5,*,14,0,*,14,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
15_pub,15,3,ChiCTR2000029544,Yes,https://www.sciencedirect.com/science/article/pii/S092809872030419X?via%3Dihub,*,Lou Y,Eur J Pharm Sci,2020,published paper,10/25/2020,Unblinded,2/3/2020,Single,Public/non profit,Zhejiang Provincial Science and technology department key R & D plan emergency project,Unclear severity,China,Treatment,Baloxavir marboxil,10,10,0,*,14,Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital discharge,6,*,14,1,*,14,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
15_pub,15,3,ChiCTR2000029544,Yes,https://www.sciencedirect.com/science/article/pii/S092809872030419X?via%3Dihub,*,Lou Y,Eur J Pharm Sci,2020,published paper,10/25/2020,Unblinded,2/3/2020,Single,Public/non profit,Zhejiang Provincial Science and technology department key R & D plan emergency project,Unclear severity,China,Control,Standard care,10,10,0,*,14,Clinical improvement was defined as a decline of two categories on the modified seven-category ordinal scale of clinical status. or hospital discharge,5,*,14,0,*,14,*,*,*,*,Some concerns,unblinded,Other,30,LIC_MIC,,,,,,,,,,,,,consistent
25_preprint,25,2,IRCT20100228003449N2,No,https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1,*,Davoudi-Monfared E,medRxiv,2020,preprint,5/30/2020,Unblinded,2/29/2020,Single,Private,"Funding: The authors did not receive any fund for this work. ReciGen was a generous gift from
CinnaGen Co. ",Moderate to critical,Iran,Treatment,IFN beta-1a,46,42,8,*,*,Clinical response was defined according to the six-category ordinal scale. This scale classifies patients in six categories according to the severity of the viral pneumonia. The six categories are: (1) discharge (2) hospital admission. not requiring ,*,*,*,8,*,*,*,*,*,*,High,unblinded,Industry_Mixed,92,LIC_MIC,,,,,,,,,,,,,consistent
25_preprint,25,2,IRCT20100228003449N2,No,https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1,*,Davoudi-Monfared E,medRxiv,2020,preprint,5/30/2020,Unblinded,2/29/2020,Single,Private,"Funding: The authors did not receive any fund for this work. ReciGen was a generous gift from
CinnaGen Co. ",Moderate to critical,Iran,Control,Standard care,46,39,17,*,*,Clinical response was defined according to the six-category ordinal scale. This scale classifies patients in six categories according to the severity of the viral pneumonia. The six categories are: (1) discharge (2) hospital admission. not requiring ,*,*,*,16,*,*,*,*,*,*,High,unblinded,Industry_Mixed,92,LIC_MIC,,,,,,,,,,,,,consistent
25_pub,25,1,IRCT20100228003449N28,No,https://aac.asm.org/content/aac/early/2020/07/08/AAC.01061-20.full.pdf,*,Davoudi-Monfared E,Antimicrob Agents Ch,2020,published paper,7/13/2020,Unblinded,2/29/2020,Single,Private,No funding; CinnaGen Co. (drug donation),Moderate to critical,Iran,Treatment,IFN beta-1a,46,42,8,*,28,At least two scores improvement in the six-category ordinal scale or patient���s discharge,*,*,*,8,*,28,*,*,*,*,High,unblinded,Industry_Mixed,92,LIC_MIC,,,,,,,,,,,,,consistent
25_pub,25,2,IRCT20100228003449N28,No,https://aac.asm.org/content/aac/early/2020/07/08/AAC.01061-20.full.pdf,*,Davoudi-Monfared E,Antimicrob Agents Ch,2020,published paper,7/13/2020,Unblinded,2/29/2020,Single,Private,No funding; CinnaGen Co. (drug donation),Moderate to critical,Iran,Control,Standard care,46,39,17,*,28,At least two scores improvement in the six-category ordinal scale or patient���s discharge,*,*,*,16,*,28,*,*,*,*,High,unblinded,Industry_Mixed,92,LIC_MIC,,,,,,,,,,,,,consistent
34_preprint,34,2,NCT04381936,No,https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1,*,Horby P,medRxiv,2020,preprint,6/22/2020,Unblinded,3/19/2020,Multicenter,Public/non profit ,The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre,Mild to critical,UK ,Treatment,Dexamethasone,2104,2104,454,*,*,Discharged from hospital within 28 days    ,1360,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,6425,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
34_preprint,34,2,NCT04381936,No,https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1,*,Horby P,medRxiv,2020,preprint,6/22/2020,Unblinded,3/19/2020,Multicenter,Public/non profit ,The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre,Mild to critical,UK ,Control,Standard care,4321,4321,1065,*,*,Discharged from hospital within 28 days    ,2639,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,6425,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
34_pub,34,1,NCT04381936,No,https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=featured_coronavirus,RECOVERY (Dex),Horby P,N Engl J Med,2021,published paper,2/25/2021,Unblinded,3/19/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to critical,UK ,Treatment,Dexamethasone,2104,2104,482,*,28,Discharged from hospital within 28 days    ,1413,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,6425,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
34_pub,34,2,NCT04381936,No,https://www.nejm.org/doi/full/10.1056/NEJMoa2021436?query=featured_coronavirus,RECOVERY (Dex),Horby P,N Engl J Med,2021,published paper,2/25/2021,Unblinded,3/19/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to critical,UK ,Control,Standard care,4321,4321,1110,*,28,Discharged from hospital within 28 days    ,2745,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,6425,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
45_preprint,45,2,NCT04342182,No,https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1.full.pdf,*,Gharbharan A,medRxiv,2020,preprint,7/3/2020,Unblinded,4/8/2020,Multicenter,Mixed,"The Erasmusfoundation, Ypsilon",Moderate to critical,Netherlands,Treatment,Convalescent plasma,43,43,6,*,*,Improvement on the 8-point WHO COVID-19 disease severity scale from inclusion to day 15,25,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,86,HIC,,,,,,,,,,,,,add_delete
45_preprint,45,2,NCT04342182,No,https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1.full.pdf,*,Gharbharan A,medRxiv,2020,preprint,7/3/2020,Unblinded,4/8/2020,Multicenter,Mixed,"The Erasmusfoundation, Ypsilon",Moderate to critical,Netherlands,Control,Standard care,43,43,11,*,*,Improvement on the 8-point WHO COVID-19 disease severity scale from inclusion to day 15,25,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,86,HIC,,,,,,,,,,,,,add_delete
45_pub,45,1,NCT04342182,No,https://www.nature.com/articles/s41467-021-23469-2,*,Gharbharan A,Nat Commun,2021,published paper,5/27/2021,Unblinded,4/8/2020,Multicenter,Mixed,"The Erasmusfoundation, Ypsilo and Health Holland",Moderate to critical,Netherlands,Treatment,Convalescent plasma,43,43,*,*,*,"Improvement on the eight-point WHO COVID-19 disease severity scale on day 15
and day 30",25,*,15,*,*,*,*,*,*,15,Some concerns,unblinded,Industry_Mixed,86,HIC,,,,,,,,,,,,,add_delete
45_pub,45,2,NCT04342182,No,https://www.nature.com/articles/s41467-021-23469-2,*,Gharbharan A,Nat Commun,2021,published paper,5/27/2021,Unblinded,4/8/2020,Multicenter,Mixed,"The Erasmusfoundation, Ypsilo and Health Holland",Moderate to critical,Netherlands,Control,Standard care,43,43,*,*,*,"Improvement on the eight-point WHO COVID-19 disease severity scale on day 15
and day 30",25,*,15,*,*,*,*,*,*,15,Some concerns,unblinded,Industry_Mixed,86,HIC,,,,,,,,,,,,,add_delete
48_preprint,48,2,NCT04381936,No,https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1,*,Horby P,medRxiv,2020,preprint,7/15/2020,Unblinded,3/25/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to Critical,UK,Treatment,Hydroxychloroquine,1561,1561,418,*,*,Discharged from hospital within 28 days    ,941,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,4716,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
48_preprint,48,2,NCT04381936,No,https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1,*,Horby P,medRxiv,2020,preprint,7/15/2020,Unblinded,3/25/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to Critical,UK,Control,Standard care,3155,3155,788,*,*,Discharged from hospital within 28 days    ,1982,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,4716,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
48_pub,48,1,NCT04381936,No,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022926?articleTools=true,RECOVERY (HCQ),Horby P,N Engl J Med,2020,published paper,10/8/2020,Unblinded,3/25/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to critical,UK,Treatment,Hydroxychloroquine,1561,1561,421,*,28,Discharged from hospital within 28 days    ,931,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,4716,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
48_pub,48,2,NCT04381936,No,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022926?articleTools=true,RECOVERY (HCQ),Horby P,N Engl J Med,2020,published paper,10/8/2020,Unblinded,3/25/2020,Multicenter,Mixed,University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK,Mild to critical,UK,Control,Standard care,3155,3155,790,*,28,Discharged from hospital within 28 days    ,1983,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,4716,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
52_preprint,52,2,NCT04411667,No,https://www.medrxiv.org/content/10.1101/2020.07.20.20157891v1,*,Sakoulas G,medRxiv,2020,preprint,7/25/2020,Unblinded,5/1/2020,Multicenter,Private,"IVIG (Octagam 10%) was provided by Octapharma USA, Hoboken, NJ",Moderate/Severe,USA,Treatment,IV Ig,17,16,1,*,*,Discharged from Hospital on Room Air/Off O2,*,*,*,*,*,*,0,*,*,*,Some concerns,unblinded,Industry_Mixed,34,HIC,,N,Y,Y,N,N,,,,,,,consistent
52_preprint,52,2,NCT04411667,No,https://www.medrxiv.org/content/10.1101/2020.07.20.20157891v1,*,Sakoulas G,medRxiv,2020,preprint,7/25/2020,Unblinded,5/1/2020,Multicenter,Private,"IVIG (Octagam 10%) was provided by Octapharma USA, Hoboken, NJ",Moderate/Severe,USA,Control,Standard care,17,17,3,*,*,Discharged from Hospital on Room Air/Off O2,*,*,*,*,*,*,0,*,*,*,Some concerns,unblinded,Industry_Mixed,34,HIC,,N,Y,Y,N,N,,,,,,,consistent
52_pub,52,1,NCT04411667,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671875/pdf/cc9-2-e0280.pdf,*,Sakoulas G,Crit Care Expl ,2020,published paper,11/16/2020,Unblinded,5/1/2020,Multicenter,Private,"IVIG (Octagam 10%) was provided by Octapharma USA, Hoboken, NJ",Moderate/Severe,USA,Treatment,IV Ig,17,16,1,*,30,Discharged from Hospital on Room Air/Off O2,*,16,30,*,*,30,0,*,*,*,Some concerns,unblinded,Industry_Mixed,34,HIC,,N,Y,Y,N,N,,,,,,,consistent
52_pub,52,2,NCT04411667,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671875/pdf/cc9-2-e0280.pdf,*,Sakoulas G,Crit Care Expl ,2020,published paper,11/16/2020,Unblinded,5/1/2020,Multicenter,Private,"IVIG (Octagam 10%) was provided by Octapharma USA, Hoboken, NJ",Moderate/Severe,USA,Control,Standard care,17,17,3,*,30,Discharged from Hospital on Room Air/Off O2,*,16,30,*,*,30,0,*,*,*,Some concerns,unblinded,Industry_Mixed,34,HIC,,N,Y,Y,N,N,,,,,,,consistent
54_preprint,54,3,NCT04434248,No,https://www.medrxiv.org/content/10.1101/2020.07.26.20154724v1,*,Ivashchenko AA,medRxiv,2020,preprint,8/4/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation, The Skolkovo Innovation Center. Development, manufacturing, and marketing of the investigational product used in this study was provided by ChemRar group of companies.",Moderate,Russia,Treatment,Favipiravir,40,40,*,*,*,Discharge from the hospital,36,*,*,*,*,*,15,*,*,,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,N,,N,,,,,,,,add_delete
54_preprint,54,3,NCT04434248,No,https://www.medrxiv.org/content/10.1101/2020.07.26.20154724v1,*,Ivashchenko AA,medRxiv,2020,preprint,8/4/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation, The Skolkovo Innovation Center. Development, manufacturing, and marketing of the investigational product used in this study was provided by ChemRar group of companies.",Moderate,Russia,Control,Standard care,20,20,*,*,*,Discharge from the hospital,19,*,*,*,*,*,5,*,*,*,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,N,,N,,,,,,,,add_delete
54_pub,54,3,NCT04434248,No,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024,*,Ivashchenko AA,Clin Infect Dis,2020,published paper,8/9/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation, The Skolkovo Innovation Center. ",Mild/Moderate,Russia,Treatment,Favipiravir,40,40,*,*,*,Discharge from the hospital,*,*,28,*,*,*,*,*,*,,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,N,,N,,,,,,,,add_delete
54_pub,54,3,NCT04434248,No,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1176/5890024,*,Ivashchenko AA,Clin Infect Dis,2020,published paper,8/9/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Russian Direct Investment Fund, the Ministry of Industry and Trade of the Russian Federation, The Skolkovo Innovation Center. ",Mild/Moderate,Russia,Control,Standard care,20,20,*,*,*,Discharge from the hospital,*,*,28,*,*,*,*,*,*, ,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,N,,N,,,,,,,,add_delete
55_preprint,55,2,NCT04384380,No,https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1.full.pdf,*,Chen CP,medRxiv,2020,preprint,7/10/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare; Taiwan Biotech Co. Ltd.",Mild/Moderate,Taiwan,Treatment,Hydroxychloroquine,21,21,0,*,*,*,*,*,*,*,*,*,*,0,*,*,Some concerns,unblinded,Industry_Mixed,33,HIC,,N,,Y,,N,,,,,,,consistent
55_preprint,55,2,NCT04384380,No,https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1.full.pdf,*,Chen CP,medRxiv,2020,preprint,7/10/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare; Taiwan Biotech Co. Ltd.",Mild/Moderate,Taiwan,Control,Standard care,12,12,0,*,*,*,*,*,*,*,*,*,*,0,*,*,Some concerns,unblinded,Industry_Mixed,33,HIC,,N,,Y,,N,,,,,,,consistent
55_pub,55,1,NCT04384380,No,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242763#sec021 https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1,*,Chen CP,Plos one,2020,published paper,12/2/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare",Mild/Moderate,Taiwan,Treatment,Hydroxychloroquine,21,21,0,*,14,*,*,*,*,*,*,14,*,0,*,14,Some concerns,unblinded,Industry_Mixed,33,HIC,,N,,Y,,N,,,,,,,consistent
55_pub,55,2,NCT04384380,No,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242763#sec021 https://www.medrxiv.org/content/10.1101/2020.07.08.20148841v1,*,Chen CP,Plos one,2020,published paper,12/2/2020,Unblinded,4/1/2020,Multicenter,Mixed,"Hospital and Social Welfare Organizations Administration Commission, Ministry of Health and Welfare",Mild/Moderate,Taiwan,Control,Standard care,12,12,0,*,14,*,*,*,*,*,*,14,*,0,*,14,Some concerns,unblinded,Industry_Mixed,33,HIC,,N,,Y,,N,,,,,,,consistent
61_preprint,61,2,NCT04333420,No,https://dx.doi.org/10.2139/ssrn.3658226,*,Vlaar APJ,SSRN,2020,preprint,7/30/2020,Unblinded,3/31/2020,Multicenter,Private,InflaRx GmbH,Moderate to critical,The Netherlands,Treatment,IFX-1,15,15,2,*,*,*,*,*,*,*,*,*,*,9,*,*,Some concerns,unblinded,Industry_Mixed,30,HIC,,N,,,N,N,,,,,,,add_delete
61_preprint,61,2,NCT04333420,No,https://dx.doi.org/10.2139/ssrn.3658226,*,Vlaar APJ,SSRN,2020,preprint,7/30/2020,Unblinded,3/31/2020,Multicenter,Private,InflaRx GmbH,Moderate to critical,The Netherlands,Control,Standard care,15,15,4,*,*,*,*,*,*,*,*,*,*,7,*,*,Some concerns,unblinded,Industry_Mixed,30,HIC,,N,,,N,N,,,,,,,add_delete
61_pub,61,1,NCT04333420,No,https://bit.ly/3cfmn0A,PANAMO,Vlaar APJ,Lancet Rheumatol,2020,published paper,9/28/2020,Unblinded,3/31/2020,Multicenter,Private,InflaRx GmbH,Moderate to critical,The Netherlands,Treatment,IFX-1,15,15,2,*,28,*,*,*,*,*,*,*,14,9,*,*,Some concerns,unblinded,Industry_Mixed,30,HIC,,N,,,N,N,,,,,,,add_delete
61_pub,61,2,NCT04333420,No,https://bit.ly/3cfmn0A,PANAMO,Vlaar APJ,Lancet Rheumatol,2020,published paper,9/28/2020,Unblinded,3/31/2020,Multicenter,Private,InflaRx GmbH,Moderate to critical,The Netherlands,Control,Standard care,15,15,4,*,28,*,*,*,*,*,*,*,14,7,*,*,Some concerns,unblinded,Industry_Mixed,30,HIC,,N,,,N,N,,,,,,,add_delete
62_preprint,62,2,NCT04355936,Yes,https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2.full.pdf,*,Duarte M,medRxiv,2020,preprint,8/11/2020,Unblinded,5/14/2020,Multicenter,No specific funding,*,Unclear severity,Argentina,Treatment,Telmisartan,41,40,2,*,*,Hospital discharge,29,*,*,*,*,*,0,*,*,*,Some concerns,unblinded,Other,82,LIC_MIC,,N,N,,N,,N,sample size,N,N,N,"mort, CI, AE",exclude_diffanalysis
62_preprint,62,2,NCT04355936,Yes,https://www.medrxiv.org/content/10.1101/2020.08.04.20167205v2.full.pdf,*,Duarte M,medRxiv,2020,preprint,8/11/2020,Unblinded,5/14/2020,Multicenter,No specific funding,*,Unclear severity,Argentina,Control,Standard care,41,38,4,*,*,Hospital discharge ,18,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,82,LIC_MIC,,N,N,,N,,N,sample size,N,N,N,"mort, CI, AE",exclude_diffanalysis
62_pub,62,1,NCT04355936,Yes,https://bit.ly/3h9c0y5,*,Duarte M,EClinicalMedicine,2021,published paper,6/18/2021,Unblinded,5/14/2020,Multicenter,Mixed,"School of Medicine, University of Buenos Aires, Argentina; Laboratorio Elea Phoenix S.A.",Unclear severity,Argentina,Treatment,Telmisartan,80,78,3,70,30,Hospital discharge,57,*,15,*,*,*,0,*,*,14,Some concerns,unblinded,Industry_Mixed,162,LIC_MIC,,N,N,,N,,N,sample size,N,N,N,"mort, CI, AE",exclude_diffanalysis
62_pub,62,2,NCT04355936,Yes,https://bit.ly/3h9c0y5,*,Duarte M,EClinicalMedicine,2021,published paper,6/18/2021,Unblinded,5/14/2020,Multicenter,Mixed,"School of Medicine, University of Buenos Aires, Argentina; Laboratorio Elea Phoenix S.A.",Unclear severity,Argentina,Control,Standard care,82,80,16,71,30,Hospital discharge ,37,*,15,*,*,*,0,*,*,14,Some concerns,unblinded,Industry_Mixed,162,LIC_MIC,,N,N,,N,,N,sample size,N,N,N,"mort, CI, AE",exclude_diffanalysis
70_preprint,70,2,NCT04264533,Yes,https://doi.org/10.21203/rs.3.rs-52778/v1,*,Zhang J,Research Square,2020,preprint,8/10/2020,triple blinding,2/14/2020,Multicenter,Public/non profit,Science and Technology Department of Hubei Province; Fundamental Research Funds for the Central Universities,Severe/Critical,China,Treatment,Vitamin C,27,26,5,*,*,Patient requiring ECMO or IMV on day 1 and switching to HFNC.NIV. or discharged from the ICU after 7 days of treatment,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,56,LIC_MIC,,N,,,N,,,,,,,,discrepTE
70_preprint,70,2,NCT04264533,Yes, https://doi.org/10.21203/rs.3.rs-52778/v1,*,Zhang J,Research Square,2020,preprint,8/10/2020,triple blinding,2/14/2020,Multicenter,Public/non profit,Science and Technology Department of Hubei Province; Fundamental Research Funds for the Central Universities,Severe/Critical,China,Control,Placebo,29,28,9,*,*,Patient requiring ECMO or IMV on day 1 and switching to HFNC.NIV. or discharged from the ICU after 7 days of treatment,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,56,LIC_MIC,,N,,,N,,,,,,,,discrepTE
70_pub,70,1,NCT04264533,Yes,https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-020-00792-3,*,Zhang J,Ann Intensive Care,2021,published paper,1/9/2021,"Participants, outcome assessor and health care pro",2/14/2020,Multicenter,Public/non profit,Science and Technology Department of Hubei Province; Fundamental Research Funds for the Central Universities,Severe/Critical,China,Treatment,Vitamin C,27,27,6,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,56,LIC_MIC,,N,,,N,,,,,,,,discrepTE
70_pub,70,2,NCT04264533,Yes,https://annalsofintensivecare.springeropen.com/articles/10.1186/s13613-020-00792-3,*,Zhang J,Ann Intensive Care,2021,published paper,1/9/2021,"Participants, outcome assessor and health care pro",2/14/2020,Multicenter,Public/non profit,Science and Technology Department of Hubei Province; Fundamental Research Funds for the Central Universities,Severe/Critical,China,Control,Placebo,29,29,10,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,56,LIC_MIC,,N,,,N,,,,,,,,discrepTE
73_preprint,73,2,NCT04345523,No,https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v1,*,AvendaÃ±o-SolÃ  C, medRxiv,2020,preprint,9/1/2020,Unblinded,4/4/2020,Multicenter,Public/non profit,"Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III",Moderate,Spain,Treatment,Convalescent plasma ,38,38,0,*,*, Improvement of one category on the 7 point ordinal scale  ,*,*,*,0,*,*,*,6,*,*,Some concerns,unblinded,Other,81,HIC,,N,,N,,N,N,sample size,N,N,N,"mort, WHO7, SAE",exclude_diffanalysis
73_preprint,73,2,NCT04345523,No,https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v1,*,AvendaÃ±o-SolÃ  C, medRxiv,2020,preprint,9/1/2020,Unblinded,4/4/2020,Multicenter,Public/non profit,"Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III",Moderate,Spain,Control,Standard care,43,43,4,*,*, Improvement of one category on the 7 point ordinal scale  ,*,*,*,6,*,*,*,7,*,*,Some concerns,unblinded,Other,81,HIC,,N,,N,,N,N,sample size,N,N,N,"mort, WHO7, SAE",exclude_diffanalysis
73_pub,73,1,NCT04345523,No,https://www.jci.org/articles/view/152740 https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v2.full.pdf,ConPlas-19,Avendano-Sola C,J Clin Invest,2021,published paper,9/2/2021,Unblinded,4/4/2020,Multicenter,Public/non profit,"Government of Spain, Instituto de Salud Carlos III",Mild/Moderate,Spain,Treatment,Convalescent plasma ,179,179,7,*,28,Improvement of one category on the 7 point ordinal scale  ,*,*,*,13,*,28,*,15,179,28,Some concerns,unblinded,Other,350,HIC,,N,,N,,N,N,sample size,N,N,N,"mort, WHO7, SAE",exclude_diffanalysis
73_pub,73,2,NCT04345523,No,https://www.jci.org/articles/view/152740 https://www.medrxiv.org/content/10.1101/2020.08.26.20182444v2.full.pdf,ConPlas-19,Avendano-Sola C,J Clin Invest,2021,published paper,9/2/2021,Unblinded,4/4/2020,Multicenter,Public/non profit,"Government of Spain, Instituto de Salud Carlos III",Mild/Moderate,Spain,Control,Standard care,171,171,14,*,28,Improvement of one category on the 7 point ordinal scale  ,*,*,*,21,*,28,*,16,172,28,Some concerns,unblinded,Other,350,HIC,,N,,N,,N,N,sample size,N,N,N,"mort, WHO7, SAE",exclude_diffanalysis
78_preprint,78,2,NCT04320615,Yes,https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2.full.pdf,*,Rosas I,medRxiv,2020,preprint,9/1/2020, double blinding,4/3/2020,Multicenter,Mixed,"F. Hoffmann-La Roche Ltd; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Mild to critical,"Canada, Denmark, France, Germany, Italy, Netherlands, Spain, UK, USA",Treatment,Tocilizumab,301,294,58,*,*,Hospital discharge,166,*,*,102,*,*,228,103,*,28,Low,blinded,Industry_Mixed,452,HIC,,N,N,N,N,N,Y,,,,,,consistent
78_preprint,78,2,NCT04320615,Yes,https://www.medrxiv.org/content/10.1101/2020.08.27.20183442v2.full.pdf,*,Rosas I,medRxiv,2020,preprint,9/1/2020, double blinding,4/3/2020,Multicenter,Mixed,"F. Hoffmann-La Roche Ltd; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Mild to critical,"Canada, Denmark, France, Germany, Italy, Netherlands, Spain, UK, USA",Control,Placebo,151,144,28,*,*,Hospital discharge,71,*,*,51,*,*,116,55,*,28,Low,blinded,Industry_Mixed,452,HIC,,N,N,N,N,N,Y,,,,,,consistent
78_pub,78,1,NCT04320615,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2028700#article_supplementary_material,COVACTA,Rosas I,N Engl J Med,2021,published paper,2/25/2021, ,4/3/2020,Multicenter,Mixed,"F. Hoffmann-La Roche Ltd; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Mild to critical,"Canada, Denmark, France, Germany, Italy, Netherlands, Spain, UK, USA",Treatment,Tocilizumab,301,294,58,*,28,Hospital discharge,166,*,28,102,*,28,228,103,*,28,Low,blinded,Industry_Mixed,452,HIC,,N,N,N,N,N,Y,,,,,,consistent
78_pub,78,2,NCT04320615,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2028700#article_supplementary_material,COVACTA,Rosas I,N Engl J Med,2021,published paper,2/25/2021, ,4/3/2020,Multicenter,Mixed,"F. Hoffmann-La Roche Ltd; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Mild to critical,"Canada, Denmark, France, Germany, Italy, Netherlands, Spain, UK, USA",Control,Placebo,151,144,28,*,28,Hospital discharge,71,*,28,51,*,28,116,55,*,28,Low,blinded,Industry_Mixed,452,HIC,,N,N,N,N,N,Y,,,,,,consistent
79_preprint,79,2,RBR-8jyhxh,No,https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2.full.pdf,*,Lopes MIF,medRxiv,2020,preprint,8/12/2020,*,4/11/2020,Single,Public/non profit,"FAPESP, CNPq and CAPES grants.",Moderate to critical,Brazil,Treatment,Colchicine,19,17,0,*,*,Discharge from the hospital,19,*,*,0,*,*,10,2,*,*,Some concerns,unclear,Other,38,LIC_MIC,,N,N,Y,N,,N,sample size,N,"WHO7, SAE",N,"mort, CI",exclude_diffanalysis
79_preprint,79,2,RBR-8jyhxh,No,https://www.medrxiv.org/content/10.1101/2020.08.06.20169573v2.full.pdf,*,Lopes MIF,medRxiv,2020,preprint,8/12/2020,*,4/11/2020,Single,Public/non profit,"FAPESP, CNPq and CAPES grants.",Moderate to critical,Brazil,Control,Placebo,19,18,0,*,*,Discharge from the hospital,19,*,*,0,*,*,8,2,*,*,Some concerns,unclear,Other,38,LIC_MIC,,N,N,Y,N,,N,sample size,N,"WHO7, SAE",N,"mort, CI",exclude_diffanalysis
79_pub,79,1,RBR-8jyhxh,No,https://rmdopen.bmj.com/content/7/1/e001455,*,Lopes MIF,RMD Open,2021,published paper,2/4/2021,"Double blinded, no restrictions",4/11/2020,Single,Public/non profit,"FAPESP, CNPq and CAPES grants.",Moderate/Severe,Brazil,Treatment,Colchicine,38,36,0,*,15,Discharge from the hospital,35,*,15,*,*,*,10,*,*,*,Some concerns,blinded,Other,75,LIC_MIC,,N,N,Y,N,,N,sample size,N,"WHO7, SAE",N,"mort, CI",exclude_diffanalysis
79_pub,79,2,RBR-8jyhxh,No,https://rmdopen.bmj.com/content/7/1/e001455,*,Lopes MIF,RMD Open,2021,published paper,2/4/2021,"Double blinded, no restrictions",4/11/2020,Single,Public/non profit,"FAPESP, CNPq and CAPES grants.",Moderate/Severe,Brazil,Control,Placebo,37,36,2,*,15,Discharge from the hospital,32,*,15,*,*,*,8,*,*,*,Some concerns,blinded,Other,75,LIC_MIC,,N,N,Y,N,,N,sample size,N,"WHO7, SAE",N,"mort, CI",exclude_diffanalysis
80_preprint,80,2,ChiCTR2000029765,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,*,Wang D,SSRN,2020,preprint,8/29/2020,Unblinded,2/13/2020,Multicenter,Public/non profit,"Department of Science and Technology of Anhui Province and Health Commission of Anhui Province, China National Center for Biotechnology Development",Moderate/Severe,China,Treatment,Tocilizumab,33,34,*,*,*,*,*,*,*,*,*,*,20,0,*,*,Some concerns,unblinded,Other,65,LIC_MIC,,,,,N,N,,,,,,,consistent
80_preprint,80,2,ChiCTR2000029765,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,*,Wang D,SSRN,2020,preprint,8/29/2020,Unblinded,2/13/2020,Multicenter,Public/non profit,"Department of Science and Technology of Anhui Province and Health Commission of Anhui Province, China National Center for Biotechnology Development",Moderate/Severe,China,Control,Standard care,32,31,*,*,*,*,*,*,*,*,*,*,4,1,*,*,Some concerns,unblinded,Other,65,LIC_MIC,,,,,N,N,,,,,,,consistent
80_pub,80,1,ChiCTR2000029765,Yes,https://link.springer.com/article/10.1007/s11684-020-0824-3#Sec1 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,*,Wang D,Front Med,2021,published paper,3/9/2021,Unblinded,2/13/2020,Multicenter,Public/non profit,Department of Science and Technology of Anhui Province and Health Commission of Anhui Province; China National Center for Biotechnology Development,Moderate/Severe,China,Treatment,Tocilizumab,33,34,*,*,*,*,*,*,*,*,*,*,20,0,*,*,Some concerns,unblinded,Other,65,LIC_MIC,,,,,N,N,,,,,,,consistent
80_pub,80,2,ChiCTR2000029765,Yes,https://link.springer.com/article/10.1007/s11684-020-0824-3#Sec1 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3667681,*,Wang D,Front Med,2021,published paper,3/9/2021,Unblinded,2/13/2020,Multicenter,Public/non profit,Department of Science and Technology of Anhui Province and Health Commission of Anhui Province; China National Center for Biotechnology Development,Moderate/Severe,China,Control,Standard care,32,31,*,*,*,*,*,*,*,*,*,*,4,1,*,*,Some concerns,unblinded,Other,65,LIC_MIC,,,,,N,N,,,,,,,consistent
81_preprint,81,2,CTRI/2020/04/024775,Yes,https://www.medrxiv.org/content/10.1101/2020.09.03.20187252v1.full.pdf,*,Agarwal A,medRxiv,2020,preprint,9/8/2020,Unblinded,4/22/2020,Multicenter,Public/non profit,"This multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved",Moderate/Severe,India,Treatment,Convalescent plasma,235,235,34,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,464,LIC_MIC,,N,,,,,,,,,,,consistent
81_preprint,81,2,CTRI/2020/04/024775,Yes,https://www.medrxiv.org/content/10.1101/2020.09.03.20187252v1.full.pdf,*,Agarwal A,medRxiv,2020,preprint,9/8/2020,Unblinded,4/22/2020,Multicenter,Public/non profit,"This multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved",Moderate/Severe,India,Control,Standard care,229,229,31,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,464,LIC_MIC,,N,,,,,,,,,,,consistent
81_pub,81,1,CTRI/2020/04/024775,Yes,https://doi.org/10.1136/bmj.m3939 ,PLACID,Agarwal A,BMJ,2020,published paper,10/22/2020,Unblinded,4/22/2020,Multicenter,Public/non profit,Indian Council of Medical Research (ICMR),Mild to severe,India,Treatment,Convalescent plasma,235,235,34,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,464,LIC_MIC,,N,,,,,,,,,,,consistent
81_pub,81,2,CTRI/2020/04/024775,Yes,https://doi.org/10.1136/bmj.m3939 ,PLACID,Agarwal A,BMJ,2020,published paper,10/22/2020,Unblinded,4/22/2020,Multicenter,Public/non profit,Indian Council of Medical Research (ICMR),Mild to severe,India,Control,Standard care,229,229,31,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,464,LIC_MIC,,N,,,,,,,,,,,consistent
88_preprint,88,2,RPCEC00000309,No,https://www.researchsquare.com/article/rs-68403/v1,*,Delgado-Enciso I,Research Square,2020,preprint,9/10/2020, single blinding,5/1/2020,Multicenter,Mixed,Consejo Estatal de Ciencia yTecnologÃ­a del Estado de Colima; Esteripharma S.A. de C.V.,Mild,Mexico,Treatment,N-electrolyzed saline ,*,45,0,*,*,*,*,*,*,*,*,*,3,0,*,*,Some concerns,blinded,Industry_Mixed,84,LIC_MIC,,N,,,,,N,sample size,nrando,N,N,mort,exclude_diffanalysis
88_preprint,88,2,RPCEC00000309,No,https://www.researchsquare.com/article/rs-68403/v1,*,Delgado-Enciso I,Research Square,2020,preprint,9/10/2020, single blinding,5/1/2020,Multicenter,Mixed,Consejo Estatal de Ciencia yTecnologÃ­a del Estado de Colima; Esteripharma S.A. de C.V.,Mild,Mexico,Control,Standard care,*,39,5,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,84,LIC_MIC,,N,,,,,N,sample size,nrando,N,N,mort,exclude_diffanalysis
88_pub,88,1,RPCEC00000309,No,https://www.spandidos-publications.com/10.3892/etm.2021.10347 https://www.researchsquare.com/article/rs-68403/v1,*,Delgado-Enciso I,Exp Ther Med,2021,published paper,6/29/2021,Outcome assessor,5/1/2020,Multicenter,Mixed,Consejo Estatal de Ciencia y Tecnolog��a del Estado de Colima; Esteripharma S.A. de C.V.,Outpatients,Mexico,Treatment,N-electrolyzed saline ,113,110,2,*,20,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,217,LIC_MIC,,N,,,,,N,sample size,nrando,N,N,mort,exclude_diffanalysis
88_pub,88,2,RPCEC00000309,No,https://www.spandidos-publications.com/10.3892/etm.2021.10347 https://www.researchsquare.com/article/rs-68403/v1,*,Delgado-Enciso I,Exp Ther Med,2021,published paper,6/29/2021,Outcome assessor,5/1/2020,Multicenter,Mixed,Consejo Estatal de Ciencia y Tecnolog��a del Estado de Colima; Esteripharma S.A. de C.V.,Outpatients,Mexico,Control,Standard care,104,104,9,*,20,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,217,LIC_MIC,,N,,,,,N,sample size,nrando,N,N,mort,exclude_diffanalysis
90_preprint,90,2,NCT04316377,Yes,https://www.researchsquare.com/article/rs-44055/v1,*,Lyngbakken MN,Research Square,2020,preprint,7/17/2020,Unblinded,3/25/2020,Single,No specific funding,"University Hospital, Akershus; No external funding was received.",Mild to severe,Norway,Treatment,Hydroxychloroquine,27,26,*,*,*,*,*,*,*,*,*,*,*,5,*,*,High,unblinded,Other,53,HIC,,N,N,N,,N,Y,,,,,,add_delete
90_preprint,90,2,NCT04316377,Yes,https://www.researchsquare.com/article/rs-44055/v1,*,Lyngbakken MN,Research Square,2020,preprint,7/17/2020,Unblinded,3/25/2020,Single,No specific funding,"University Hospital, Akershus; No external funding was received.",Mild to severe,Norway,Control,Standard care,26,25,*,*,*,*,*,*,*,*,*,*,*,6,*,*,High,unblinded,Other,53,HIC,,N,N,N,,N,Y,,,,,,add_delete
90_pub,90,1,NCT04316377,Yes,https://www.nature.com/articles/s41467-020-19056-6#Sec14,NO COVID-19,Lyngbakken MN,Nature,2020,published paper,10/20/2020,Unblinded,3/25/2020,Single,Public/non profit,"University Hospital, Akershus;European Virus Archive Global (EVA-GLOBAL) project [publication]",Mild to severe,Norway,Treatment,Hydroxychloroquine,27,26,1,*,30,Discharge,23,*,14,1,*,14,*,5,*,*,High,unblinded,Other,53,HIC,,N,N,N,,N,Y,,,,,,add_delete
90_pub,90,2,NCT04316377,Yes,https://www.nature.com/articles/s41467-020-19056-6#Sec14,NO COVID-19,Lyngbakken MN,Nature,2020,published paper,10/20/2020,Unblinded,3/25/2020,Single,Public/non profit,"University Hospital, Akershus;European Virus Archive Global (EVA-GLOBAL) project [publication]",Mild to severe,Norway,Control,Standard care,26,25,1,*,30,Discharge,21,*,14,2,*,14,*,6,*,*,High,unblinded,Other,53,HIC,,N,N,N,,N,Y,,,,,,add_delete
91_preprint,91,2,NCT04434144,No,https://www.researchsquare.com/article/rs-38896/v1,*,Mohiuddin Chowdhury ATM,Research Square,2020,preprint,7/14/2020, *,5/2/2020,Single,No specific funding,Not applicable,Mild,Bangladesh,Treatment,IVM+DX,63,60,*,*,*,*,*,*,*,*,*,*,19,*,*,*,High,unclear,Other,125,LIC_MIC,,,,,N,,,,,,,,consistent
91_preprint,91,2,NCT04434144,No,https://www.researchsquare.com/article/rs-38896/v1,*,Mohiuddin Chowdhury ATM,Research Square,2020,preprint,7/14/2020, *,5/2/2020,Single,No specific funding,Not applicable,Mild,Bangladesh,Control,HCQ+AZM,62,56,*,*,*,*,*,*,*,*,*,*,26,*,*,*,High,unclear,Other,125,LIC_MIC,,,,,N,,,,,,,,consistent
91_pub,91,1,NCT04434144,No,https://ejmo.org/10.14744/ejmo.2021.16263/,*,Chowdhury ATMM,EJMO,2021,published paper,2/25/2021,*,5/2/2020,Single,No specific funding,Not applicable,Outpatients,Bangladesh,Treatment,IVM+DX,63,60,*,*,*,*,*,*,*,*,*,*,19,*,*,35,High,unclear,Other,125,LIC_MIC,,,,,N,,,,,,,,consistent
91_pub,91,2,NCT04434144,No,https://ejmo.org/10.14744/ejmo.2021.16263/,*,Chowdhury ATMM,EJMO,2021,published paper,2/25/2021,*,5/2/2020,Single,No specific funding,Not applicable,Outpatients,Bangladesh,Control,HCQ+AZM,62,56,*,*,*,*,*,*,*,*,*,*,26,*,*,35,High,unclear,Other,125,LIC_MIC,,,,,N,,,,,,,,consistent
93_preprint,93,2,IRCT20180725040596N2,Yes,https://www.researchsquare.com/article/rs-78316/v1,*,Nojomi M,Research Square,2020,preprint,9/16/2020,Unblinded,4/20/2020,Single,Public/non profit,Iran University of Medical Sciences,Moderate/Severe,Iran,Treatment,HCQ+LPV/r,50,50,2,*,*,*,*,*,*,*,*,*,12,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,N,,,N,,,,,,,,consistent
93_preprint,93,2,IRCT20180725040596N2,Yes,https://www.researchsquare.com/article/rs-78316/v2,*,Nojomi M,Research Square,2020,preprint,9/16/2020,Unblinded,4/20/2020,Single,Public/non profit,Iran University of Medical Sciences,Moderate/Severe,Iran,Control,HCQ+Umif,50,50,1,*,*,*,*,*,*,*,*,*,3,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,N,,,N,,,,,,,,consistent
93_pub,93,1,IRCT20180725040596N2,Yes,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w,*,Nojomi M,BMC Infect Dis,2020,published paper,12/14/2020,Unblinded,4/20/2020,Single,Public/non profit,Iran University of Medical Sciences,Moderate/Severe,Iran,Treatment,HCQ+LPV/r,50,50,2,*,30,*,*,*,*,*,*,*,12,*,*,30,Some concerns,unblinded,Other,100,LIC_MIC,,N,,,N,,,,,,,,consistent
93_pub,93,2,IRCT20180725040596N2,Yes,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w,*,Nojomi M,BMC Infect Dis,2020,published paper,12/14/2020,Unblinded,4/20/2020,Single,Public/non profit,Iran University of Medical Sciences,Moderate/Severe,Iran,Control,HCQ+Umif,50,50,1,*,30,*,*,*,*,*,*,*,3,*,*,30,Some concerns,unblinded,Other,100,LIC_MIC,,N,,,N,,,,,,,,consistent
97_preprint,97,2,ChiCTR2000029638,Yes,https://www.researchsquare.com/article/rs-65224/v1,*,Li C,Research Square,2020,preprint,8/31/2020, single blinding,2/10/2020,Multicenter,Mixed,"New Coronavirus (2019-nCoV) Emergency Project of Sichuan University and the Novel Coronavirus Pneumonia Epidemic Research Project in West China Hospital, Sichuan University. Sichuan Huiyang Life Science & Technology Corp",Moderate/Severe,China,Treatment,rSIFN-co,48,46,0,*,*,Improvement of two points on a seven-category ordinal scale,43,*,*,0,*,*,13,0,*,*,Some concerns,blinded,Industry_Mixed,96,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
97_preprint,97,2,ChiCTR2000029638,Yes,https://www.researchsquare.com/article/rs-65224/v2,*,Li C,Research Square,2020,preprint,8/31/2020, single blinding,2/10/2020,Multicenter,Mixed,"New Coronavirus (2019-nCoV) Emergency Project of Sichuan University and the Novel Coronavirus Pneumonia Epidemic Research Project in West China Hospital, Sichuan University. Sichuan Huiyang Life Science & Technology Corp",Moderate/Severe,China,Control,IFN alpha,48,48,0,*,*,Improvement of two points on a seven-category ordinal scale,37,*,*,1,*,*,18,1,*,*,Some concerns,blinded,Industry_Mixed,96,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
97_pub,97,1,ChiCTR2000029638,Yes,https://www.tandfonline.com/doi/full/10.1080/07853890.2021.1890329,*,Li C,Ann Med,2021,published paper,2/23/2021, single blinding,2/10/2020,Multicenter,Mixed,"New Coronavirus (2019-nCoV) Emergency Project of Sichuan University and the Novel Coronavirus Pneumonia Epidemic Research Project in West China Hospital, Sichuan University. Sichuan Huiyang Life Science & Technology Corp",Moderate/Severe,China,Treatment,rSIFN-co,48,46,0,*,28,Improvement of two points on a seven-category ordinal scale,43,*,28,0,*,28,13,0,*,28,Some concerns,blinded,Industry_Mixed,96,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
97_pub,97,2,ChiCTR2000029638,Yes,https://www.tandfonline.com/doi/full/10.1080/07853890.2021.1890329,*,Li C,Ann Med,2021,published paper,2/23/2021, single blinding,2/10/2020,Multicenter,Mixed,"New Coronavirus (2019-nCoV) Emergency Project of Sichuan University and the Novel Coronavirus Pneumonia Epidemic Research Project in West China Hospital, Sichuan University. Sichuan Huiyang Life Science & Technology Corp",Moderate/Severe,China,Control,IFN alpha,48,48,0,*,28,Improvement of two points on a seven-category ordinal scale,37,*,28,1,*,28,18,1,*,28,Some concerns,blinded,Industry_Mixed,96,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
99_preprint,99,2,RPCEC00000317,Yes,https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v1,*,Cruz LR,medRxiv,2020,preprint,9/15/2020,Unblinded,6/1/2020,Single,Public/non profit,British Embassy in Cuba (FCDO); Center for Genetic Engineering and Biotechnology (CIGB); Ministry of Public Health.,Mild to severe,Cuba,Treatment,CIGB-325,10,10,*,*,*,*,4,*,*,*,*,*,*,0,*,*,Some concerns,unblinded,Other,20,LIC_MIC,,,N,,,N,,,,,,,consistent
99_preprint,99,2,RPCEC00000317,Yes,https://www.medrxiv.org/content/10.1101/2020.09.03.20187112v1,*,Cruz LR,medRxiv,2020,preprint,9/15/2020,Unblinded,6/1/2020,Single,Public/non profit,British Embassy in Cuba (FCDO); Center for Genetic Engineering and Biotechnology (CIGB); Ministry of Public Health.,Mild to severe,Cuba,Control,Standard care,10,10,*,*,*,*,1,*,*,*,*,*,*,0,*,*,Some concerns,unblinded,Other,20,LIC_MIC,,,N,,,N,,,,,,,consistent
99_pub,99,1,RPCEC00000317,Yes,https://bit.ly/3h0Qgo7,ATENEA-Co-300 ,Cruz LR,ACS Pharmacol Trans,2020,published paper,12/11/2020,Unblinded,6/1/2020,Single,Public/non profit,British Embassy in Cuba (FCDO); Center for Genetic Engineering and Biotechnology (CIGB); Ministry of Public Health.,Mild to severe,Cuba,Treatment,CIGB-325,10,10,*,*,*,Improve in clinical status (asymptomatic. mild. moderate. or severe disease) ,4,*,6,*,*,*,*,0,*,*,Some concerns,unblinded,Other,20,LIC_MIC,,,N,,,N,,,,,,,consistent
99_pub,99,2,RPCEC00000317,Yes,https://bit.ly/3h0Qgo7,ATENEA-Co-300 ,Cruz LR,ACS Pharmacol Trans,2020,published paper,12/11/2020,Unblinded,6/1/2020,Single,Public/non profit,British Embassy in Cuba (FCDO); Center for Genetic Engineering and Biotechnology (CIGB); Ministry of Public Health.,Mild to severe,Cuba,Control,Standard care,10,10,*,*,*,Improve in clinical status (asymptomatic. mild. moderate. or severe disease) ,1,*,6,*,*,*,*,0,*,*,Some concerns,unblinded,Other,20,LIC_MIC,,,N,,,N,,,,,,,consistent
102_preprint,102,2,NCT04375098,Yes,https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1,*,Balcells M,medRxiv,2020,preprint,9/18/2020,Unblinded,5/10/2020,Single,Mixed,"Fondo de AdopciÃ³n TecnolÃ³gica SiEmpre, SOFOFA Hub, and Ministerio de Ciencia, TecnologÃ­a, Conocimiento e InnovaciÃ³n, Chile",Moderate/Severe,Chile,Treatment,Early CP,28,28,5,*,*,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Industry_Mixed,58,HIC,,N,Y,Y,Y,Y,Y,,,,,,consistent
102_preprint,102,2,NCT04375098,Yes,https://www.medrxiv.org/content/10.1101/2020.09.17.20196212v1,*,Balcells M,medRxiv,2020,preprint,9/18/2020,Unblinded,5/10/2020,Single,Mixed,"Fondo de AdopciÃ³n TecnolÃ³gica SiEmpre, SOFOFA Hub, and Ministerio de Ciencia, TecnologÃ­a, Conocimiento e InnovaciÃ³n, Chile",Moderate/Severe,Chile,Control,Late CP,30,30,2,*,*,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Industry_Mixed,58,HIC,,N,Y,Y,Y,Y,Y,,,,,,consistent
102_pub,102,1,NCT04375098,Yes,https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003415#sec026,*,Balcells M,PLoS Med,2021,published paper,3/3/2021,Unblinded,5/10/2020,Single,Mixed,"Fondo de Adopci��n Tecnol��gica SiEmpre, SOFOFA Hub, and Ministerio de Ciencia, Tecnolog��a, Conocimiento e Innovaci��n, Chile",Moderate/Severe,Chile,Treatment,Early CP,28,28,5,*,30,"Discharge from the
hospital",*,*,28,*,*,28,*,*,*,42,High,unblinded,Industry_Mixed,58,HIC,,N,Y,Y,Y,Y,Y,,,,,,consistent
102_pub,102,2,NCT04375098,Yes,https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003415#sec026,*,Balcells M,PLoS Med,2021,published paper,3/3/2021,Unblinded,5/10/2020,Single,Mixed,"Fondo de Adopci��n Tecnol��gica SiEmpre, SOFOFA Hub, and Ministerio de Ciencia, Tecnolog��a, Conocimiento e Innovaci��n, Chile",Moderate/Severe,Chile,Control,Late CP,30,30,2,*,30,"Discharge from the
hospital",*,*,28,*,*,28,*,*,*,42,High,unblinded,Industry_Mixed,58,HIC,,N,Y,Y,Y,Y,Y,,,,,,consistent
109_preprint,109,2,ISRCTN83971151; NCT0,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Gilead Sciences (drug donation),Mild to critical,Multinational (30),Treatment,Remdesivir,2750,2743,301,*,*,*,*,*,*,301,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,5475,Mixed,,N,,,,,,,,,,,add_delete
109_preprint,109,2,ISRCTN83971151; NCT0,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Gilead Sciences (drug donation),Mild to critical,Multinational (30),Control,Standard care,2725,2708,303,*,*,*,*,*,*,303,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,5475,Mixed,,N,,,,,,,,,,,add_delete
109_pub,109,1,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (RDV),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Gilead Sciences (drug donation),Mild to critical,Multinational (30),Treatment,Remdesivir,2750,2743,301,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,5475,Mixed,,N,,,,,,,,,,,add_delete
109_pub,109,2,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (RDV),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Gilead Sciences (drug donation),Mild to critical,Multinational (30),Control,Standard care,2725,2708,303,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,5475,Mixed,,N,,,,,,,,,,,add_delete
110_preprint,110,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Merck KGaA and Faron (drug donation),Mild to critical,Multinational (30),Treatment,IFN beta-1a,2063,2050,243,*,*,*,*,*,*,243,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,4127,Mixed,,N,,,,,,,,,,,add_delete
110_preprint,110,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Merck KGaA and Faron (drug donation),Mild to critical,Multinational (30),Control,Standard care,2064,2050,216,*,*,*,*,*,*,216,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,4127,Mixed,,N,,,,,,,,,,,add_delete
110_pub,110,1,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (IFN),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Merck KGaA and Faron (drug donation),Mild to critical,Multinational (30),Treatment,IFN beta-1a,2063,2050,243,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,4127,Mixed,,N,,,,,,,,,,,add_delete
110_pub,110,2,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (IFN),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Merck KGaA and Faron (drug donation),Mild to critical,Multinational (30),Control,Standard care,2064,2050,216,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,4127,Mixed,,N,,,,,,,,,,,add_delete
111_preprint,111,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,"World Health Organization; Abbvie, Cipla and Mylan (drug donation)",Mild to critical,Multinational (30),Treatment,Lopinavir-Ritonavir,1411,1399,148,*,*,*,*,*,*,148,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,2791,Mixed,,N,,,,,,,,,,,add_delete
111_preprint,111,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,"World Health Organization; Abbvie, Cipla and Mylan (drug donation)",Mild to critical,Multinational (30),Control,Standard care,1380,1372,146,*,*,*,*,*,*,146,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,2791,Mixed,,N,,,,,,,,,,,add_delete
111_pub,111,1,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (LPV/r),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,"World Health Organization; Abbvie, Cipla and Mylan (drug donation)",Mild to critical,Multinational (30),Treatment,Lopinavir-Ritonavir,1411,1399,148,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,2791,Mixed,,N,,,,,,,,,,,add_delete
111_pub,111,2,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (LPV/r),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,"World Health Organization; Abbvie, Cipla and Mylan (drug donation)",Mild to critical,Multinational (30),Control,Standard care,1380,1372,146,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,2791,Mixed,,N,,,,,,,,,,,add_delete
112_preprint,112,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Mylan (drug donation),Mild to critical,Multinational (30),Treatment,Hydroxychloroquine,954,947,104,*,*,*,*,*,*,104,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,1863,Mixed,,N,,,,,,,,,,,add_delete
112_preprint,112,2,ISRCTN83971151,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1,*,Pan H,medRxiv,2020,preprint,10/15/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Mylan (drug donation),Mild to critical,Multinational (30),Control,Standard care,909,906,84,*,*,*,*,*,*,84,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,1863,Mixed,,N,,,,,,,,,,,add_delete
112_pub,112,1,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (HCQ),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Mylan (drug donation),Mild to critical,Multinational (30),Treatment,Hydroxychloroquine,954,947,104,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,1863,Mixed,,N,,,,,,,,,,,add_delete
112_pub,112,2,ISRCTN83971151; NCT04315948,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2023184,SOLIDARITY (HCQ),Pan H,N Engl J Med,2020,published paper,11/2/2020,Unblinded,3/22/2020,Multicenter,Mixed,World Health Organization; Mylan (drug donation),Mild to critical,Multinational (30),Control,Standard care,909,906,84,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Industry_Mixed,1863,Mixed,,N,,,,,,,,,,,add_delete
115_preprint,115,2,NCT04573153,No,https://www.medrxiv.org/content/10.1101/2020.10.02.20202614v1,*,Altay O,medRxiv,2020,preprint,10/5/2020,Unblinded,7/15/2020,Single,Private,"This work was supported by Knut and Alice Wallenberg Foundation. ChromaDex (Irvine, CA, USA) for providing NR (nicotinamide riboside).",Mild,Turkey,Treatment,CMCS,71,71,*,*,*,*,*,*,*,*,*,*,2,0,*,*,Some concerns,unblinded,Industry_Mixed,93,LIC_MIC,,,,,N,N,,,,,,,consistent
115_preprint,115,2,NCT04573153,No,https://www.medrxiv.org/content/10.1101/2020.10.02.20202614v1,*,Altay O,medRxiv,2020,preprint,10/5/2020,Unblinded,7/15/2020,Single,Private,"This work was supported by Knut and Alice Wallenberg Foundation. ChromaDex (Irvine, CA, USA) for providing NR (nicotinamide riboside).",Mild,Turkey,Control,Placebo,22,22,*,*,*,*,*,*,*,*,*,*,0,0,*,*,Some concerns,unblinded,Industry_Mixed,93,LIC_MIC,,,,,N,N,,,,,,,consistent
115_pub,115,1,NCT04573153,No,https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222,*,Altay O,Adv Sci,2021,published paper,6/28/2021,Unblinded,7/15/2020,Single,Private,"ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation; The Plasma
Profiling Facility team at SciLifeLab; Metabolon Inc.; ChromaDex (nicotinamide riboside provision)",Outpatients,Turkey,Treatment,CMCS,71,71,*,*,*,*,*,*,*,*,*,*,2,0,*,*,Some concerns,unblinded,Industry_Mixed,93,LIC_MIC,,,,,N,N,,,,,,,consistent
115_pub,115,2,NCT04573153,No,https://onlinelibrary.wiley.com/doi/10.1002/advs.202101222,*,Altay O,Adv Sci,2021,published paper,6/28/2021,Unblinded,7/15/2020,Single,Private,"ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation; The Plasma
Profiling Facility team at SciLifeLab; Metabolon Inc.; ChromaDex (nicotinamide riboside provision)",Outpatients,Turkey,Control,Placebo,22,22,*,*,*,*,*,*,*,*,*,*,0,0,*,*,Some concerns,unblinded,Industry_Mixed,93,LIC_MIC,,,,,N,N,,,,,,,consistent
122_preprint,122,2,NCT04325893,Yes,https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1.full.pdf,*,DubÃ©e V,medRxiv,2020,preprint,10/21/2020, double blinding,4/1/2020,Multicenter,Public/non profit,"French Ministry of Health, Pays de la Loire region, Angers Loire Metropole conurbation",Mild/Moderate,"France, Monaco",Treatment,Hydroxychloroquine,125,124,6,*,28,Decrease of at least one point on the ordinal scale - WHO 8-point Ordinal Scale for Clinical Improvement (OSCI),98,*,28,9,*,28,70,3,124,28,Some concerns,blinded,Other,250,HIC,,N,N,N,N,N,,,,,,,consistent
122_preprint,122,2,NCT04325893,Yes,https://www.medrxiv.org/content/10.1101/2020.10.19.20214940v1.full.pdf,*,DubÃ©e V,medRxiv,2020,preprint,10/21/2020, double blinding,4/1/2020,Multicenter,Public/non profit,"French Ministry of Health, Pays de la Loire region, Angers Loire Metropole conurbation",Mild/Moderate,"France, Monaco",Control,Placebo,125,123,11,*,28,Decrease of at least one point on the ordinal scale - WHO 8-point Ordinal Scale for Clinical Improvement (OSCI),93,*,28,12,*,28,61,4,120,28,Some concerns,blinded,Other,250,HIC,,N,N,N,N,N,,,,,,,consistent
122_pub,122,1,NCT04325893,Yes,https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2821%2900140-3,*,Dubee V,Clin Microbiol Infec,2021,published paper,4/1/2021,"Participants, outcome assessor and health care pro",4/1/2020,Multicenter,Public/non profit,"French Ministry of Health, Pays de la Loire region, Angers Loire Metropole conurbation",Mild/Moderate,"France, Monaco",Treatment,Hydroxychloroquine,125,124,6,*,28,Decrease of at least one point on the ordinal scale - WHO 8-point Ordinal Scale for Clinical Improvement (OSCI),98,*,28,9,*,28,70,3,124,28,Some concerns,blinded,Other,250,HIC,,N,N,N,N,N,,,,,,,consistent
122_pub,122,2,NCT04325893,Yes,https://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2821%2900140-3,*,Dubee V,Clin Microbiol Infec,2021,published paper,4/1/2021,"Participants, outcome assessor and health care pro",4/1/2020,Multicenter,Public/non profit,"French Ministry of Health, Pays de la Loire region, Angers Loire Metropole conurbation",Mild/Moderate,"France, Monaco",Control,Placebo,125,123,11,*,28,Decrease of at least one point on the ordinal scale - WHO 8-point Ordinal Scale for Clinical Improvement (OSCI),93,*,28,12,*,28,61,4,120,28,Some concerns,blinded,Other,250,HIC,,N,N,N,N,N,,,,,,,consistent
127_preprint,127,2,NCT04372186,Yes,https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1.full.pdf,*,Salama C,medRxiv,2020,preprint,10/23/2020, double blinding,5/14/2020,Multicenter,Private,"Genentech, Inc.",Severe,Multinational,Treatment,Tocilizumab,259,249,26,*,28,time to a â‰¥2 category improvement in clinical status relative to baseline on a 7-category ordinal scale,*,*,*,*,*,*,127,38,250,60,Some concerns,blinded,Industry_Mixed,388,Mixed,,N,Y,,N,N,Y,,,,,,consistent
127_preprint,127,2,NCT04372186,Yes,https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1.full.pdf,*,Salama C,medRxiv,2020,preprint,10/23/2020, double blinding,5/14/2020,Multicenter,Private,"Genentech, Inc.",Severe,Multinational,Control,Placebo,129,128,11,*,28,time to a â‰¥2 category improvement in clinical status relative to baseline on a 7-category ordinal scale,*,*,*,*,*,*,67,25,127,60,Some concerns,blinded,Industry_Mixed,388,Mixed,,N,Y,,N,N,Y,,,,,,consistent
127_pub,127,1,NCT04372186,Yes,https://www.nejm.org/doi/full/10.1056/NEJMoa2030340 https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1.full.pdf,EMPACTA,Salama C,N Engl J Med,2020,published paper,12/17/2020, double blinding,5/14/2020,Multicenter,Private,"Genentech, Inc.",Mild to severe,"Brazil, Kenya, Mexico, Peru, South Africa, USA",Treatment,Tocilizumab,259,249,26,*,28,"At least a two-category improvement in
clinical status relative to baseline on the seven-category
ordinal scale (for patients in category 2
at baseline. those with a clinical status of category
1 were considered to have met the threshold)",*,*,28,*,*,*,127,38,250,60,Some concerns,blinded,Industry_Mixed,388,Mixed,,N,Y,,N,N,Y,,,,,,consistent
127_pub,127,2,NCT04372186,Yes,https://www.nejm.org/doi/full/10.1056/NEJMoa2030340 https://www.medrxiv.org/content/10.1101/2020.10.21.20210203v1.full.pdf,EMPACTA,Salama C,N Engl J Med,2020,published paper,12/17/2020, double blinding,5/14/2020,Multicenter,Private,"Genentech, Inc.",Mild to severe,"Brazil, Kenya, Mexico, Peru, South Africa, USA",Control,Placebo,129,128,11,*,28,"At least a two-category improvement in
clinical status relative to baseline on the seven-category
ordinal scale (for patients in category 2
at baseline. those with a clinical status of category
1 were considered to have met the threshold)",*,*,28,*,*,*,67,25,127,60,Some concerns,blinded,Industry_Mixed,388,Mixed,,N,Y,,N,N,Y,,,,,,consistent
128_preprint,128,2,NCT04288102,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2.full.pdf,*,Shi L,medRxiv,2020,preprint,10/20/2020, double blinding,3/5/2020,Multicenter,Public/non profit,The National Key R&D Program of China; The Innovation Groups of the National Natural Science Foundation of China; The National Science and Technology Major Project,Severe,China,Treatment,hUC-MSC,66,65,0,*,28,Six-category scale at day 10: Not hospitalized,11,*,10,0,*,10,36,1,*,*,Some concerns,blinded,Other,101,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
128_preprint,128,2,NCT04288102,Yes,https://www.medrxiv.org/content/10.1101/2020.10.15.20213553v2.full.pdf,*,Shi L,medRxiv,2020,preprint,10/20/2020, double blinding,3/5/2020,Multicenter,Public/non profit,The National Key R&D Program of China; The Innovation Groups of the National Natural Science Foundation of China; The National Science and Technology Major Project,Severe,China,Control,Placebo,35,35,0,*,28,Six-category scale at day 10: Not hospitalized,6,*,10,0,*,10,21,0,*,*,Some concerns,blinded,Other,101,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
128_pub,128,1,NCT04288102,Yes,https://www.nature.com/articles/s41392-021-00488-5.pdf,*,Shi L,Signal Transduction ,2021,published paper,2/10/2021,Participants and outcome assessor,3/5/2020,Multicenter,Public/non profit,The National Key R&D Program of China; The Innovation Groups of the National Natural Science Foundation of China; The National Science and Technology Major Project,Severe,China,Treatment,hUC-MSC,66,65,0,*,28,Six-category scale at day 10: Not hospitalized,11,*,10,0,*,10,36,1,*,*,Some concerns,blinded,Other,101,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
128_pub,128,2,NCT04288102,Yes,https://www.nature.com/articles/s41392-021-00488-5.pdf,*,Shi L,Signal Transduction ,2021,published paper,2/10/2021,Participants and outcome assessor,3/5/2020,Multicenter,Public/non profit,The National Key R&D Program of China; The Innovation Groups of the National Natural Science Foundation of China; The National Science and Technology Major Project,Severe,China,Control,Placebo,35,35,0,*,28,Six-category scale at day 10: Not hospitalized,6,*,10,0,*,10,21,0,*,*,Some concerns,blinded,Other,101,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
129_preprint,129,2,NCT04552483 ; RBR-4n,No,https://www.medrxiv.org/content/10.1101/2020.10.21.20217208v1.full.pdf,*,Rocco PRM,medRxiv,2020,preprint,10/23/2020, double blinding,6/8/2020,Multicenter,Mixed,"Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, and Funding Authority for Studies and Projects, Brasil",Mild,Brazil,Treatment,Nitazoxanide ,238,194,*,*,*,*,*,*,*,*,*,*,60,0,*,*,Some concerns,blinded,Industry_Mixed,475,LIC_MIC,,N,Y,Y,N,N,Y,,,,,,add_delete
129_preprint,129,2,NCT04552483 ; RBR-4n,No,https://www.medrxiv.org/content/10.1101/2020.10.21.20217208v1.full.pdf,*,Rocco PRM,medRxiv,2020,preprint,10/23/2020, double blinding,6/8/2020,Multicenter,Mixed,"Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, and Funding Authority for Studies and Projects, Brasil",Mild,Brazil,Control,Placebo,237,198,*,*,*,*,*,*,*,*,*,*,60,0,*,*,Some concerns,blinded,Industry_Mixed,475,LIC_MIC,,N,Y,Y,N,N,Y,,,,,,add_delete
129_pub,129,1,NCT04552483,No,https://erj.ersjournals.com/content/erj/early/2020/12/17/13993003.03725-2020.full.pdf,*,Rocco PRM,Eur Respir J,2020,published paper,12/24/2020,Participants and outcome assessor,6/8/2020,Multicenter,Mixed,"Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, and Funding Authority for Studies and Projects, Brasil",Outpatients,Brazil,Treatment,Nitazoxanide ,238,194,0,*,14,*,*,*,5,*,*,5,60,0,*,14,Some concerns,blinded,Industry_Mixed,475,LIC_MIC,,N,Y,Y,N,N,Y,,,,,,add_delete
129_pub,129,2,NCT04552483,No,https://erj.ersjournals.com/content/erj/early/2020/12/17/13993003.03725-2020.full.pdf,*,Rocco PRM,Eur Respir J,2020,published paper,12/24/2020,Participants and outcome assessor,6/8/2020,Multicenter,Mixed,"Brazilian Council for Scientific and Technological Development (CNPq), Brazilian Ministry of Science, Technology, and Innovation for Virus Network; Brasilia, Brazil, and Funding Authority for Studies and Projects, Brasil",Outpatients,Brazil,Control,Placebo,237,198,0,*,14,*,*,*,5,*,*,5,60,0,*,14,Some concerns,blinded,Industry_Mixed,475,LIC_MIC,,N,Y,Y,N,N,Y,,,,,,add_delete
140_preprint,140,2,NCT04381884,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649,*,Krolewiecki A,SSRN,2020,preprint,11/11/2020,Unblinded,5/18/2020,Multicenter,Mixed,"Agencia Nacional de PromociÃ³n de la InvestigaciÃ³n, el Desarrollo TecnolÃ³gico y la InnovaciÃ³n, Argentina and Laboratorio ELEA/Phoenix, Argentina",Mild/Moderate,Argentina,Treatment,Ivermectin,30,30,0,*,*,*,*,*,*,1,*,*,13,1,*,*,Some concerns,unblinded,Industry_Mixed,45,LIC_MIC,,N,,N,N,N,,,,,,,consistent
140_preprint,140,2,NCT04381884,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649,*,Krolewiecki A,SSRN,2020,preprint,11/11/2020,Unblinded,5/18/2020,Multicenter,Mixed,"Agencia Nacional de PromociÃ³n de la InvestigaciÃ³n, el Desarrollo TecnolÃ³gico y la InnovaciÃ³n, Argentina and Laboratorio ELEA/Phoenix, Argentina",Mild/Moderate,Argentina,Control,Standard care,15,15,0,*,*,*,*,*,*,0,*,*,5,0,*,*,Some concerns,unblinded,Industry_Mixed,45,LIC_MIC,,N,,N,N,N,,,,,,,consistent
140_pub,140,1,NCT04381884,Yes,https://bit.ly/3iFdr7I https://bit.ly/2TGUok5,*,Krolewiecki A,EClinicalMedicine,2021,published paper,6/17/2021,Outcome assessor,5/18/2020,Multicenter,Mixed,"Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion, Argentina and Laboratorio ELEA/Phoenix, Argentina",Mild/Moderate,Argentina,Treatment,Ivermectin,30,30,0,*,30,*,*,*,*,1,*,7,13,1,*,30,Some concerns,blinded,Industry_Mixed,45,LIC_MIC,,N,,N,N,N,,,,,,,consistent
140_pub,140,2,NCT04381884,Yes,https://bit.ly/3iFdr7I https://bit.ly/2TGUok5,*,Krolewiecki A,EClinicalMedicine,2021,published paper,6/17/2021,Outcome assessor,5/18/2020,Multicenter,Mixed,"Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion, Argentina and Laboratorio ELEA/Phoenix, Argentina",Mild/Moderate,Argentina,Control,Standard care,15,15,0,*,30,*,*,*,*,0,*,7,5,0,*,30,Some concerns,blinded,Industry_Mixed,45,LIC_MIC,,N,,N,N,N,,,,,,,consistent
144_preprint,144,2,NCT04449718,No,https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1.full.pdf,*,Murai IH,medRxiv,2020,preprint,11/17/2020, double blinding,6/2/2020,Multicenter,Public/non profit,Sao Paulo Research Foundation (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,Mild to severe,Brazil,Treatment,Cholecalciferol ,120,120,8,*,*,*,*,*,*,*,*,*,1,*,*,*,Some concerns,blinded,Other,240,LIC_MIC,,N,,,N,,,,,,,,discrepTE
144_preprint,144,2,NCT04449718,No,https://www.medrxiv.org/content/10.1101/2020.11.16.20232397v1.full.pdf,*,Murai IH,medRxiv,2020,preprint,11/17/2020, double blinding,6/2/2020,Multicenter,Public/non profit,Sao Paulo Research Foundation (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,Mild to severe,Brazil,Control,Placebo,120,120,6,*,*,*,*,*,*,*,*,*,0,*,*,*,Some concerns,blinded,Other,240,LIC_MIC,,N,,,N,,,,,,,,discrepTE
144_pub,144,1,NCT04449718,No,https://jamanetwork.com/journals/jama/fullarticle/2776738,*,Murai IH,JAMA,2021,published paper,2/17/2021,"Double blinded, no restrictions",6/2/2020,Multicenter,Public/non profit,Sao Paulo Research Foundation (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,Mild to severe,Brazil,Treatment,Cholecalciferol ,120,119,9,*,40,Hospital Discharge,*,*,*,*,*,*,1,*,*,*,Some concerns,blinded,Other,240,LIC_MIC,,N,,,N,,,,,,,,discrepTE
144_pub,144,2,NCT04449718,No,https://jamanetwork.com/journals/jama/fullarticle/2776738,*,Murai IH,JAMA,2021,published paper,2/17/2021,"Double blinded, no restrictions",6/2/2020,Multicenter,Public/non profit,Sao Paulo Research Foundation (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,Mild to severe,Brazil,Control,Placebo,120,118,6,*,40,Hospital Discharge,*,*,*,*,*,*,0,*,*,*,Some concerns,blinded,Other,240,LIC_MIC,,N,,,N,,,,,,,,discrepTE
145_preprint,145,2,NCT04501783,No,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907,*,Ruzhentsova TA,SSRN,2020,preprint,10/26/2020,Unblinded,5/23/2020,Multicenter,Private,R-Pharm Group of Companies,Mild/Moderate,Russia,Treatment,Favipiravir,112,112,*,*,*,Reduction of patient clinical status on at least 1 score according to WHO 8-Category Ordinal Scale for Clinical Improvement compared to screening. ,96,*,28,*,*,*,80,2,108,28,Some concerns,unblinded,Industry_Mixed,168,LIC_MIC,,,N,,N,N,,,,,,,consistent
145_preprint,145,2,NCT04501783,No,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907,*,Ruzhentsova TA,SSRN,2020,preprint,10/26/2020,Unblinded,5/23/2020,Multicenter,Private,R-Pharm Group of Companies,Mild/Moderate,Russia,Control,Standard care,56,56,*,*,*,Reduction of patient clinical status on at least 1 score according to WHO 8-Category Ordinal Scale for Clinical Improvement compared to screening. ,44,*,28,*,*,*,33,0,55,28,Some concerns,unblinded,Industry_Mixed,168,LIC_MIC,,,N,,N,N,,,,,,,consistent
145_pub,145,1,NCT04501783,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661194/ https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907,*,Ruzhentsova TA,Am J Transl Res,2021,published paper,11/30/2021,Unblinded,5/23/2020,Multicenter,Private,R-Pharm Group of Companies,Mild/Moderate,Russia,Treatment,Favipiravir,112,112,*,*,*,Reduction of patient clinical status on at least 1 score according to WHO 8-Category Ordinal Scale for Clinical Improvement compared to screening. ,96,*,28,*,*,*,80,2,108,28,Some concerns,unblinded,Industry_Mixed,168,LIC_MIC,,,N,,N,N,,,,,,,consistent
145_pub,145,2,NCT04501783,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661194/ https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696907,*,Ruzhentsova TA,Am J Transl Res,2021,published paper,11/30/2021,Unblinded,5/23/2020,Multicenter,Private,R-Pharm Group of Companies,Mild/Moderate,Russia,Control,Standard care,56,56,*,*,*,Reduction of patient clinical status on at least 1 score according to WHO 8-Category Ordinal Scale for Clinical Improvement compared to screening. ,44,*,28,*,*,*,33,0,55,28,Some concerns,unblinded,Industry_Mixed,168,LIC_MIC,,,N,,N,N,,,,,,,consistent
147_preprint,147,2,NCT04356534,No,https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full.pdf,*,AlQahtani M,medRxiv,2020,preprint,11/4/2020,Unblinded,4/15/2020,Multicenter,Public/non profit,Ministry of Health Bahrain and the College of Surgeons in Ireland-Bahrain,Severe,Bahrain,Treatment,Convalescent plasma,20,20,1,*,*,Discharged alive,19,*,*,*,*,*,*,*,*, ,Some concerns,unblinded,Other,40,HIC,,N,N,,,,,,,,,,consistent
147_preprint,147,2,NCT04356534,No,https://www.medrxiv.org/content/10.1101/2020.11.02.20224303v1.full.pdf,*,AlQahtani M,medRxiv,2020,preprint,11/4/2020,Unblinded,4/15/2020,Multicenter,Public/non profit,Ministry of Health Bahrain and the College of Surgeons in Ireland-Bahrain,Severe,Bahrain,Control,Standard care,20,20,2,*,*,Discharged alive,18,*,*,*,*,*,*,*,*, ,Some concerns,unblinded,Other,40,HIC,,N,N,,,,,,,,,,consistent
147_pub,147,1,NCT04356534,No,https://www.nature.com/articles/s41598-021-89444-5,*,AlQahtani M,Sci Rep,2021,published paper,5/11/2021,Unblinded,4/19/2020,Multicenter,Public/non profit,Ministry of Health Bahrain and the College of Surgeons in Ireland-Bahrain,Severe,Bahrain,Treatment,Convalescent plasma,20,20,1,*,28,Discharged alive,19,*,28,*,*,*,*,*,*, ,Some concerns,unblinded,Other,40,HIC,,N,N,,,,,,,,,,consistent
147_pub,147,2,NCT04356534,No,https://www.nature.com/articles/s41598-021-89444-5,*,AlQahtani M,Sci Rep,2021,published paper,5/11/2021,Unblinded,4/19/2020,Multicenter,Public/non profit,Ministry of Health Bahrain and the College of Surgeons in Ireland-Bahrain,Severe,Bahrain,Control,Standard care,20,20,2,*,28,Discharged alive,18,*,28,*,*,*,*,*,*, ,Some concerns,unblinded,Other,40,HIC,,N,N,,,,,,,,,,consistent
149_preprint,149,2,NCT04331899,Yes,https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1.full.pdf,*,Jagannathan P,medRxiv,2020,preprint,11/23/2020, single blinding,4/25/2020,Single,Mixed,Anonymous donors to Stanford University; Eiger BioPharmaceuticals (drug),Mild,USA,Treatment,Peginterferon Lambda-1a,60,60,*,*,*,*,*,*,*,*,*,*,25,2,*,28,Some concerns,blinded,Industry_Mixed,120,HIC,,,,,N,N,,,,,,,consistent
149_preprint,149,2,NCT04331899,Yes,https://www.medrxiv.org/content/10.1101/2020.11.18.20234161v1.full.pdf,*,Jagannathan P,medRxiv,2020,preprint,11/23/2020, single blinding,4/25/2020,Single,Mixed,Anonymous donors to Stanford University; Eiger BioPharmaceuticals (drug),Mild,USA,Control,Placebo,60,60,*,*,*,*,*,*,*,*,*,*,21,2,*,28,Some concerns,blinded,Industry_Mixed,120,HIC,,,,,N,N,,,,,,,consistent
149_pub,149,1,NCT04331899,Yes,https://www.nature.com/articles/s41467-021-22177-1.pdf,*,Jagannathan P,Nature,2021,published paper,3/30/2021,Participants and outcome assessor,4/25/2020,Single,Mixed,Anonymous donors to Stanford University; Eiger BioPharmaceuticals (drug),Outpatients,USA,Treatment,Peginterferon Lambda-1a,60,60,*,*,*,*,*,*,*,*,*,*,25,2,*,28,Some concerns,blinded,Industry_Mixed,120,HIC,,,,,N,N,,,,,,,consistent
149_pub,149,2,NCT04331899,Yes,https://www.nature.com/articles/s41467-021-22177-1.pdf,*,Jagannathan P,Nature,2021,published paper,3/30/2021,Participants and outcome assessor,4/25/2020,Single,Mixed,Anonymous donors to Stanford University; Eiger BioPharmaceuticals (drug),Outpatients,USA,Control,Placebo,60,60,*,*,*,*,*,*,*,*,*,*,21,2,*,28,Some concerns,blinded,Industry_Mixed,120,HIC,,,,,N,N,,,,,,,consistent
152_preprint,152,2,NCT04479163; PAEPCC1,No,https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1.full.pdf,*,Libster R,medRxiv,2020,preprint,11/21/2020, double blinding,6/4/2020,Multicenter,Public/non profit,The Bill & Melinda Gates Foundation; The Fundacion INFANT Pandemic Fund,Mild,Argentina,Treatment,Convalescent plasma,80,80,*,*,*,*,*,*,*,*,*,*,0,0,*,25,Some concerns,blinded,Other,160,LIC_MIC,,Y,,Y,N,N,,,,,,,consistent
152_preprint,152,2,NCT04479163; PAEPCC1,No,https://www.medrxiv.org/content/10.1101/2020.11.20.20234013v1.full.pdf,*,Libster R,medRxiv,2020,preprint,11/21/2020, double blinding,6/4/2020,Multicenter,Public/non profit,The Bill & Melinda Gates Foundation; The Fundacion INFANT Pandemic Fund,Mild,Argentina,Control,Placebo,80,80,*,*,*,*,*,*,*,*,*,*,0,0,*,25,Some concerns,blinded,Other,160,LIC_MIC,,Y,,Y,N,N,,,,,,,consistent
152_pub,152,1,NCT04479163,No,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033700?articleTools=true,*,Libster R,N Engl J Med,2021,published paper,1/6/2021, double blinding,6/4/2020,Multicenter,Public/non profit,The Bill & Melinda Gates Foundation; The Fundacion INFANT Pandemic Fund,Mild,Argentina,Treatment,Convalescent plasma,80,80,*,*,25,*,*,*,*,*,*,25,0,0,*,25,Some concerns,blinded,Other,160,LIC_MIC,,Y,,Y,N,N,,,,,,,consistent
152_pub,152,2,NCT04479163,No,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033700?articleTools=true,*,Libster R,N Engl J Med,2021,published paper,1/6/2021, double blinding,6/4/2020,Multicenter,Public/non profit,The Bill & Melinda Gates Foundation; The Fundacion INFANT Pandemic Fund,Mild,Argentina,Control,Placebo,80,80,*,*,25,*,*,*,*,*,*,25,0,0,*,25,Some concerns,blinded,Other,160,LIC_MIC,,Y,,Y,N,N,,,,,,,consistent
156_preprint,156,2,CTRI/2020/05/025209,Yes,https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1.full.pdf,*,Ray Y,medRxiv,2020,preprint,11/29/2020,Unblinded,5/31/2020,Single,Public/non profit,"Council of Scientific Industrial Research (CSIR), Govt. of India and Fondation Botnar",Severe,India,Treatment,Convalescent plasma,40,40,10,*,30,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Other,80,LIC_MIC,,,,,,,,,,,,,consistent
156_preprint,156,2,CTRI/2020/05/025209,Yes,https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1.full.pdf,*,Ray Y,medRxiv,2020,preprint,11/29/2020,Unblinded,5/31/2020,Single,Public/non profit,"Council of Scientific Industrial Research (CSIR), Govt. of India and Fondation Botnar",Severe,India,Control,Standard care,40,40,14,*,30,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Other,80,LIC_MIC,,,,,,,,,,,,,consistent
156_pub,156,1,CTRI/2020/05/025209,Yes,https://www.nature.com/articles/s41467-022-28064-7#Sec23 https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1.full.pdf,*,Ray Y,Nat Commun,2022,published paper,1/19/2022,Unblinded,5/31/2020,Single,Public/non profit,"Council of Scientific Industrial Research (CSIR), Govt. of India and Fondation Botnar",Severe,India,Treatment,Convalescent plasma,40,40,10,*,30,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Other,80,LIC_MIC,,,,,,,,,,,,,consistent
156_pub,156,1,CTRI/2020/05/025209,Yes,https://www.nature.com/articles/s41467-022-28064-7#Sec23 https://www.medrxiv.org/content/10.1101/2020.11.25.20237883v1.full.pdf,*,Ray Y,Nat Commun,2022,published paper,1/19/2022,Unblinded,5/31/2020,Single,Public/non profit,"Council of Scientific Industrial Research (CSIR), Govt. of India and Fondation Botnar",Severe,India,Control,Standard care,40,40,14,*,30,*,*,*,*,*,*,*,*,*,*,*,High,unblinded,Other,80,LIC_MIC,,,,,,,,,,,,,consistent
159_preprint,159,2,NCT04512027; CTRI/20,Yes,https://www.medrxiv.org/content/10.1101/2020.12.03.20238840v2.full.pdf,*,Sigamani A,medRxiv,2020,preprint,12/4/2020,Unblinded,9/15/2020,Single,Private,Pharmalectin Inc contracted the trial to a Contract Research Organisation â€“ CIMED Life Sciences,Mild,India,Treatment,Prolectin-M,5,5,*,*,*,Discharge (not hospitalized: score 1 or 2 on 7-point ordinal scale),5,*,28,*,*,*,1,0,*,28,Some concerns,unblinded,Industry_Mixed,10,LIC_MIC,,N,N,,N,N,,,,,,,consistent
159_preprint,159,2,NCT04512027; CTRI/20,Yes,https://www.medrxiv.org/content/10.1101/2020.12.03.20238840v2.full.pdf,*,Sigamani A,medRxiv,2020,preprint,12/4/2020,Unblinded,9/15/2020,Single,Private,Pharmalectin Inc contracted the trial to a Contract Research Organisation â€“ CIMED Life Sciences,Mild,India,Control,Standard care,5,5,*,*,*,Discharge (not hospitalized: score 1 or 2 on 7-point ordinal scale),5,*,28,*,*,*,0,0,*,28,Some concerns,unblinded,Industry_Mixed,10,LIC_MIC,,N,N,,N,N,,,,,,,consistent
159_pub,159,1,NCT04512027; CTRI/2020/09/027833,Yes,https://www.longdom.org/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial.pdf,*,Sigamani A,J Vaccines Vaccin,2020,published paper,12/30/2020,Unblinded,9/15/2020,Single,Private,Pharmalectin Inc contracted the trial to a Contract Research Organisation ��� CIMED Life Sciences,Mild,India,Treatment,Prolectin-M,5,5,*,*,*,Discharge (not hospitalized: score 1 or 2 on 7-point ordinal scale),5,*,28,*,*,*,1,0,*,28,Some concerns,unblinded,Industry_Mixed,10,LIC_MIC,,N,N,,N,N,,,,,,,consistent
159_pub,159,2,NCT04512027; CTRI/2020/09/027833,Yes,https://www.longdom.org/open-access/galectin-antagonist-use-in-mild-cases-of-sarscov2-pilot-feasibility-randomised-open-label-controlled-trial.pdf,*,Sigamani A,J Vaccines Vaccin,2020,published paper,12/30/2020,Unblinded,9/15/2020,Single,Private,Pharmalectin Inc contracted the trial to a Contract Research Organisation ��� CIMED Life Sciences,Mild,India,Control,Standard care,5,5,*,*,*,Discharge (not hospitalized: score 1 or 2 on 7-point ordinal scale),5,*,28,*,*,*,0,0,*,28,Some concerns,unblinded,Industry_Mixed,10,LIC_MIC,,N,N,,N,N,,,,,,,consistent
160_preprint,160,2,NCT04390022,Yes,https://assets.researchsquare.com/files/rs-116547/v1/362c43d8-cfa9-463c-b0d3-1da8a1c48676.pdf,SAINT,Chaccour C,Research square ,2020,preprint,12/7/2020, double blinding,7/31/2020,Single,Mixed,ISGlobal; University of Navarra. Unitaid; Spanish Ministry of Science and Innovation; Generalitat de Catalunya; Idipharma SL (placebo donation),Mild,Spain,Treatment,Ivermectin,12,12,*,*,*,*,*,*,*,*,*,*,5,*,*,28,Some concerns,blinded,Industry_Mixed,24,HIC,cannot find WHO7 data in pp nor pub,Y,,,N,Y,,,,,,,consistent
160_preprint,160,2,NCT04390022,Yes,https://assets.researchsquare.com/files/rs-116547/v1/362c43d8-cfa9-463c-b0d3-1da8a1c48676.pdf,SAINT,Chaccour C,Research square ,2020,preprint,12/7/2020, double blinding,7/31/2020,Single,Mixed,ISGlobal; University of Navarra. Unitaid; Spanish Ministry of Science and Innovation; Generalitat de Catalunya; Idipharma SL (placebo donation),Mild,Spain,Control,Placebo,12,12,*,*,*,*,*,*,*,*,*,*,5,*,*,28,Some concerns,blinded,Industry_Mixed,24,HIC,cannot find WHO7 data in pp nor pub,Y,,,N,Y,,,,,,,consistent
160_pub,160,1,NCT04390022,Yes,https://www.thelancet.com/action/showPdf?pii=S2589-5370%2820%2930464-8,SAINT,Chaccour C,EClinicalMedicine,2021,published paper,1/19/2021,Participants and outcome assessor,7/31/2020,Single,Mixed,ISGlobal; University of Navarra. Unitaid; Spanish Ministry of Science and Innovation; Generalitat de Catalunya; Idipharma SL (placebo donation),Outpatients,Spain,Treatment,Ivermectin,12,12,*,*,28,*,*,*,*,*,*,28,5,*,*,28,Some concerns,blinded,Industry_Mixed,24,HIC,cannot find WHO7 data in pp nor pub,Y,,,N,Y,,,,,,,consistent
160_pub,160,2,NCT04390022,Yes,https://www.thelancet.com/action/showPdf?pii=S2589-5370%2820%2930464-8,SAINT,Chaccour C,EClinicalMedicine,2021,published paper,1/19/2021,Participants and outcome assessor,7/31/2020,Single,Mixed,ISGlobal; University of Navarra. Unitaid; Spanish Ministry of Science and Innovation; Generalitat de Catalunya; Idipharma SL (placebo donation),Outpatients,Spain,Control,Placebo,12,12,*,*,28,*,*,*,*,*,*,28,5,*,*,28,Some concerns,blinded,Industry_Mixed,24,HIC,cannot find WHO7 data in pp nor pub,Y,,,N,Y,,,,,,,consistent
163_preprint,163,2,NCT04501978,Yes,https://www.medrxiv.org/content/10.1101/2021.07.19.21260559v1 https://www.nejm.org/doi/10.1056/NEJMoa2033130,ACTIV-3/TICO,Lundgren J,medRxiv,2021,preprint,7/22/2021, double blinding,8/5/2020,Multicenter,Mixed,"U.S. Operation Warp Speed; National Institute of Allergy & Infectious Diseases; Leidos Biomedical Research; National Heart, Lung & Blood Institute; Research Triangle Institute; U.S. Dept of Veterans Affairs; Denmark, Aus",Mild to severe,"Denmark, Singapore, USA",Treatment,LY-CoV555,169,163,*,*,28,Discharge alive from hospital,*,*,*,9,*,5,*,9,*,90,Some concerns,blinded,Industry_Mixed,326,HIC,,N,,N,,,,,,,,,consistent
163_preprint,163,2,NCT04501978,Yes,https://www.medrxiv.org/content/10.1101/2021.07.19.21260559v1 https://www.nejm.org/doi/10.1056/NEJMoa2033130,ACTIV-3/TICO,Lundgren J,medRxiv,2021,preprint,7/22/2021, double blinding,8/5/2020,Multicenter,Mixed,"U.S. Operation Warp Speed; National Institute of Allergy & Infectious Diseases; Leidos Biomedical Research; National Heart, Lung & Blood Institute; Research Triangle Institute; U.S. Dept of Veterans Affairs; Denmark, Aus",Mild to severe,"Denmark, Singapore, USA",Control,Placebo,157,151,*,*,28,Discharge alive from hospital,*,*,*,5,*,5,*,12,*,90,Some concerns,blinded,Industry_Mixed,326,HIC,,N,,N,,,,,,,,,consistent
163_pub,163,1,NCT04501978,Yes,https://www.acpjournals.org/doi/10.7326/M21-3507 https://www.medrxiv.org/content/10.1101/2021.07.19.21260559v1 https://www.nejm.org/doi/10.1056/NEJMoa2033130,ACTIV-3/TICO,Lundgren J,J Ann Intern Med,2021,published paper,12/21/2021,quadruple blinding,8/5/2020,Multicenter,Mixed,"U.S. Operation Warp Speed; National Institute of Allergy & Infectious Diseases; Leidos Biomedical Research; National Heart, Lung & Blood Institute; Research Triangle Institute; U.S. Dept of Veterans Affairs; Denmark, Aus",Mild to severe,"Denmark, Singapore, USA",Treatment,LY-CoV555,169,163,*,*,28,"defined as discharge to home and remaining home for 14 consecutive
days",*,*,*,9,*,5,*,9,*,90,Some concerns,blinded,Industry_Mixed,326,HIC,,N,,N,,,,,,,,,consistent
163_pub,163,2,NCT04501978,Yes,https://www.acpjournals.org/doi/10.7326/M21-3507 https://www.medrxiv.org/content/10.1101/2021.07.19.21260559v1 https://www.nejm.org/doi/10.1056/NEJMoa2033130,ACTIV-3/TICO,Lundgren J,J Ann Intern Med,2021,published paper,12/21/2021,quadruple blinding,8/5/2020,Multicenter,Mixed,"U.S. Operation Warp Speed; National Institute of Allergy & Infectious Diseases; Leidos Biomedical Research; National Heart, Lung & Blood Institute; Research Triangle Institute; U.S. Dept of Veterans Affairs; Denmark, Aus",Mild to severe,"Denmark, Singapore, USA",Control,Placebo,157,151,*,*,28,"defined as discharge to home and remaining home for 14 consecutive
days",*,*,*,5,*,5,*,12,*,90,Some concerns,blinded,Industry_Mixed,326,HIC,,N,,N,,,,,,,,,consistent
165_preprint,165,2,ISRCTN59048638,Yes,https://www.medrxiv.org/content/10.1101/2020.12.04.20242073v1.full.pdf,ERSul,Gonzalez-Ochoa AJ ,medRxiv,2020,preprint,12/7/2020, double blinding,6/5/2020,Single,Private,Study independently initiated by lead researcher; partially funded by Alfasigma Mexico.,Mild outpatients,Mexico,Treatment,Sulodexide,157,124,3,*,21,*,*,*,*,*,*,*,96,*,*,21,Some concerns,blinded,Industry_Mixed,312,LIC_MIC,,N,,,N,,,,,,,,consistent
165_preprint,165,2,ISRCTN59048638,Yes,https://www.medrxiv.org/content/10.1101/2020.12.04.20242073v1.full.pdf,ERSul,Gonzalez-Ochoa AJ ,medRxiv,2020,preprint,12/7/2020, double blinding,6/5/2020,Single,Private,Study independently initiated by lead researcher; partially funded by Alfasigma Mexico.,Mild outpatients,Mexico,Control,Placebo,155,119,7,*,21,*,*,*,*,*,*,*,85,*,*,21,Some concerns,blinded,Industry_Mixed,312,LIC_MIC,,N,,,N,,,,,,,,consistent
165_pub,165,1,ISRCTN59048638,Yes,https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1414-5216,ERSul,Gonzalez-Ochoa AJ ,Thromb Haemost,2021,published paper,3/7/2021,Participants and outcome assessor,6/5/2020,Single,Private,Study independently initiated by lead researcher; partially funded by Alfasigma Mexico.,Outpatients,Mexico,Treatment,Sulodexide,157,124,3,*,26,*,*,*,*,*,*,*,96,*,*,21,Some concerns,blinded,Industry_Mixed,312,LIC_MIC,,N,,,N,,,,,,,,consistent
165_pub,165,2,ISRCTN59048638,Yes,https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1414-5216,ERSul,Gonzalez-Ochoa AJ ,Thromb Haemost,2021,published paper,3/7/2021,Participants and outcome assessor,6/5/2020,Single,Private,Study independently initiated by lead researcher; partially funded by Alfasigma Mexico.,Outpatients,Mexico,Control,Placebo,155,119,7,*,26,*,*,*,*,*,*,*,85,*,*,21,Some concerns,blinded,Industry_Mixed,312,LIC_MIC,,N,,,N,,,,,,,,consistent
166_preprint,166,2,NCT04381936 ; ISRCTN,Yes,https://www.medrxiv.org/content/10.1101/2020.12.10.20245944v1,RECOVERY,Horby P,medRxiv,2020,preprint,12/14/2020,Unblinded,4/7/2020,Multicenter,Mixed,"UK Medical Research Council, National Institute for Health Research, Wellcome,â€¯Bill and Melinda Gates Foundation,â€¯Dept for Int'l Development,â€¯Health Data Research UK. Drugs were donated by Abbvie, Roche & Regeneron.",Mild to critical,UK,Treatment,Azithromycin,2582,2582,496,*,*,Discharged alive from hospital within 28 days,1554,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,7764,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
166_preprint,166,2,NCT04381936 ; ISRCTN,Yes,https://www.medrxiv.org/content/10.1101/2020.12.10.20245944v1,RECOVERY,Horby P,medRxiv,2020,preprint,12/14/2020,Unblinded,4/7/2020,Multicenter,Mixed,"UK Medical Research Council, National Institute for Health Research, Wellcome,â€¯Bill and Melinda Gates Foundation,â€¯Dept for Int'l Development,â€¯Health Data Research UK. Drugs were donated by Abbvie, Roche & Regeneron.",Mild to critical,UK,Control,Standard care,5182,5182,997,*,*,Discharged alive from hospital within 28 days,3066,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,7764,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
166_pub,166,1,NCT04381936 ; ISRCTN (50189673),Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900149-5,RECOVERY (AZM),Horby P,Lancet,2021,published paper,2/2/2021,Unblinded,4/7/2020,Multicenter,Mixed,"UK Medical Research Council, National Institute for Health Research, Wellcome,���Bill and Melinda Gates Foundation,���Dept for Int'l Development,���Health Data Research UK. Drugs were donated by Abbvie, Roche & Regeneron.",Mild to critical,UK,Treatment,Azithromycin,2582,2582,561,*,28,Discharged alive from hospital within 28 days,1788,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,7763,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
166_pub,166,2,NCT04381936 ; ISRCTN (50189673),Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900149-5,RECOVERY (AZM),Horby P,Lancet,2021,published paper,2/2/2021,Unblinded,4/7/2020,Multicenter,Mixed,"UK Medical Research Council, National Institute for Health Research, Wellcome,���Bill and Melinda Gates Foundation,���Dept for Int'l Development,���Health Data Research UK. Drugs were donated by Abbvie, Roche & Regeneron.",Mild to critical,UK,Control,Standard care,5181,5181,1162,*,28,Discharged alive from hospital within 28 days,3525,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,7763,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
169_preprint,169,2,CTRI/2020/05/024959,Yes,https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.full.pdf,*,Kumar S,medRxiv,2020,preprint,12/2/2020,Unblinded,5/2/2020,Multicenter,Private,Biocon Biologics India Limited,Severe,India,Treatment,Itolizumab,22,20,0,*,30,Discharged,16,*,*,0,*,*,18,2,*,30,Some concerns,unblinded,Industry_Mixed,32,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
169_preprint,169,2,CTRI/2020/05/024959,Yes,https://www.medrxiv.org/content/10.1101/2020.12.01.20239574v1.full.pdf,*,Kumar S,medRxiv,2020,preprint,12/2/2020,Unblinded,5/2/2020,Multicenter,Private,Biocon Biologics India Limited,Severe,India,Control,Standard care,10,10,3,*,30,Discharged,6,*,*,3,*,*,4,3,*,30,Some concerns,unblinded,Industry_Mixed,32,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
169_pub,169,1,CTRI/2020/05/024959,Yes,https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1905794?needAccess=true,*,Kumar S,Exp Opin Biol Ther,2021,published paper,4/9/2021,Unblinded,5/2/2020,Multicenter,Private,Biocon Biologics India Limited,Severe,India,Treatment,Itolizumab,22,20,0,*,30,Discharged,16,*,*,0,*,30,18,2,*,30,Some concerns,unblinded,Industry_Mixed,32,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
169_pub,169,2,CTRI/2020/05/024959,Yes,https://www.tandfonline.com/doi/pdf/10.1080/14712598.2021.1905794?needAccess=true,*,Kumar S,Exp Opin Biol Ther,2021,published paper,4/9/2021,Unblinded,5/2/2020,Multicenter,Private,Biocon Biologics India Limited,Severe,India,Control,Standard care,10,10,3,*,30,Discharged,6,*,*,3,*,30,4,3,*,30,Some concerns,unblinded,Industry_Mixed,32,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
170_preprint,170,3,NCT02735707,Yes, https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,medRxiv,2021,preprint,1/7/2021,Unblinded,4/19/2020,Multicenter,Mixed,PREPARE consortium by the EU; FP7-HEALTH-2013-INNOVATION-1; RECOVER consortium by the EU's Horizon 2020 research & innovation programme;  Australian National Health & Medical Research Council; Health Research Council of ,Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Treatment,Tocilizumab,366,350,98,*,*,hospital discharge,*,*,*,*,*,*,*,9,353,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
170_preprint,170,3,NCT02735707,Yes, https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,medRxiv,2021,preprint,1/7/2021,Unblinded,4/19/2020,Multicenter,Mixed,PREPARE consortium by the EU; FP7-HEALTH-2013-INNOVATION-1; RECOVER consortium by the EU's Horizon 2020 research & innovation programme;  Australian National Health & Medical Research Council; Health Research Council of ,Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Treatment,Sarilumab,48,45,10,*,*,hospital discharge,*,*,*,*,*,*,*,0,48,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
170_preprint,170,3,NCT02735707,Yes, https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,medRxiv,2021,preprint,1/7/2021,Unblinded,4/19/2020,Multicenter,Mixed,PREPARE consortium by the EU; FP7-HEALTH-2013-INNOVATION-1; RECOVER consortium by the EU's Horizon 2020 research & innovation programme;  Australian National Health & Medical Research Council; Health Research Council of ,Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Control,Standard care,412,397,142,*,*,Time to hospital discharge,*,*,*,*,*,*,*,11,402,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
170_pub,170,3,NCT02735707,Yes,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433?articleTools=true  https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,N Engl J Med,2021,published paper,2/25/2021,Unblinded,4/19/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors; Roche
Products Ltd and Sanofi (drug provision in UK)",Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Treatment,Tocilizumab,366,350,98,*,21,hospital discharge,*,*,*,*,*,*,*,9,353,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
170_pub,170,3,NCT02735707,Yes,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433?articleTools=true  https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,N Engl J Med,2021,published paper,2/25/2021,Unblinded,4/19/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors; Roche
Products Ltd and Sanofi (drug provision in UK)",Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Treatment,Sarilumab,48,45,10,*,21,hospital discharge,*,*,*,*,*,*,*,0,48,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
170_pub,170,3,NCT02735707,Yes,https://www.nejm.org/doi/pdf/10.1056/NEJMoa2100433?articleTools=true  https://www.medrxiv.org/content/10.1101/2021.01.07.21249390v1.full.pdf,REMAP-CAP,Gordon AC,N Engl J Med,2021,published paper,2/25/2021,Unblinded,4/19/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors; Roche
Products Ltd and Sanofi (drug provision in UK)",Severe/Critical,"Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK",Control,Standard care,412,397,142,*,21,hospital discharge,*,*,*,*,*,*,*,11,402,90,Some concerns,unblinded,Industry_Mixed,826,HIC,,N,,,,N,,,,,,,consistent
172_preprint,172,3,ISRCTN40302986,Yes,https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1.full.pdf,IVERCOVID,Babalola OE,medRxiv,2021,preprint,1/6/2021, double blinding,6/22/2020,Single,Private,"Rachel Eye Center, Abuja; Crystal Optics (Nig) Ltd.",Mild/Moderate,Nigeria,Treatment,Ivermectin,*,42,0,*,*,*,*,*,*,*,*,*,*,*,*,,Some concerns,blinded,Industry_Mixed,62,LIC_MIC,,N,,,,,,,,,,,consistent
172_preprint,172,3,ISRCTN40302986,Yes,https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1.full.pdf,IVERCOVID,Babalola OE,medRxiv,2021,preprint,1/6/2021, double blinding,6/22/2020,Single,Private,"Rachel Eye Center, Abuja; Crystal Optics (Nig) Ltd.",Mild/Moderate,Nigeria,Control,Lopinavir-ritonavir,*,20,0,*,*,*,*,*,*,*,*,*,*,*,*,14,Some concerns,blinded,Industry_Mixed,62,LIC_MIC,,N,,,,,,,,,,,consistent
172_pub,172,3,ISRCTN40302986,Yes,https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab035/6143037,IVERCOVID,Babalola OE,QJM,2021,published paper,2/18/2021,"Double blinded, no restrictions",6/22/2020,Single,Private,"Rachel Eye Center, Abuja; Crystal Optics (Nig) Ltd.",Mild/Moderate,Nigeria,Treatment,Ivermectin,*,42,0,*,14,*,*,*,*,*,*,*,*,*,*,,Some concerns,blinded,Industry_Mixed,62,LIC_MIC,,N,,,,,,,,,,,consistent
172_pub,172,3,ISRCTN40302986,Yes,https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab035/6143037,IVERCOVID,Babalola OE,QJM,2021,published paper,2/18/2021,"Double blinded, no restrictions",6/22/2020,Single,Private,"Rachel Eye Center, Abuja; Crystal Optics (Nig) Ltd.",Mild/Moderate,Nigeria,Control,Lopinavir-ritonavir,*,20,0,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,62,LIC_MIC,,N,,,,,,,,,,,consistent
176_preprint,176,2,NCT04354259,Yes,https://www.medrxiv.org/content/10.1101/2020.11.09.20228098v1,ILIAD,Feld JJ,medRxiv,2020,preprint,11/12/2020, double blinding,5/18/2020,Multicenter,Mixed,Toronto COVID-19 Action Initiative; University of Toronto; Ontario First COVID-19 Rapid Research Fund; Eiger BioPharma (drug provision),Mild outpatients,Canada,Treatment,Peginterferon Lambda-1,30,30,0,*,*,*,*,*,*,*,*,*,*,1,*,14,Some concerns,blinded,Industry_Mixed,60,HIC,,N,,,,N,,,,,,,consistent
176_preprint,176,2,NCT04354259,Yes,https://www.medrxiv.org/content/10.1101/2020.11.09.20228098v1,ILIAD,Feld JJ,medRxiv,2020,preprint,11/12/2020, double blinding,5/18/2020,Multicenter,Mixed,Toronto COVID-19 Action Initiative; University of Toronto; Ontario First COVID-19 Rapid Research Fund; Eiger BioPharma (drug provision),Mild outpatients,Canada,Control,Placebo,30,30,0,*,*,*,*,*,*,*,*,*,*,1,*,14,Some concerns,blinded,Industry_Mixed,60,HIC,,N,,,,N,,,,,,,consistent
176_pub,176,1,NCT04354259,Yes,https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930566-X,ILIAD,Feld JJ,Lancet Respir Med,2021,published paper,2/5/2021, ,5/18/2020,Multicenter,Mixed,Toronto COVID-19 Action Initiative; University of Toronto; Ontario First COVID-19 Rapid Research Fund; Eiger BioPharma (drug provision),Outpatients,Canada,Treatment,Peginterferon Lambda-1,30,30,0,*,14,*,*,*,*,*,*,*,*,1,*,14,Some concerns,blinded,Industry_Mixed,60,HIC,,N,,,,N,,,,,,,consistent
176_pub,176,2,NCT04354259,Yes,https://www.thelancet.com/action/showPdf?pii=S2213-2600%2820%2930566-X,ILIAD,Feld JJ,Lancet Respir Med,2021,published paper,2/5/2021, ,5/18/2020,Multicenter,Mixed,Toronto COVID-19 Action Initiative; University of Toronto; Ontario First COVID-19 Rapid Research Fund; Eiger BioPharma (drug provision),Outpatients,Canada,Control,Placebo,30,30,0,*,14,*,*,*,*,*,*,*,*,1,*,14,Some concerns,blinded,Industry_Mixed,60,HIC,,N,,,,N,,,,,,,consistent
177_preprint,177,2,NCT04355728,Yes,https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875,*,Lanzoni G,SSRN,2020,preprint,10/26/2020, double blinding,4/25/2020,Single,Mixed,"Ugo Colombo;
Simkins Family Foundation; Fondazione Silvio
Tronchetti Provera; Barilla Group & Family; Diabetes Research Institute Foundation;
The Cure Alliance; NABTU; NCATS",Severe,USA,Treatment,UC-MSC,12,12,2,*,*,*,*,*,*,*,*,*,8,2,*,31,Some concerns,blinded,Industry_Mixed,24,HIC,,N,Y,,N,N,Y,,,,,,consistent
177_preprint,177,2,NCT04355728,Yes,https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875,*,Lanzoni G,SSRN,2020,preprint,10/26/2020, double blinding,4/25/2020,Single,Mixed,"Ugo Colombo;
Simkins Family Foundation; Fondazione Silvio
Tronchetti Provera; Barilla Group & Family; Diabetes Research Institute Foundation;
The Cure Alliance; NABTU; NCATS",Severe,USA,Control,Placebo,12,12,7,*,*,*,*,*,*,*,*,*,11,8,*,31,Some concerns,blinded,Industry_Mixed,24,HIC,,N,Y,,N,N,Y,,,,,,consistent
177_pub,177,1,NCT04355728,Yes,https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875,*,Lanzoni G,Stem Cells Transl Me,2021,published paper,1/5/2021,"Participants, outcome assessor and health care pro",4/25/2020,Single,Mixed,"Ugo Colombo;
Simkins Family Foundation; Fondazione Silvio
Tronchetti Provera; Barilla Group & Family; Diabetes Research Institute Foundation;
The Cure Alliance; NABTU; NCATS",Severe/Critical,USA,Treatment,UC-MSC,12,12,2,*,31,Number of patients discharged from the hospital,*,*,31,*,*,*,8,2,*,31,Some concerns,blinded,Industry_Mixed,24,HIC,,N,Y,,N,N,Y,,,,,,consistent
177_pub,177,2,NCT04355728,Yes,https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/sctm.20-0472 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3696875,*,Lanzoni G,Stem Cells Transl Me,2021,published paper,1/5/2021,"Participants, outcome assessor and health care pro",4/25/2020,Single,Mixed,"Ugo Colombo;
Simkins Family Foundation; Fondazione Silvio
Tronchetti Provera; Barilla Group & Family; Diabetes Research Institute Foundation;
The Cure Alliance; NABTU; NCATS",Severe/Critical,USA,Control,Placebo,12,12,7,*,31,Number of patients discharged from the hospital,*,*,31,*,*,*,11,8,*,31,Some concerns,blinded,Industry_Mixed,24,HIC,,N,Y,,N,N,Y,,,,,,consistent
178_preprint,178,2,CTRI/2020/08/027225,Yes,https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1.full.pdf,*,Kirti R,medRxiv,2021,preprint,1/9/2021, double blinding,8/28/2020,Single,Mixed,All India Institute of Medical Sciences. Sun Pharma Pvt. Ltd. (placebo provision),Mild to severe,India,Treatment,Ivermectin,57,55,0,*,*,Discharge from hospital. Discharge criteria were: 1. Ten days from the onset of symptoms. 2. Afebrile for three days and 3. Maintaining O2 saturation above 94% without supplemental oxygen for four days.,44,*,*,*,*,*,*,*,*,*,High,blinded,Industry_Mixed,115,LIC_MIC,,N,N,,,,,,,,,,consistent
178_preprint,178,2,CTRI/2020/08/027225,Yes,https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1.full.pdf,*,Kirti R,medRxiv,2021,preprint,1/9/2021, double blinding,8/28/2020,Single,Mixed,All India Institute of Medical Sciences. Sun Pharma Pvt. Ltd. (placebo provision),Mild to severe,India,Control,Placebo,58,57,1,*,*,Discharge from hospital. Discharge criteria were: 1. Ten days from the onset of symptoms. 2. Afebrile for three days and 3. Maintaining O2 saturation above 94% without supplemental oxygen for four days.,42,*,*,*,*,*,*,*,*,*,High,blinded,Industry_Mixed,115,LIC_MIC,,N,N,,,,,,,,,,consistent
178_pub,178,1,CTRI/2020/08/027225,Yes,https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32105 https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1.full.pdf,*,Ravikirti R,J Pharm Pharm Sci,2021,published paper,7/15/2021, double blinding,8/28/2020,Single,Mixed,All India Institute of Medical Sciences; Sun Pharma Pvt. Ltd. (placebo provision); learning resource allowance of the principal investigator (ivermectin procurement),Mild to severe,India,Treatment,Ivermectin,57,55,0,*,6,Discharged by day 10,44,*,10,*,*,*,*,*,*,*,High,blinded,Industry_Mixed,115,LIC_MIC,,N,N,,,,,,,,,,consistent
178_pub,178,2,CTRI/2020/08/027225,Yes,https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32105 https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1.full.pdf,*,Ravikirti R,J Pharm Pharm Sci,2021,published paper,7/15/2021, double blinding,8/28/2020,Single,Mixed,All India Institute of Medical Sciences; Sun Pharma Pvt. Ltd. (placebo provision); learning resource allowance of the principal investigator (ivermectin procurement),Mild to severe,India,Control,Placebo,58,57,1,*,6,Discharged by day 10,42,*,10,*,*,*,*,*,*,*,High,blinded,Industry_Mixed,115,LIC_MIC,,N,N,,,,,,,,,,consistent
180_preprint,180,4,NCT04315948; EudraCT,Yes,https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1,DisCoVeRy,Ader F,medRxiv,2021,preprint,1/9/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ÃŽle-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,Lopinavir-Ritonavir,150,145,14,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,31,*,29,119,76,144,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_preprint,180,4,NCT04315948; EudraCT,Yes,https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1,DisCoVeRy,Ader F,medRxiv,2021,preprint,1/9/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ÃŽle-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,LPV/r+IFN beta-1a,150,145,18,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,37,*,29,117,78,144,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_preprint,180,4,NCT04315948; EudraCT,Yes,https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1,DisCoVeRy,Ader F,medRxiv,2021,preprint,1/9/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ÃŽle-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,Hydroxychloroquine,151,145,11,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,27,*,29,109,63,143,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_preprint,180,4,NCT04315948; EudraCT,Yes,https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1,DisCoVeRy,Ader F,medRxiv,2021,preprint,1/9/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ÃŽle-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Control,Standard care,152,148,12,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,26,*,29,105,57,148,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_pub,180,4,NCT04315948,Yes,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext,DisCoVeRy,Ader F,Clin Microbiol Infec,2021,published paper,5/25/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ��le-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,Lopinavir-Ritonavir,150,145,14,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,31,*,29,119,76,144,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_pub,180,4,NCT04315948,Yes,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext,DisCoVeRy,Ader F,Clin Microbiol Infec,2021,published paper,5/25/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ��le-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,LPV/r+IFN beta-1a,150,145,18,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,37,*,29,117,78,144,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_pub,180,4,NCT04315948,Yes,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext,DisCoVeRy,Ader F,Clin Microbiol Infec,2021,published paper,5/25/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ��le-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Treatment,Hydroxychloroquine,151,145,11,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,27,*,29,109,63,143,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
180_pub,180,4,NCT04315948,Yes,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00259-7/fulltext,DisCoVeRy,Ader F,Clin Microbiol Infec,2021,published paper,5/25/2021,Unblinded,3/22/2020,Multicenter,Mixed,"Programme Hospitalier de Recherche Clinique, DIM One Health ��le-de-France, REACTing, INSERM. GILEAD, SANOFI, MERCK and ABBVIE (drug provision) ",Mild to critical,"France, Luxembourg",Control,Standard care,152,148,12,*,29,Improvement of 2 categories of the 7-point ordinal scale or hospital discharge within day 29,*,*,*,26,*,29,105,57,148,29,Some concerns,unblinded,Industry_Mixed,603,HIC,,,,N,N,N,,,,,,,consistent
183_preprint,183,6,IRCT20200408046987N1,Yes,https://assets.researchsquare.com/files/rs-109670/v1/262874c7-d892-4fba-99c5-289f2b81fae1.pdf,,Niaee MS,Research Square ,2020,preprint,11/24/2020, double blinding,6/1/2020,Multicenter,Mixed,Qazvin University of Medical Sciences and Science (pre-print); Chistasazan Notash Fartak Company Limited (registry),,Iran,Treatment,Ivermectin,120,120,4,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,180,LIC_MIC,,,,,,,,,,,,,consistent
183_preprint,183,6,IRCT20200408046987N1,Yes,https://assets.researchsquare.com/files/rs-109670/v1/262874c7-d892-4fba-99c5-289f2b81fae1.pdf,,Niaee MS,Research Square ,2020,preprint,11/24/2020, double blinding,6/1/2020,Multicenter,Mixed,Qazvin University of Medical Sciences and Science (pre-print); Chistasazan Notash Fartak Company Limited (registry),,Iran,Control,Standard care,60,60,11,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,180,LIC_MIC,,,,,,,,,,,,,consistent
183_pub,183,6,IRCT20200408046987N1,Yes,https://bit.ly/39sH9b0,,Niaee MS,Asian Pac J Trop Med,2021,published paper,6/25/2021,"Double blinded, no restrictions",6/1/2020,Multicenter,Mixed,Qazvin University of Medical Sciences and Science (publication); Chistasazan Notash Fartak Company Limited (registry),,Iran,Treatment,Ivermectin,120,120,4,*,45,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,180,LIC_MIC,,,,,,,,,,,,,consistent
183_pub,183,6,IRCT20200408046987N1,Yes,https://bit.ly/39sH9b0,,Niaee MS,Asian Pac J Trop Med,2021,published paper,6/25/2021,"Double blinded, no restrictions",6/1/2020,Multicenter,Mixed,Qazvin University of Medical Sciences and Science (publication); Chistasazan Notash Fartak Company Limited (registry),,Iran,Control,Standard care,60,60,11,*,45,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,180,LIC_MIC,,,,,,,,,,,,,consistent
184_preprint,184,3,"NCT04327388, EudraCT",Yes,https://www.medrxiv.org/content/10.1101/2021.02.01.21250769v1,,Lescure FX,medRxiv,2021,preprint,2/3/2021,quadruple blinding,3/28/2020,Multicenter,Private,"Sanofi and Regeneron Pharmaceuticals, Inc",,"Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain",Treatment,Sarilumab,334,332,30,*,28,Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale or discharge. 1â€”Death; 2â€”Hospitalised. on invasive mechanical ventilation or extracorporeal membrane oxygenation; 3â€”Hospitalised. on noninvasive ventilation or high-flow oxygen devices; 4â€”Hospitalised.requiring supplemental oxygen; 5â€”Hospitalised. not requiring supplemental oxygen â€“ requiring ongoing medical care (COVID-19 related or otherwise); 6â€”Hospitalised. not requiring supplemental oxygen â€“ no longer requiring ongoing medical care; 7â€”Not hospitalised. Discharge prior to day 29 was considered as a 2-point improvement.,*,*,28,*,*,*,224,93,*,59,Some concerns,blinded,Industry_Mixed,420,Mixed,,N,,,N,N,,,,,,,consistent
184_preprint,184,3,"NCT04327388, EudraCT",Yes,https://www.medrxiv.org/content/10.1101/2021.02.01.21250769v1,*,Lescure FX,medRxiv,2021,preprint,2/3/2021,quadruple blinding,3/28/2020,Multicenter,Private,"Sanofi and Regeneron Pharmaceuticals, Inc",Moderate to critical,"Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain",Control,Placebo,86,84,7,*,28,Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale or discharge. 1â€”Death; 2â€”Hospitalised. on invasive mechanical ventilation or extracorporeal membrane oxygenation; 3â€”Hospitalised. on noninvasive ventilation or high-flow oxygen devices; 4â€”Hospitalised.requiring supplemental oxygen; 5â€”Hospitalised. not requiring supplemental oxygen â€“ requiring ongoing medical care (COVID-19 related or otherwise); 6â€”Hospitalised. not requiring supplemental oxygen â€“ no longer requiring ongoing medical care; 7â€”Not hospitalised. Discharge prior to day 29 was considered as a 2-point improvement.,*,*,28,*,*,*,55,20,*,59,Some concerns,blinded,Industry_Mixed,420,Mixed,,N,,,N,N,,,,,,,consistent
184_pub,184,3,NCT04327388; EudraCT2020-001162-12; U1111-1249-602,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext#seccestitle10 https://www.medrxiv.org/content/10.1101/2021.02.01.2,,Lescure FX,Lancet Respir Med,2021,published paper,3/4/2021, double blinding,3/28/2020,Multicenter,Private,"Sanofi and Regeneron Pharmaceuticals, Inc",,"Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain",Treatment,Sarilumab,334,332,30,*,28,Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale or discharge. 1���Death; 2���Hospitalised. on invasive mechanical ventilation or extracorporeal membrane oxygenation; 3���Hospitalised. on noninvasive ventilation or high-flow oxygen devices; 4���Hospitalised.requiring supplemental oxygen; 5���Hospitalised. not requiring supplemental oxygen ��� requiring ongoing medical care (COVID-19 related or otherwise); 6���Hospitalised. not requiring supplemental oxygen ��� no longer requiring ongoing medical care; 7���Not hospitalised. Discharge prior to day 29 was considered as a 2-point improvement.,*,*,28,*,*,*,224,93,*,59,Some concerns,blinded,Industry_Mixed,420,Mixed,,N,,,N,N,,,,,,,consistent
184_pub,184,3,NCT04327388; EudraCT2020-001162-12; U1111-1249-602,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00099-0/fulltext#seccestitle10 https://www.medrxiv.org/content/10.1101/2021.02.01.2,*,Lescure FX,Lancet Respir Med,2021,published paper,3/4/2021, double blinding,3/28/2020,Multicenter,Private,"Sanofi and Regeneron Pharmaceuticals, Inc",Moderate to critical,"Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain",Control,Placebo,86,84,7,*,28,Time to improvement of 2 points in clinical status assessment from baseline using the 7-point ordinal scale or discharge. 1���Death; 2���Hospitalised. on invasive mechanical ventilation or extracorporeal membrane oxygenation; 3���Hospitalised. on noninvasive ventilation or high-flow oxygen devices; 4���Hospitalised.requiring supplemental oxygen; 5���Hospitalised. not requiring supplemental oxygen ��� requiring ongoing medical care (COVID-19 related or otherwise); 6���Hospitalised. not requiring supplemental oxygen ��� no longer requiring ongoing medical care; 7���Not hospitalised. Discharge prior to day 29 was considered as a 2-point improvement.,*,*,28,*,*,*,55,20,*,59,Some concerns,blinded,Industry_Mixed,420,Mixed,,N,,,N,N,,,,,,,consistent
191_preprint,191,2,"NCT04381936, ISRCTN50189673",Yes,https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1,RECOVERY (TCZ),Horby P,medRxiv,2021,preprint,2/11/2021,Unblinded,4/14/2020,Multicenter,Public/non profit,"UK research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre, Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Clinical Trials Unit Support Funding; Abbvie (lopinavir-ritonavir);   Roche Products Ltd (tocilizumab); Regeneron (REGEN-480 COV2)",Moderate to critical,UK,Treatment,Tocilizumab,2022,2022,596,*,28,Discharged alive from hospital within 28 days,1093,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,4116,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
191_preprint,191,2,"NCT04381936, ISRCTN50189673",Yes,https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1,RECOVERY (TCZ),Horby P,medRxiv,2021,preprint,2/11/2021,Unblinded,4/14/2020,Multicenter,Public/non profit,"UK research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre, Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Clinical Trials Unit Support Funding; Abbvie (lopinavir-ritonavir);   Roche Products Ltd (tocilizumab); Regeneron (REGEN-480 COV2)",Moderate to critical,UK,Control,Standard care,2094,2094,694,*,28,Discharged alive from hospital within 28 days,990,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,4116,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
191_pub,191,1,"NCT04381936, ISRCTN50189673",Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900676-0,RECOVERY (TCZ),Horby P,Lancet,2021,published paper,5/1/2021,Unblinded,4/23/2020,Multicenter,Public/non profit,"UK research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre, Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Clinical Trials Unit Support Funding; Abbvie (lopinavir-ritonavir);   Roche Products Ltd (tocilizumab); Regeneron (REGEN-480 COV2)",Moderate to critical,UK,Treatment,Tocilizumab,2022,2022,621,*,28,Discharged alive from hospital within 28 days,1150,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,4116,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
191_pub,191,2,"NCT04381936, ISRCTN50189673",Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900676-0,RECOVERY (TCZ),Horby P,Lancet,2021,published paper,5/1/2021,Unblinded,4/23/2020,Multicenter,Public/non profit,"UK research and Innovation/National Institute for Health Research (NIHR); NIHR Oxford Biomedical Research Centre, Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Clinical Trials Unit Support Funding; Abbvie (lopinavir-ritonavir);   Roche Products Ltd (tocilizumab); Regeneron (REGEN-480 COV2)",Moderate to critical,UK,Control,Standard care,2094,2094,729,*,28,Discharged alive from hospital within 28 days,1044,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,4116,HIC,,N,N,,,,N,,N,N,N,"mort, CI",exclude_diffanalysis
192_preprint,192,2,NCT04322682,Yes,https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1,COLCORONA,Tardif JC,medRxiv,2021,preprint,1/27/2021, double blinding,3/23/2020,Multicenter,Mixed,Government of Quebec; Bill and Melinda Gates Foundation; National Institutes of Health; philanthropist Sophie Desmarais; Pharmascience (drug provision),Mild outpatients,"Brazil, Canada, Greece, South Africa, Spain, USA",Treatment,Colchicine,*,2235,5,*,30,*,*,*,*,*,*,*,532,108,2195,30,Some concerns,blinded,Industry_Mixed,4506,Mixed,,N,,,N,N,,,,,,,consistent
192_preprint,192,2,NCT04322682,Yes,https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1,COLCORONA,Tardif JC,medRxiv,2021,preprint,1/27/2021, double blinding,3/23/2020,Multicenter,Mixed,Government of Quebec; Bill and Melinda Gates Foundation; National Institutes of Health; philanthropist Sophie Desmarais; Pharmascience (drug provision),Mild outpatients,"Brazil, Canada, Greece, South Africa, Spain, USA",Control,Placebo,*,2253,9,*,30,*,*,*,*,*,*,*,344,139,2217,30,Some concerns,blinded,Industry_Mixed,4506,Mixed,,N,,,N,N,,,,,,,consistent
192_pub,192,1,NCT04322682,Yes,https://bit.ly/3xZA0Jn,COLCORONA,Tardif JC,Lancet Respir Med,2021,published paper,5/27/2021,"Double blinded, no restrictions",3/23/2020,Multicenter,Mixed,"Government of Quebec; the Bill & Melinda Gates Foundation; the National Heart, Lung, and Blood
Institute of the US National Institutes of Health; Montreal Heart Institute Foundation; NYU Grossman School
of Medicine; Rudin Family Foundation; philanthropist Sophie Desmarais.",Outpatients,"Brazil, Canada, Greece, South Africa, Spain, USA",Treatment,Colchicine,*,2235,5,*,30,*,*,*,*,*,*,*,532,108,2195,30,Some concerns,blinded,Industry_Mixed,4506,Mixed,,N,,,N,N,,,,,,,consistent
192_pub,192,2,NCT04322682,Yes,https://bit.ly/3xZA0Jn,COLCORONA,Tardif JC,Lancet Respir Med,2021,published paper,5/27/2021,"Double blinded, no restrictions",3/23/2020,Multicenter,Mixed,"Government of Quebec; the Bill & Melinda Gates Foundation; the National Heart, Lung, and Blood
Institute of the US National Institutes of Health; Montreal Heart Institute Foundation; NYU Grossman School
of Medicine; Rudin Family Foundation; philanthropist Sophie Desmarais.",Outpatients,"Brazil, Canada, Greece, South Africa, Spain, USA",Control,Placebo,*,2253,9,*,30,*,*,*,*,*,*,*,344,139,2217,30,Some concerns,blinded,Industry_Mixed,4506,Mixed,,N,,,N,N,,,,,,,consistent
194_preprint,194,2,IRCT20190810044500N7,No,https://www.researchsquare.com/article/rs-122376/v1,*,Roostaei A,Research Square ,2021,preprint,1/4/2021,quadruple blinding,4/12/2020,Single,Public/non profit,Research and Technology Department of Shahid Sadoughi University of Medical Science,Mild outpatients,Iran,Treatment,Levamisole,27,25,0,*,14,*,*,*,*,*,*,*,0,*,*,14,Some concerns,blinded,Other,52,LIC_MIC,,N,,,N,,,,,,,,consistent
194_preprint,194,2,IRCT20190810044500N7,No,https://www.researchsquare.com/article/rs-122376/v1,*,Roostaei A,Research Square ,2021,preprint,1/4/2021,quadruple blinding,4/12/2020,Single,Public/non profit,Research and Technology Department of Shahid Sadoughi University of Medical Science,Mild outpatients,Iran,Control,Placebo,25,25,0,*,14,*,*,*,*,*,*,*,0,*,*,14,Some concerns,blinded,Other,52,LIC_MIC,,N,,,N,,,,,,,,consistent
194_pub,194,1,IRCT20190810044500N7,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05983-2#author-information,*,Roostaei A,BMC Infect Dis,2021,published paper,3/24/2021,"Double blinded, no restrictions",4/12/2020,Single,Public/non profit,Research and Technology Department of Shahid Sadoughi University of Medical Science,Outpatients,Iran,Treatment,Levamisole,27,25,0,*,14,*,*,*,*,*,*,*,0,*,*,14,Some concerns,blinded,Other,52,LIC_MIC,,N,,,N,,,,,,,,consistent
194_pub,194,2,IRCT20190810044500N7,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-05983-2#author-information,*,Roostaei A,BMC Infect Dis,2021,published paper,3/24/2021,"Double blinded, no restrictions",4/12/2020,Single,Public/non profit,Research and Technology Department of Shahid Sadoughi University of Medical Science,Outpatients,Iran,Control,Placebo,25,25,0,*,14,*,*,*,*,*,*,*,0,*,*,14,Some concerns,blinded,Other,52,LIC_MIC,,N,,,N,,,,,,,,consistent
197_preprint,197,3,CTRI/2020/06/026001,Yes,https://www.researchsquare.com/article/rs-191648/v1,,Mohan A,Research Square ,2021,preprint,2/2/2021,quadruple blinding,7/28/2020,Single,Mixed,"Department of Science and Technology, Government of India; WindLas BioTech Ltd. Haryana (drug contribution)",,India,Treatment,Ivermectin,*,100,0,*,28,Discharge by day 14,75,80,14,0,*,28,14,0,*,28,Some concerns,blinded,Industry_Mixed,157,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
197_preprint,197,3,CTRI/2020/06/026001,Yes,https://www.researchsquare.com/article/rs-191648/v1,*,Mohan A,Research Square ,2021,preprint,2/2/2021,quadruple blinding,7/28/2020,Single,Mixed,"Department of Science and Technology, Government of India; WindLas BioTech Ltd. Haryana (drug contribution)",Mild/Moderate,India,Control,Placebo,*,52,0,*,28,Discharge by day 14,39,45,14,0,*,28,6,0,*,28,Some concerns,blinded,Industry_Mixed,157,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
197_pub,197,3,CTRI/2020/06/026001,Yes,https://bit.ly/39Y1XY1 https://www.researchsquare.com/article/rs-191648/v1,,Mohan A,J Infect Chemother,2021,published paper,8/25/2021,"Participants, outcome assessor and health care pro",7/28/2020,Single,Mixed,"Department of Science and Technology, Government of India; WindLas BioTech Ltd. Haryana (drug contribution)",,India,Treatment,Ivermectin,104,100,0,*,28,Discharge by day 14,75,80,14,0,*,28,14,0,*,28,Some concerns,blinded,Industry_Mixed,157,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
197_pub,197,3,CTRI/2020/06/026001,Yes,https://bit.ly/39Y1XY1 https://www.researchsquare.com/article/rs-191648/v1,RIVET-COV,Mohan A,J Infect Chemother,2021,published paper,8/25/2021,"Participants, outcome assessor and health care pro",7/28/2020,Single,Mixed,"Department of Science and Technology, Government of India; WindLas BioTech Ltd. Haryana (drug contribution)",Mild/Moderate,India,Control,Placebo,53,52,0,*,28,Discharge by day 14,39,45,14,0,*,28,6,0,*,28,Some concerns,blinded,Industry_Mixed,157,LIC_MIC,,N,N,N,N,N,,,,,,,consistent
200_preprint,200,2,NCT04521400,Yes,https://www.researchsquare.com/article/rs-138540/v2,*,Darazam I,Research square ,2021,preprint,1/5/2021,Unblinded,8/20/2020,Single,No specific funding,*,Moderate/Severe,Iran (Islamic Republic of),Treatment,IFN beta-1a High dose,83,83,34,*,21,Time to clinical improvement defined as the time from enrollment to discharge or decline of two steps on the seven-step ordinal scale,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,168,LIC_MIC,,N,,,,,,,,,,,consistent
200_preprint,200,2,NCT04521400,Yes, https://www.researchsquare.com/article/rs-138540/v2,*,Darazam I,Research square ,2021,preprint,1/5/2021,Unblinded,8/20/2020,Single,No specific funding,*,Moderate/Severe,Iran (Islamic Republic of),Control,IFN beta-1a,85,85,31,*,21,Time to clinical improvement defined as the time from enrollment to discharge or decline of two steps on the seven-step ordinal scale,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,168,LIC_MIC,,N,,,,,,,,,,,consistent
200_pub,200,1,NCT04521400,Yes,https://www.sciencedirect.com/science/article/pii/S156757692100552X?via%3Dihub#b0080 https://www.researchsquare.com/article/rs-138540/v2,*,Darazam I,Int Immunopharmacol,2021,published paper,6/29/2021,Unblinded,8/20/2020,Single,Public/non profit,"Shahid Beheshti University of Medical Sciences, Tehran, Iran",Moderate/Severe,Iran (Islamic Republic of),Treatment,IFN beta-1a High dose,83,83,34,*,21,Time to clinical improvement defined as the time from enrollment to discharge or decline of two steps on the seven-step ordinal scale,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,168,LIC_MIC,,N,,,,,,,,,,,consistent
200_pub,200,2,NCT04521400,Yes,https://www.sciencedirect.com/science/article/pii/S156757692100552X?via%3Dihub#b0080 https://www.researchsquare.com/article/rs-138540/v2,*,Darazam I,Int Immunopharmacol,2021,published paper,6/29/2021,Unblinded,8/20/2020,Single,Public/non profit,"Shahid Beheshti University of Medical Sciences, Tehran, Iran",Moderate/Severe,Iran (Islamic Republic of),Control,IFN beta-1a,85,85,31,*,21,Time to clinical improvement defined as the time from enrollment to discharge or decline of two steps on the seven-step ordinal scale,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,168,LIC_MIC,,N,,,,,,,,,,,consistent
201_preprint,201,3,NCT04343768,Yes,https://www.researchsquare.com/article/rs-136499/v1,COVIFERON,Darazam I,Research square ,2021,preprint,1/4/2021,Unblinded,4/9/2020,Single,No specific funding,*,Moderate/Severe,Iran (Islamic Republic of),Treatment,IFN beta-1a+IFN beta-1b,40,40,10,*,21,TTCI [time to clinical improvement]. defined as the time from enrollment to discharge from the hospital or a decline of two steps on the seven-step ordinal scale.,*,*,*,*,*,*,*,*,*,,Some concerns,unblinded,Other,60,LIC_MIC,,N,,,,,,,,,,,consistent
201_preprint,201,3,NCT04343768,Yes,https://www.researchsquare.com/article/rs-136499/v1,COVIFERON,Darazam I,Research square ,2021,preprint,1/4/2021,Unblinded,4/9/2020,Single,No specific funding,*,Moderate/Severe,Iran (Islamic Republic of),Control,Standard care,20,20,9,*,21,Our primary outcome measure was TTCI [time to clinical improvement]. defined as the time from enrollment to discharge from the hospital or a decline of two steps on the seven-step ordinal scale. ,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,60,LIC_MIC,,N,,,,,,,,,,,consistent
201_pub,201,3,NCT04343768,Yes,https://www.nature.com/articles/s41598-021-86859-y.pdf,COVIFERON,Darazam IA,Sci Rep,2021,published paper,4/13/2021,Unblinded,4/9/2020,Single,No specific funding,*,Moderate/Severe,Iran,Treatment,IFN beta-1a+IFN beta-1b,40,40,10,*,21,TTCI [time to clinical improvement]. defined as the time from enrollment to discharge from the hospital or a decline of two steps on the seven-step ordinal scale.,*,*,*,*,*,*,*,*,*,,Some concerns,unblinded,Other,60,LIC_MIC,,N,,,,,,,,,,,consistent
201_pub,201,3,NCT04343768,Yes,https://www.nature.com/articles/s41598-021-86859-y.pdf,COVIFERON,Darazam IA,Sci Rep,2021,published paper,4/13/2021,Unblinded,4/9/2020,Single,No specific funding,*,Moderate/Severe,Iran,Control,Standard care,20,20,9,*,21,Our primary outcome measure was TTCI [time to clinical improvement]. defined as the time from enrollment to discharge from the hospital or a decline of two steps on the seven-step ordinal scale. ,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,60,LIC_MIC,,N,,,,,,,,,,,consistent
204_preprint,204,2,NCT04452435,Yes,https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1,ATTRACT,Tornling G,medRxiv,2021,preprint,1/28/2021, triple blinding,7/21/2020,Multicenter,Mixed,Vicore Pharma; LifeArc,Mild/Moderate,India,Treatment,Compound 21,51,51,1,*,14,*,*,*,*,1,*,14,31,*,*,14,Some concerns,blinded,Industry_Mixed,106,LIC_MIC,,N,,N,N,N,,,,,,,add_delete
204_preprint,204,2,NCT04452435,Yes,https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1,ATTRACT,Tornling G,medRxiv,2021,preprint,1/28/2021, triple blinding,7/21/2020,Multicenter,Mixed,Vicore Pharma; LifeArc,Mild/Moderate,India,Control,Placebo,55,55,3,*,14,*,*,*,*,4,*,14,37,*,*,14,Some concerns,blinded,Industry_Mixed,106,LIC_MIC,,N,,N,N,N,,,,,,,add_delete
204_pub,204,1,NCT04452435,Yes,https://www.sciencedirect.com/science/article/pii/S2589537021004326?via%3Dihub https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1; https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3889369,ATTRACT,Tornling G,EClinicalMedicine,2021,published paper,10/24/2021,quadruple blinding,7/21/2020,Multicenter,Mixed,Vicore Pharma; LifeArc,Mild/Moderate,India,Treatment,Compound 21,51,51,1,*,14,*,*,*,*,1,*,14,31,1,*,14,Some concerns,blinded,Industry_Mixed,106,LIC_MIC,,N,,N,N,N,,,,,,,add_delete
204_pub,204,2,NCT04452435,Yes,https://www.sciencedirect.com/science/article/pii/S2589537021004326?via%3Dihub https://www.medrxiv.org/content/10.1101/2021.01.26.21250511v1; https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3889369,ATTRACT,Tornling G,EClinicalMedicine,2021,published paper,10/24/2021,quadruple blinding,7/21/2020,Multicenter,Mixed,Vicore Pharma; LifeArc,Mild/Moderate,India,Control,Placebo,55,55,3,*,14,*,*,*,*,4,*,14,37,3,*,14,Some concerns,blinded,Industry_Mixed,106,LIC_MIC,,N,,N,N,N,,,,,,,add_delete
209_preprint,209,2,IRCT20200204046369N1,Yes,https://www.researchsquare.com/article/rs-148529/v1,*,Ranjbar K,Research Square,2021,preprint,2/1/2021, triple blinding,8/10/2020,Single,No specific funding,No specific funding was obtained for this study,Severe,Iran,Treatment,Methylprednisolone,47,44,8,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,93,LIC_MIC,,N,,,Y,Y,,,,,,,consistent
209_preprint,209,2,IRCT20200204046369N1,Yes,https://www.researchsquare.com/article/rs-148529/v1,*,Ranjbar K,Research Square,2021,preprint,2/1/2021, triple blinding,8/10/2020,Single,No specific funding,No specific funding was obtained for this study,Severe,Iran,Control,Dexamethasone,46,42,15,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,93,LIC_MIC,,N,,,Y,Y,,,,,,,consistent
209_pub,209,1,IRCT20200204046369N1,Yes,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06045-3#availability-of-data-and-materials,*,Ranjbar K,BMC Infect Dis,2021,published paper,4/10/2021, double blinding,8/10/2020,Single,No specific funding,Research deputy chancellor of Shiraz university of medical sciences,Severe/Critical,Iran,Treatment,Methylprednisolone,47,44,8,*,28,*,*,*,*,*,*,*,*,*,*,28,Some concerns,blinded,Other,93,LIC_MIC,,N,,,Y,Y,,,,,,,consistent
209_pub,209,2,IRCT20200204046369N1,Yes,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06045-3#availability-of-data-and-materials,*,Ranjbar K,BMC Infect Dis,2021,published paper,4/10/2021, double blinding,8/10/2020,Single,No specific funding,Research deputy chancellor of Shiraz university of medical sciences,Severe/Critical,Iran,Control,Dexamethasone,46,42,15,*,28,*,*,*,*,*,*,*,*,*,*,28,Some concerns,blinded,Other,93,LIC_MIC,,N,,,Y,Y,,,,,,,consistent
210_preprint,210,2,NCT04494984,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3768544,CT-INM005-01,Lopardo G,SSRN,2021,preprint,2/1/2021,quadruple blinding,8/1/2020,Multicenter,Mixed,Inmunova; Ministries of Science and Production of Argentina,Mild to severe,Argentina,Treatment,INM005,120,118,8,*,28,Clinical improvement was defined as improvement of at least two categories based upon the WHO ordinal clinical status scale or hospital discharge. The categories were as follows: 0= no evidence of infection; 1=not hospitalized and no limitations of activities; 2=not hospitalized. with limitation of activities; 3=hospitalized. not requiring supplemental oxygen; 4=hospitalized. requiring supplemental oxygen; 5=hospitalized. requiring noninvasive ventilation or use of high-flow oxygen devices; 6=hospitalized. receiving invasive  mechanical ventilation; 7=hospitalized. receiving invasive mechanical ventilation and additional organ support-extracorporeal membrane oxygenation. pressors. or renal replacement therapy; and 8=death or hospital discharge.,*,*,28,*,*,28,52,16,119,28,Some concerns,blinded,Industry_Mixed,245,LIC_MIC,,N,N,,N,N,Y,,,,,,add_delete
210_preprint,210,2,NCT04494984,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3768544,CT-INM005-01,Lopardo G,SSRN,2021,preprint,2/1/2021,quadruple blinding,8/1/2020,Multicenter,Mixed,Inmunova; Ministries of Science and Production of Argentina,Mild to severe,Argentina,Control,Placebo,125,123,14,*,28,Clinical improvement was defined as improvement of at least two categories based upon the WHO ordinal clinical status scale or hospital discharge. The categories were as follows: 0= no evidence of infection; 1=not hospitalized and no limitations of activities; 2=not hospitalized. with limitation of activities; 3=hospitalized. not requiring supplemental oxygen; 4=hospitalized. requiring supplemental oxygen; 5=hospitalized. requiring noninvasive ventilation or use of high-flow oxygen devices; 6=hospitalized. receiving invasive  mechanical ventilation; 7=hospitalized. receiving invasive mechanical ventilation and additional organ support-extracorporeal membrane oxygenation. pressors. or renal replacement therapy; and 8=death or hospital discharge.,*,*,28,*,*,28,55,25,124,28,Some concerns,blinded,Industry_Mixed,245,LIC_MIC,,N,N,,N,N,Y,,,,,,add_delete
210_pub,210,1,NCT04494984,Yes,https://bit.ly/3oiKhN7,CT-INM005-01,Lopardo G,EClinicalMedicine,2021,published paper,4/11/2021,"Participants, outcome assessor and health care pro",8/1/2020,Multicenter,Mixed,Inmunova; Ministries of Science and Production of Argentina,Mild to severe,Argentina,Treatment,INM005,120,118,8,*,28,"Clinical improvement was defined as improvement of at least two categories based upon the WHO ordinal clinical status scale or hospital discharge. The categories were as follows: 0= no evidence of infection; 1=not hospitalized and no limitations of activities; 2=not hospitalized. with limitation of activities; 3=hospitalized. not requiring supplemental oxygen; 4=hospitalized. requiring supplemental oxygen; 5=hospitalized. requiring noninvasive ventilation or use of high-flow oxygen devices; 6=hospitalized. receiving invasive  mechanical ventilation; 7=hospitalized. receiving invasive mechanical ventilation and additional organ support-extracorporeal membrane oxygenation. pressors. or renal replacement therapy; and 8=death or hospital discharge.

For time to clinical improvement: Time to achieve improvement in at least two categories on the ordinal clinical scale (without discharge) ",106,*,28,*,*,28,52,16,119,28,Some concerns,blinded,Industry_Mixed,245,LIC_MIC,,N,N,,N,N,Y,,,,,,add_delete
210_pub,210,2,NCT04494984,Yes,https://bit.ly/3oiKhN7,CT-INM005-01,Lopardo G,EClinicalMedicine,2021,published paper,4/11/2021,"Participants, outcome assessor and health care pro",8/1/2020,Multicenter,Mixed,Inmunova; Ministries of Science and Production of Argentina,Mild to severe,Argentina,Control,Placebo,125,123,14,*,28,"Clinical improvement was defined as improvement of at least two categories based upon the WHO ordinal clinical status scale or hospital discharge. The categories were as follows: 0= no evidence of infection; 1=not hospitalized and no limitations of activities; 2=not hospitalized. with limitation of activities; 3=hospitalized. not requiring supplemental oxygen; 4=hospitalized. requiring supplemental oxygen; 5=hospitalized. requiring noninvasive ventilation or use of high-flow oxygen devices; 6=hospitalized. receiving invasive  mechanical ventilation; 7=hospitalized. receiving invasive mechanical ventilation and additional organ support-extracorporeal membrane oxygenation. pressors. or renal replacement therapy; and 8=death or hospital discharge.

For time to clinical improvement: Time to achieve improvement in at least two categories on the ordinal clinical scale (without discharge)",104,*,28,*,*,28,55,25,124,28,Some concerns,blinded,Industry_Mixed,245,LIC_MIC,,N,N,,N,N,Y,,,,,,add_delete
220_preprint,220,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.medrxiv.org/content/10.1101/2021.03.09.21252736v1,RECOVERY-CP,Horby P,medRxiv,2021,preprint,3/10/2021,Unblinded,5/28/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Treatment,Convalescent plasma,5795,5795,1398,*,28,Discharged from hospital within 28 days,3850,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11558,HIC,,N,N,,,,Y,,,,,,discrepTE
220_preprint,220,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.medrxiv.org/content/10.1101/2021.03.09.21252736v1,RECOVERY-CP,Horby P,medRxiv,2021,preprint,3/10/2021,Unblinded,5/28/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Control,Standard care,5763,5763,1408,*,28,Discharged from hospital within 28 days,3846,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11558,HIC,,N,N,,,,Y,,,,,,discrepTE
220_pub,220,1,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900897-7,RECOVERY-CP,Horby P,Lancet,2021,published paper,5/14/2021,Unblinded,5/28/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Treatment,Convalescent plasma,5795,5795,1399,*,28,Discharged from hospital within 28 days,3832,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11558,HIC,,N,N,,,,Y,,,,,,discrepTE
220_pub,220,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.thelancet.com/action/showPdf?pii=S0140-6736%2821%2900897-7,RECOVERY-CP,Horby P,Lancet,2021,published paper,5/14/2021,Unblinded,5/28/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Control,Standard care,5763,5763,1408,*,28,Discharged from hospital within 28 days,3822,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11558,HIC,,N,N,,,,Y,,,,,,discrepTE
222_preprint,222,2,NCT04315896,Yes,https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1,*,Hernandez-Cardenas C,medRxiv,2021,preprint,2/5/2021,quadruple blinding,4/8/2020,Multicenter,Mixed,Support for the trial was received from the participating hospitals; CONACYT (National Council of Science and Technology of Mexico); SANOFI,Severe/Critical,Mexico,Treatment,Hydroxychloroquine,106,106,40,*,30,*,*,*,*,*,*,*,*,55,*,30,Some concerns,blinded,Industry_Mixed,214,LIC_MIC,,N,,,,N,,,,,,,consistent
222_preprint,222,2,NCT04315896,Yes,https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1,*,Hernandez-Cardenas C,medRxiv,2021,preprint,2/5/2021,quadruple blinding,4/8/2020,Multicenter,Mixed,Support for the trial was received from the participating hospitals; CONACYT (National Council of Science and Technology of Mexico); SANOFI,Severe/Critical,Mexico,Control,Placebo,108,108,44,*,30,*,*,*,*,*,*,*,*,54,*,30,Some concerns,blinded,Industry_Mixed,214,LIC_MIC,,N,,,,N,,,,,,,consistent
222_pub,222,1,NCT04315896,Yes,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257238#sec022 https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1,*,Hernandez-Cardenas C,PloS One,2021,published paper,9/28/2021,quadruple blinding,4/8/2020,Multicenter,Mixed,Participating hospitals; CONACYT (National Council of Science and Technology of Mexico); SANOFI,Severe/Critical,Mexico,Treatment,Hydroxychloroquine,106,106,40,*,30,*,*,*,*,*,*,*,*,55,*,30,Some concerns,blinded,Industry_Mixed,214,LIC_MIC,,N,,,,N,,,,,,,consistent
222_pub,222,2,NCT04315896,Yes,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257238#sec022 https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1,*,Hernandez-Cardenas C,PloS One,2021,published paper,9/28/2021,quadruple blinding,4/8/2020,Multicenter,Mixed,Participating hospitals; CONACYT (National Council of Science and Technology of Mexico); SANOFI,Severe/Critical,Mexico,Control,Placebo,108,108,44,*,30,*,*,*,*,*,*,*,*,54,*,30,Some concerns,blinded,Industry_Mixed,214,LIC_MIC,,N,,,,N,,,,,,,consistent
223_preprint,223,2,NCT04348409,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3763773,*,Fontanesi Blum V,SSRN,2021,preprint,1/22/2021, double blinding,5/20/2020,Multicenter,Not reported/unclear,*,Mild/Moderate,Brazil,Treatment,Nitazoxanide ,25,25,2,*,*,Discharge from hospital,*,*,*,*,*,21,*,*,*,21,Some concerns,blinded,Other,50,LIC_MIC,,N,,N,N,,,,,,,,add_delete
223_preprint,223,2,NCT04348409,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3763773,*,Fontanesi Blum V,SSRN,2021,preprint,1/22/2021, double blinding,5/20/2020,Multicenter,Not reported/unclear,*,Mild/Moderate,Brazil,Control,Placebo,25,25,6,*,*,Discharge from hospital,*,*,*,*,*,21,*,*,*,21,Some concerns,blinded,Other,50,LIC_MIC,,N,,N,N,,,,,,,,add_delete
223_pub,223,1, NCT04348409,Yes,https://bit.ly/3j1d86J https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3763773,*,Blum VF,EClinicalMedicine,2021,published paper,6/26/2021, double blinding,5/20/2020,Multicenter,Private,"Farmoquimica (FQM), Brazil",Mild/Moderate,Brazil,Treatment,Nitazoxanide ,25,25,2,*,*,Discharge from hospital,*,*,*,*,*,21,8,*,*,21,Some concerns,blinded,Industry_Mixed,50,LIC_MIC,,N,,N,N,,,,,,,,add_delete
223_pub,223,2, NCT04348409,Yes,https://bit.ly/3j1d86J https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3763773,*,Blum VF,EClinicalMedicine,2021,published paper,6/26/2021, double blinding,5/20/2020,Multicenter,Private,"Farmoquimica (FQM), Brazil",Mild/Moderate,Brazil,Control,Placebo,25,25,6,*,*,Discharge from hospital,*,*,*,*,*,21,13,*,*,21,Some concerns,blinded,Industry_Mixed,50,LIC_MIC,,N,,N,N,,,,,,,,add_delete
228_preprint,228,2,NCT04646109,No,https://www.researchsquare.com/article/rs-224203/v1,*,Okumus N,Research Square,2021,preprint,2/24/2021, single blinding,5/11/2020,Multicenter,Public/non profit,Afyonkarahisar Health Science University,Severe,Turkey,Treatment,Ivermectin,36,30,*,*,*,"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as ""clinical response"": Extubation in mechanically ventilated patients. respiratory rate <26/min. SpO2 level in room air >90%. PaO2/FiO2 >300 in patients receiving oxygen. presence of at least two of the 2-point reduction criteria in ""Sequential Organ Failure Assessment (SOFA)"" score.",*,*,*,*,*,*,5,5,*,10,High,blinded,Other,66,LIC_MIC,,,,,,,,,,,,,consistent
228_preprint,228,2,NCT04646109,No,https://www.researchsquare.com/article/rs-224203/v1,*,Okumus N,Research Square,2021,preprint,2/24/2021, single blinding,5/11/2020,Multicenter,Public/non profit,Afyonkarahisar Health Science University,Severe,Turkey,Control,Standard care,30,30,*,*,*,"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as ""clinical response"": Extubation in mechanically ventilated patients. respiratory rate <26/min. SpO2 level in room air >90%. PaO2/FiO2 >300 in patients receiving oxygen. presence of at least two of the 2-point reduction criteria in ""Sequential Organ Failure Assessment (SOFA)"" score.",*,*,*,*,*,*,3,0,*,10,High,blinded,Other,66,LIC_MIC,,,,,,,,,,,,,consistent
228_pub,228,1,NCT04646109,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06104-9,*,Okumus N,BMC Infect Dis,2021,published paper,5/4/2021,"Single blinded, no restrictions",5/11/2020,Multicenter,Public/non profit,Afyonkarahisar Health Science University,Severe,Turkey,Treatment,Ivermectin,36,30,*,*,*,"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as ""clinical response"": Extubation in mechanically ventilated patients. respiratory rate <26/min. SpO2 level in room air >90%. PaO2/FiO2 >300 in patients receiving oxygen. presence of at least two of the 2-point reduction criteria in ""Sequential Organ Failure Assessment (SOFA)"" score.",*,*,*,*,*,*,5,5,*,10,High,blinded,Other,66,LIC_MIC,,,,,,,,,,,,,consistent
228_pub,228,2,NCT04646109,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06104-9,*,Okumus N,BMC Infect Dis,2021,published paper,5/4/2021,"Single blinded, no restrictions",5/11/2020,Multicenter,Public/non profit,Afyonkarahisar Health Science University,Severe,Turkey,Control,Standard care,30,30,*,*,*,"The presence of at least two of the following criteria in patients at the end of 5th day were accepted as ""clinical response"": Extubation in mechanically ventilated patients. respiratory rate <26/min. SpO2 level in room air >90%. PaO2/FiO2 >300 in patients receiving oxygen. presence of at least two of the 2-point reduction criteria in ""Sequential Organ Failure Assessment (SOFA)"" score.",*,*,*,*,*,*,3,0,*,10,High,blinded,Other,66,LIC_MIC,,,,,,,,,,,,,consistent
233_preprint,233,2,NCT04321616,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (RDV),Barratt-Due A,SSRN,2021,preprint,2/11/2021,Unblinded,4/7/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Gilead Sciences (drug donation)",Unclear severity,Norway,Treatment,Remdesivir,43,42,*,*,*,*,*,*,*,*,*,*,*,*,*,90,Low,unblinded,Industry_Mixed,101,HIC,,N,,,,,,,,,,,add_delete
233_preprint,233,2,NCT04321616,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (RDV),Barratt-Due A,SSRN,2021,preprint,2/11/2021,Unblinded,4/7/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Gilead Sciences (drug donation)",Unclear severity,Norway,Control,Standard care,58,57,*,*,*,*,*,*,*,*,*,*,*,*,*,90,Low,unblinded,Industry_Mixed,101,HIC,,N,,,,,,,,,,,add_delete
233_pub,233,1,NCT04321616,Yes,https://www.acpjournals.org/doi/full/10.7326/M21-0653  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (RDV),Barratt-Due A,Ann Intern Med,2021,published paper,7/13/2021,Unblinded,4/7/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Gilead Sciences (drug donation)",Unclear severity,Norway,Treatment,Remdesivir,43,42,1,*,28,*,*,*,*,*,*,*,*,*,*,90,Low,unblinded,Industry_Mixed,101,HIC,,N,,,,,,,,,,,add_delete
233_pub,233,2,NCT04321616,Yes,https://www.acpjournals.org/doi/full/10.7326/M21-0653  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (RDV),Barratt-Due A,Ann Intern Med,2021,published paper,7/13/2021,Unblinded,4/7/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Gilead Sciences (drug donation)",Unclear severity,Norway,Control,Standard care,58,57,3,*,28,*,*,*,*,*,*,*,*,*,*,90,Low,unblinded,Industry_Mixed,101,HIC,,N,,,,,,,,,,,add_delete
237_preprint,237,2,NCT04321616,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (HCQ),Barratt-Due A,SSRN,2021,preprint,2/11/2021,Unblinded,3/28/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Mylan (drug donation)
",Unclear severity,Norway,Treatment,Hydroxychloroquine,54,52,*,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,108,HIC,,N,,,,,,,,,,,add_delete
237_preprint,237,2,NCT04321616,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (HCQ),Barratt-Due A,SSRN,2021,preprint,2/11/2021,Unblinded,3/28/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Mylan (drug donation)
",Unclear severity,Norway,Control,Standard care,54,54,*,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,108,HIC,,N,,,,,,,,,,,add_delete
237_pub,237,1,NCT04321616,Yes,https://www.acpjournals.org/doi/full/10.7326/M21-0653 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (HCQ),Barratt-Due A,Ann Intern Med,2021,published paper,7/13/2021,Unblinded,3/28/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Mylan (drug donation)
",Unclear severity,Norway,Treatment,Hydroxychloroquine,54,52,4,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,108,HIC,,N,,,,,,,,,,,add_delete
237_pub,237,2,NCT04321616,Yes,https://www.acpjournals.org/doi/full/10.7326/M21-0653 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3774182,NOR-SOLIDARITY (HCQ),Barratt-Due A,Ann Intern Med,2021,published paper,7/13/2021,Unblinded,3/28/2020,Multicenter,Mixed,"National Clinical Therapy Research in the Specialist Health Services, Norway; Mylan (drug donation)
",Unclear severity,Norway,Control,Standard care,54,54,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,108,HIC,,N,,,,,,,,,,,add_delete
238_preprint,238,2,NCT04359810,Yes,https://www.medrxiv.org/content/10.1101/2021.03.12.21253373v1,*,O Donnell M,medRxiv,2021,preprint,3/13/2021, double blinding,4/21/2020,Multicenter,Public/non profit,Amazon Foundation,Mild to critical,"Brazil, USA",Treatment,Convalescent plasma,150,150,19,*,28,Improvement in at least one point from baseline on the ordinal scale or alive at discharge from hospital (whichever came first): 1. not hospitalized with resumption of normal activities; 2. not hospitalized. but unable to resume normal activities; 3. hospitalized. not requiring supplemental oxygen; 4. hospitalized. requiring supplemental oxygen; 5. hospitalized. requiring high-flow oxygen therapy or noninvasive mechanical ventilation; 6. hospitalized. requiring ECMO. IMV. or both; 7. death.,*,*,*,31,*,28,96,39,147,28,Low,blinded,Other,223,Mixed,,N,,N,N,N,,,,,,,consistent
238_preprint,238,2,NCT04359810,Yes,https://www.medrxiv.org/content/10.1101/2021.03.12.21253373v1,*,O Donnell M,medRxiv,2021,preprint,3/13/2021, double blinding,4/21/2020,Multicenter,Public/non profit,Amazon Foundation,Mild to critical,"Brazil, USA",Control,Standard plasma,73,73,18,*,28,Improvement in at least one point from baseline on the ordinal scale or alive at discharge from hospital (whichever came first):1. not hospitalized with resumption of normal activities; 2. not hospitalized. but unable to resume normal activities; 3. hospitalized. not requiring supplemental oxygen; 4. hospitalized. requiring supplemental oxygen; 5. hospitalized. requiring high-flow oxygen therapy or noninvasive mechanical ventilation; 6. hospitalized. requiring ECMO. IMV. or both; 7. death.,*,*,*,22,*,28,40,26,72,28,Low,blinded,Other,223,Mixed,,N,,N,N,N,,,,,,,consistent
238_pub,238,1,NCT04359810,Yes,https://www.jci.org/articles/view/150646,*,O Donnell M,J Clin Invest,2021,published paper,5/11/2021, ,4/21/2020,Multicenter,Public/non profit,Amazon Foundation,Mild to critical,"Brazil, USA",Treatment,Convalescent plasma,150,150,19,*,28,Improvement in at least one point from baseline on the ordinal scale or alive at discharge from hospital (whichever came first): 1. not hospitalized with resumption of normal activities; 2. not hospitalized. but unable to resume normal activities; 3. hospitalized. not requiring supplemental oxygen; 4. hospitalized. requiring supplemental oxygen; 5. hospitalized. requiring high-flow oxygen therapy or noninvasive mechanical ventilation; 6. hospitalized. requiring ECMO. IMV. or both; 7. death.,*,*,*,31,*,28,96,39,147,28,Low,blinded,Other,223,Mixed,,N,,N,N,N,,,,,,,consistent
238_pub,238,2,NCT04359810,Yes,https://www.jci.org/articles/view/150646,*,O Donnell M,J Clin Invest,2021,published paper,5/11/2021, ,4/21/2020,Multicenter,Public/non profit,Amazon Foundation,Mild to critical,"Brazil, USA",Control,Standard plasma,73,73,18,*,28,Improvement in at least one point from baseline on the ordinal scale or alive at discharge from hospital (whichever came first):1. not hospitalized with resumption of normal activities; 2. not hospitalized. but unable to resume normal activities; 3. hospitalized. not requiring supplemental oxygen; 4. hospitalized. requiring supplemental oxygen; 5. hospitalized. requiring high-flow oxygen therapy or noninvasive mechanical ventilation; 6. hospitalized. requiring ECMO. IMV. or both; 7. death.,*,*,*,22,*,28,40,26,72,28,Low,blinded,Other,223,Mixed,,N,,N,N,N,,,,,,,consistent
239_preprint,239,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1.full-text,*,Goligher E,medRxiv,2021,preprint,3/12/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors",Severe/Critical,"Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA",Treatment,Therapeutic heparin,590,529,*,*,*,Survival to hospital discharge,340,*,21,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,1205,Mixed,,N,N,,,,N,"longer fu, sample size",mort,N,N,CI,exclude_diffanalysis
239_preprint,239,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1.full-text,*,Goligher E,medRxiv,2021,preprint,3/12/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors",Severe/Critical,"Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA",Control,Prophylactic anticoagul,615,545,*,*,*,Survival to hospital discharge,356,*,21,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,1205,Mixed,,N,N,,,,N,"longer fu, sample size",mort,N,N,CI,exclude_diffanalysis
239_pub,239,1,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.nejm.org/doi/10.1056/NEJMoa2103417 https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1.full-text,*,Goligher E,N Engl J Med,2021,published paper,8/4/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors",Severe/Critical,"Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA",Treatment,Therapeutic heparin,591,534,199,*,28,Survival to hospital discharge,335,*,21,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,1207,Mixed,,N,N,,,,N,"longer fu, sample size",mort,N,N,CI,exclude_diffanalysis
239_pub,239,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.nejm.org/doi/10.1056/NEJMoa2103417 https://www.medrxiv.org/content/10.1101/2021.03.10.21252749v1.full-text,*,Goligher E,N Engl J Med,2021,published paper,8/4/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Multiple funders, internationally, with multiple regional sponsors",Severe/Critical,"Australia, Brazil, Canada, Ireland, Mexico, Netherlands, New Zealand, Saudi Arabia, UK, USA",Control,Prophylactic anticoagul,616,564,200,*,28,Survival to hospital discharge,364,*,21,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,1207,Mixed,,N,N,,,,N,"longer fu, sample size",mort,N,N,CI,exclude_diffanalysis
242_preprint,242,2,IRCT20200624047908N1,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3792895,DISCOVER,Mobarak S,SSRN,2021,preprint,2/25/2021, double blinding,7/13/2020,Multicenter,Public/non profit,International Treatment Preparedness coalition,Moderate/Severe,Iran,Treatment,Sofosbuvir-Daclatasvir,541,541,68,*,28,Hospital discharge within 10 days,358,*,10,*,*,*,*,*,*,*,Some concerns,blinded,Other,1083,LIC_MIC,,N,N,,,,Y,,,,,,discrepTE
242_preprint,242,2,IRCT20200624047908N1,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3792895,DISCOVER,Mobarak S,SSRN,2021,preprint,2/25/2021, double blinding,7/13/2020,Multicenter,Public/non profit,International Treatment Preparedness coalition,Moderate/Severe,Iran,Control,Placebo,542,542,60,*,28,Hospital discharge within 10 days,370,*,10,*,*,*,*,*,*,*,Some concerns,blinded,Other,1083,LIC_MIC,,N,N,,,,Y,,,,,,discrepTE
242_pub,242,1,IRCT20200624047908N1,Yes,https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkab433/6445131 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3792895,DISCOVER,Mobarak S,J Antimicrob Chemoth,2021,published paper,11/28/2021, double blinding,7/13/2020,Multicenter,Public/non profit,International Treatment Preparedness coalition,Moderate/Severe,Iran,Treatment,Sofosbuvir-Daclatasvir,541,541,71,*,28,Hospital discharge within 10 days,415,*,10,*,*,*,*,*,*,*,Some concerns,blinded,Other,1083,LIC_MIC,,N,N,,,,Y,,,,,,discrepTE
242_pub,242,2,IRCT20200624047908N1,Yes,https://academic.oup.com/jac/advance-article/doi/10.1093/jac/dkab433/6445131 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3792895,DISCOVER,Mobarak S,J Antimicrob Chemoth,2021,published paper,11/28/2021, double blinding,7/13/2020,Multicenter,Public/non profit,International Treatment Preparedness coalition,Moderate/Severe,Iran,Control,Placebo,542,542,62,*,28,Hospital discharge within 10 days,411,*,10,*,*,*,*,*,*,*,Some concerns,blinded,Other,1083,LIC_MIC,,N,N,,,,Y,,,,,,discrepTE
254_preprint,254,2,ISRCTN86534580; EudraCT 2020-001209-22,Yes,https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1,PRINCIPLE ,Yu LM,medRxiv,2021,preprint,4/12/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research,Mild outpatients,UK,Treatment,Budesonide,1032,961,*,*,*,Self-assessed recovery,*,*,*,*,*,*,*,2,*,28,Some concerns,unblinded,Other,2112,HIC,,N,,N,,,N,"longer enrollment, sample size","mort, WHO7",SAE,N,N,exclude_diffanalysis
254_preprint,254,2,ISRCTN86534580; EudraCT 2020-001209-22,Yes,https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1,PRINCIPLE ,Yu LM,medRxiv,2021,preprint,4/12/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research,Mild outpatients,UK,Control,Standard care,1080,996,*,*,*,"Self-assessed recovery
",*,*,*,*,*,*,*,0,*,28,Some concerns,unblinded,Other,2112,HIC,,N,,N,,,N,"longer enrollment, sample size","mort, WHO7",SAE,N,N,exclude_diffanalysis
254_pub,254,1,ISRCTN86534580; EudraCT 2020-001209-22,Yes,https://bit.ly/2XSLLEJ https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1,PRINCIPLE ,Yu LM,Lancet,2021,published paper,8/10/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research,Outpatients,UK,Treatment,Budesonide,1073,990,9,*,*,Self-assessed recovery,*,*,*,23,*,28,*,*,*,*,Some concerns,unblinded,Other,,HIC,,N,,N,,,N,"longer enrollment, sample size","mort, WHO7",SAE,N,N,exclude_diffanalysis
254_pub,254,2,ISRCTN86534580; EudraCT 2020-001209-22,Yes,https://bit.ly/2XSLLEJ https://www.medrxiv.org/content/10.1101/2021.04.10.21254672v1,PRINCIPLE ,Yu LM,Lancet,2021,published paper,8/10/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research,Outpatients,UK,Control,Standard care,*,987,10,*,*,"Self-assessed recovery
",*,*,*,20,*,28,*,*,*,*,Some concerns,unblinded,Other,,HIC,,N,,N,,,N,"longer enrollment, sample size","mort, WHO7",SAE,N,N,exclude_diffanalysis
260_preprint,260,2,NCT04412057,Yes,https://www.medrxiv.org/content/10.1101/2021.04.03.21254748v1,*,Perlin DS ,medRxiv,2021,preprint,4/7/2021, double blinding,7/1/2020,Multicenter,No specific funding,No external funding was received for this study,Severe,USA,Treatment,CERC-002,41,41,*,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,83,HIC,,N,,,N,N,,,,,,,add_delete
260_preprint,260,2,NCT04412057,Yes,https://www.medrxiv.org/content/10.1101/2021.04.03.21254748v1,*,Perlin DS ,medRxiv,2021,preprint,4/7/2021, double blinding,7/1/2020,Multicenter,No specific funding,No external funding was received for this study,Severe,USA,Control,Placebo,42,41,*,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,83,HIC,,N,,,N,N,,,,,,,add_delete
260_pub,260,1,NCT04412057,Yes,https://www.jci.org/articles/view/153173; https://www.medrxiv.org/content/10.1101/2021.04.03.21254748v1,*,Perlin DS ,J Clin Invest,2021,published paper,12/6/2021, double blinding,7/17/2020,Multicenter,Private,Avalo Therapeutics.,Severe,USA,Treatment,CERC-002,41,40,3,39,28,*,*,*,*,*,*,*,16,8,*,*,Some concerns,blinded,Industry_Mixed,83,HIC,,N,,,N,N,,,,,,,add_delete
260_pub,260,2,NCT04412057,Yes,https://www.jci.org/articles/view/153173; https://www.medrxiv.org/content/10.1101/2021.04.03.21254748v1,*,Perlin DS ,J Clin Invest,2021,published paper,12/6/2021, double blinding,7/17/2020,Multicenter,Private,Avalo Therapeutics.,Severe,USA,Control,Placebo,42,42,6,42,28,*,*,*,*,*,*,*,21,12,*,*,Some concerns,blinded,Industry_Mixed,83,HIC,,N,,,N,N,,,,,,,add_delete
262_preprint,262,2,NCT04486313,Yes,https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1,*,Rossignol JF,medRxiv,2021,preprint,4/20/2021, double blinding,8/18/2020,Multicenter,Private,Romark Institute of Medical Research,Mild outpatients,"Puerto Rico, USA",Treatment,Nitazoxanide ,*,184,2,472,28,The primary endpoint was time from the first dose to sustained response (TSR). a measure of meaningful within-subject change in symptoms. Subjects were considered to have reached sustained response when they experienced (i) a decrease in total FLU-PRO score from the previous diary entry. (ii) with a corresponding patient assessment that symptoms were at least ���������somewhat better than yesterday.��������� (iii) no oral temperature ���������100.4������F during the past 24 hours. and (iv) no future increase in any of the FLU-PRO domain or subdomain scores through study day 21 except to pre-defined background levels that were considered not m,*,*,*,*,*,*,63,2,472,28,Some concerns,blinded,Industry_Mixed,1092,HIC,,,,,,,,,,,,,consistent
262_preprint,262,2,NCT04486313,Yes,https://www.medrxiv.org/content/10.1101/2021.04.19.21255441v1,*,Rossignol JF,medRxiv,2021,preprint,4/20/2021, double blinding,8/18/2020,Multicenter,Private,Romark Institute of Medical Research,Mild outpatients,"Puerto Rico, USA",Control,Placebo,*,195,0,463,28,The primary endpoint was time from the first dose to sustained response (TSR). a measure of meaningful within-subject change in symptoms. Subjects were considered to have reached sustained response when they experienced (i) a decrease in total FLU-PRO score from the previous diary entry. (ii) with a corresponding patient assessment that symptoms were at least ���������somewhat better than yesterday.��������� (iii) no oral temperature ���������100.4������F during the past 24 hours. and (iv) no future increase in any of the FLU-PRO domain or subdomain scores through study day 21 except to pre-defined background levels that were considered not m,*,*,*,*,*,*,75,7,463,28,Some concerns,blinded,Industry_Mixed,1092,HIC,,,,,,,,,,,,,consistent
262_pub,262,1,NCT04486313,Yes,https://www.sciencedirect.com/science/article/pii/S2589537022000402?via%3Dihub#sec0017 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3937568 https://www.medrxiv.org/node/382002.external-links.html https://www.medrxiv.org/content/10.1101/2021.04,*,Rossignol JF,EClinicalMedicine,2022,published paper,2/28/2022, double blinding,8/18/2020,Multicenter,Private,Romark Institute of Medical Research,Outpatients,"Puerto Rico, USA",Treatment,Nitazoxanide ,*,184,2,472,28,The primary endpoint was time from the first dose to sustained response (TSR). a measure of meaningful within-subject change in symptoms. Subjects were considered to have reached sustained response when they experienced (i) a decrease in total FLU-PRO score from the previous diary entry. (ii) with a corresponding patient assessment that symptoms were at least ���������somewhat better than yesterday.��������� (iii) no oral temperature ���������100.4������F during the past 24 hours. and (iv) no future increase in any of the FLU-PRO domain or subdomain scores through study day 21 except to pre-defined background levels that were considered not m,*,*,*,*,*,*,63,2,472,28,Some concerns,blinded,Industry_Mixed,1092,HIC,,,,,,,,,,,,,consistent
262_pub,262,2,NCT04486313,Yes,https://www.sciencedirect.com/science/article/pii/S2589537022000402?via%3Dihub#sec0017 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3937568 https://www.medrxiv.org/node/382002.external-links.html https://www.medrxiv.org/content/10.1101/2021.04,*,Rossignol JF,EClinicalMedicine,2022,published paper,2/28/2022, double blinding,8/18/2020,Multicenter,Private,Romark Institute of Medical Research,Outpatients,"Puerto Rico, USA",Control,Placebo,*,195,0,463,28,The primary endpoint was time from the first dose to sustained response (TSR). a measure of meaningful within-subject change in symptoms. Subjects were considered to have reached sustained response when they experienced (i) a decrease in total FLU-PRO score from the previous diary entry. (ii) with a corresponding patient assessment that symptoms were at least ���������somewhat better than yesterday.��������� (iii) no oral temperature ���������100.4������F during the past 24 hours. and (iv) no future increase in any of the FLU-PRO domain or subdomain scores through study day 21 except to pre-defined background levels that were considered not m,*,*,*,*,*,*,75,7,463,28,Some concerns,blinded,Industry_Mixed,1092,HIC,,,,,,,,,,,,,consistent
276_preprint,276,2,NCT04421027,Yes,https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1#p-5,*,Marconi V,medRxiv,2021,preprint,5/3/2021, double blinding,6/11/2020,Multicenter,Private,Eli Lilly and Company (Incyte Corporation licence),Mild to severe,"Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA (including Puerto Rico)",Treatment,Baricitinib,764,764,62,*,28,â‰¥2-point improvement on NIAID-OS or live discharge from hospital,593,758,28,104,758,28,334,110,750,28,Some concerns,blinded,Industry_Mixed,1525,Mixed,,N,N,N,N,N,,,,,,,consistent
276_preprint,276,2,NCT04421027,Yes,https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1#p-5,*,Marconi V,medRxiv,2021,preprint,5/3/2021, double blinding,6/11/2020,Multicenter,Private,Eli Lilly and Company (Incyte Corporation licence),Mild to severe,"Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA (including Puerto Rico)",Control,Placebo,761,761,100,*,28,â‰¥2-point improvement on NIAID-OS or live discharge from hospital,592,754,28,127,754,28,334,135,752,28,Some concerns,blinded,Industry_Mixed,1525,Mixed,,N,N,N,N,N,,,,,,,consistent
276_pub,276,1,NCT04421027,Yes,https://bit.ly/3uiXGYL https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v2 https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1#p-5,COV-BARRIER,Marconi V,Lancet Respir Med,2021,published paper,9/1/2021, single blinding,6/11/2020,Multicenter,Private,Eli Lilly and Company (Incyte Corporation licence),Mild to severe,"Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA (including Puerto Rico)",Treatment,Baricitinib,764,764,62,*,28,���2-point improvement on NIAID-OS or live discharge from hospital,593,758,28,104,758,28,334,110,750,28,Some concerns,blinded,Industry_Mixed,1525,Mixed,,N,N,N,N,N,,,,,,,consistent
276_pub,276,2,NCT04421027,Yes,https://bit.ly/3uiXGYL https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v2 https://www.medrxiv.org/content/10.1101/2021.04.30.21255934v1#p-5,COV-BARRIER,Marconi V,Lancet Respir Med,2021,published paper,9/1/2021, single blinding,6/11/2020,Multicenter,Private,Eli Lilly and Company (Incyte Corporation licence),Mild to severe,"Argentina, Brazil, Germany, India, Italy, Japan, Mexico, Russia, South Korea, Spain, UK, USA (including Puerto Rico)",Control,Placebo,761,761,100,*,28,���2-point improvement on NIAID-OS or live discharge from hospital,592,754,28,127,754,28,334,135,752,28,Some concerns,blinded,Industry_Mixed,1525,Mixed,,N,N,N,N,N,,,,,,,consistent
281_preprint,281,2,NCT04381962,Yes,https://www.medrxiv.org/content/10.1101/2021.04.21.21255807v1.full.pdf,ATOMIC2,Hinks T,medRxiv,2021,preprint,4/27/2021,Unblinded,6/3/2020,Multicenter,Mixed,"NIHR Oxford BRC, University of Oxford and Pfizer Inc",Mild outpatients,UK,Treatment,Azithromycin,147,145,1,*,28,*,*,*,*,*,*,*,*,0,*,28,Some concerns,unblinded,Industry_Mixed,298,HIC,,N,,N,,N,,,,,,,consistent
281_preprint,281,2,NCT04381962,Yes,https://www.medrxiv.org/content/10.1101/2021.04.21.21255807v1.full.pdf,ATOMIC2,Hinks T,medRxiv,2021,preprint,4/27/2021,Unblinded,6/3/2020,Multicenter,Mixed,"NIHR Oxford BRC, University of Oxford and Pfizer Inc",Mild outpatients,UK,Control,Standard care,148,147,1,*,28,*,*,*,*,*,*,*,*,0,*,28,Some concerns,unblinded,Industry_Mixed,298,HIC,,N,,N,,N,,,,,,,consistent
281_pub,281,1,NCT04381962,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00263-0/fulltext,ATOMIC2,Hinks T,Lancet Respir Med,2021,published paper,7/9/2021,Unblinded,6/3/2020,Multicenter,Mixed,"NIHR Oxford BRC, University of Oxford and Pfizer Inc",Outpatients,UK,Treatment,Azithromycin,147,145,1,*,28,*,*,*,*,*,*,*,*,0,*,28,Some concerns,unblinded,Industry_Mixed,298,HIC,,N,,N,,N,,,,,,,consistent
281_pub,281,2,NCT04381962,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00263-0/fulltext,ATOMIC2,Hinks T,Lancet Respir Med,2021,published paper,7/9/2021,Unblinded,6/3/2020,Multicenter,Mixed,"NIHR Oxford BRC, University of Oxford and Pfizer Inc",Outpatients,UK,Control,Standard care,148,147,1,*,28,*,*,*,*,*,*,*,*,0,*,28,Some concerns,unblinded,Industry_Mixed,298,HIC,,N,,N,,N,,,,,,,consistent
282_preprint,282,2,NCT04311177,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787463,*,Puskarich M,SSRN,2021,preprint,2/17/2021,quadruple blinding,4/9/2020,Multicenter,Public/non profit,Minnesota Partnership for Biotechnology and Medical Genomics,Mild outpatients,USA,Treatment,Losartan ,58,58,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,117,HIC,,N,,,,,,,,,,,consistent
282_preprint,282,2,NCT04311177,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3787463,*,Puskarich M,SSRN,2021,preprint,2/17/2021,quadruple blinding,4/9/2020,Multicenter,Public/non profit,Minnesota Partnership for Biotechnology and Medical Genomics,Mild outpatients,USA,Control,Placebo,59,59,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,117,HIC,,N,,,,,,,,,,,consistent
282_pub,282,1,NCT04311177,Yes,https://bit.ly/3AhZ2Wh,*,Puskarich M,EClinicalMedicine,2021,published paper,6/17/2021,"Participants, outcome assessor and health care pro",4/9/2020,Multicenter,Public/non profit,Minnesota Partnership for Biotechnology and Medical Genomics,Outpatients,USA,Treatment,Losartan ,58,58,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,117,HIC,,N,,,,,,,,,,,consistent
282_pub,282,2,NCT04311177,Yes,https://bit.ly/3AhZ2Wh,*,Puskarich M,EClinicalMedicine,2021,published paper,6/17/2021,"Participants, outcome assessor and health care pro",4/9/2020,Multicenter,Public/non profit,Minnesota Partnership for Biotechnology and Medical Genomics,Outpatients,USA,Control,Placebo,59,59,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,117,HIC,,N,,,,,,,,,,,consistent
285_preprint,285,2,NCT04351152,Yes,https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1,*,Temesgen Z,medRxiv,2021,preprint,5/5/2021, double blinding,5/5/2020,Multicenter,Private,"Humanigen, Inc.",Moderate/Severe,"Brazil, USA",Treatment,Lenzilumab,261,236,23,*,28,Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized. not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized. limitation on activities and/or requiring home oxygen; Not hospitalized. no limitations on activities).,*,*,*,36,*,28,*,63,255,28,Some concerns,blinded,Industry_Mixed,520,Mixed,,N,,N,,N,,,,,,,discrepTE
285_preprint,285,2,NCT04351152,Yes,https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1,*,Temesgen Z,medRxiv,2021,preprint,5/5/2021, double blinding,5/5/2020,Multicenter,Private,"Humanigen, Inc.",Moderate/Severe,"Brazil, USA",Control,Placebo,259,243,34,*,28,Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized. not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized. limitation on activities and/or requiring home oxygen; Not hospitalized. no limitations on activities).,*,*,*,52,*,28,*,76,257,28,Some concerns,blinded,Industry_Mixed,520,Mixed,,N,,N,,N,,,,,,,discrepTE
285_pub,285,1,NCT04351152,Yes,https://www.sciencedirect.com/science/article/pii/S221326002100494X?via%3Dihub#sec1 https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1,LIVE-AIR,Temesgen Z,Lancet Respir Med,2021,published paper,12/1/2021, double blinding,5/5/2020,Multicenter,Private,"Humanigen, Inc.",Moderate/Severe,"Brazil, USA",Treatment,Lenzilumab,261,236,24,*,28,Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized. not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized. limitation on activities and/or requiring home oxygen; Not hospitalized. no limitations on activities).,*,*,*,35,*,28,*,64,255,28,Some concerns,blinded,Industry_Mixed,520,Mixed,,N,,N,,N,,,,,,,discrepTE
285_pub,285,2,NCT04351152,Yes,https://www.sciencedirect.com/science/article/pii/S221326002100494X?via%3Dihub#sec1 https://www.medrxiv.org/content/10.1101/2021.05.01.21256470v1,LIVE-AIR,Temesgen Z,Lancet Respir Med,2021,published paper,12/1/2021, double blinding,5/5/2020,Multicenter,Private,"Humanigen, Inc.",Moderate/Severe,"Brazil, USA",Control,Placebo,259,243,34,*,28,Time to recovery is defined as the first day on which a subject satisfies one of the following 3 categories from the 8-point ordinal scale (Hospitalized. not requiring supplemental oxygen-no longer requires ongoing medical care; Not hospitalized. limitation on activities and/or requiring home oxygen; Not hospitalized. no limitations on activities).,*,*,*,51,*,28,*,77,257,28,Some concerns,blinded,Industry_Mixed,520,Mixed,,N,,N,,N,,,,,,,discrepTE
290_preprint,290,2,NCT04433910 ; EudraCT 2020-001310-38,Yes,https://www.medrxiv.org/content/10.1101/2021.05.10.21256192v1,CAPSID,Koerper S,medRxiv,2021,preprint,5/10/2021,Unblinded,8/30/2020,Multicenter,Public/non profit,Bundesministerium fuer Gesundheit (German Federal Ministry of Health),Mild to critical,Germany,Treatment,Convalescent plasma,53,53,8, *,35,Clinical improvement was defined as an increase by at least two points on an ordinal severity scale: 0. no clinical or virological evidence of infection; 1. ambulatory without limitation of activities; 2. ambulatory with limitation of activities; 3. hospitalized without oxygen therapy; 4. hospitalized with supplemental oxygen by mask or nasal prongs; 5. hospitalized. non-invasive ventilation or high-flow oxygen; 6. hospitalized. intubation and mechanical ventilation; 7. hospitalized. ventilation and additional organ support (vasopressors. renal replacement therapy or ECMO); 8. death ,*,*,*,*,*,*,42,22,*,60,Some concerns,unblinded,Other,105,HIC,,N,,,N,N,,,,,,,consistent
290_preprint,290,2,NCT04433910 ; EudraCT 2020-001310-38,Yes,https://www.medrxiv.org/content/10.1101/2021.05.10.21256192v1,CAPSID,Koerper S,medRxiv,2021,preprint,5/10/2021,Unblinded,8/30/2020,Multicenter,Public/non profit,Bundesministerium fuer Gesundheit (German Federal Ministry of Health),Mild to critical,Germany,Control,Standard care,52,52,14, *,35,Clinical improvement was defined as an increase by at least two points on an ordinal severity scale: 0. no clinical or virological evidence of infection; 1. ambulatory without limitation of activities; 2. ambulatory with limitation of activities; 3. hospitalized without oxygen therapy; 4. hospitalized with supplemental oxygen by mask or nasal prongs; 5. hospitalized. non-invasive ventilation or high-flow oxygen; 6. hospitalized. intubation and mechanical ventilation; 7. hospitalized. ventilation and additional organ support (vasopressors. renal replacement therapy or ECMO); 8. death ,*,*,*,*,*,*,43,25,*,60,Some concerns,unblinded,Other,105,HIC,,N,,,N,N,,,,,,,consistent
290_pub,290,1,NCT04433910; EudraCT 2020-001310-38,Yes,https://www.jci.org/articles/view/152264 https://www.medrxiv.org/content/10.1101/2021.05.10.21256192v1,CAPSID,Koerper S,J Clin Invest,2021,published paper,8/31/2021,Unblinded,8/30/2020,Multicenter,Public/non profit,Bundesministerium fuer Gesundheit (German Federal Ministry of Health),Mild to critical,Germany,Treatment,Convalescent plasma,53,53,8, *,35,Clinical improvement was defined as an increase by at least two points on an ordinal severity scale: 0. no clinical or virological evidence of infection; 1. ambulatory without limitation of activities; 2. ambulatory with limitation of activities; 3. hospitalized without oxygen therapy; 4. hospitalized with supplemental oxygen by mask or nasal prongs; 5. hospitalized. non-invasive ventilation or high-flow oxygen; 6. hospitalized. intubation and mechanical ventilation; 7. hospitalized. ventilation and additional organ support (vasopressors. renal replacement therapy or ECMO); 8. death ,*,*,*,*,*,*,42,22,*,60,Some concerns,unblinded,Other,105,HIC,,N,,,N,N,,,,,,,consistent
290_pub,290,2,NCT04433910; EudraCT 2020-001310-38,Yes,https://www.jci.org/articles/view/152264 https://www.medrxiv.org/content/10.1101/2021.05.10.21256192v1,CAPSID,Koerper S,J Clin Invest,2021,published paper,8/31/2021,Unblinded,8/30/2020,Multicenter,Public/non profit,Bundesministerium fuer Gesundheit (German Federal Ministry of Health),Mild to critical,Germany,Control,Standard care,52,52,14, *,35,Clinical improvement was defined as an increase by at least two points on an ordinal severity scale: 0. no clinical or virological evidence of infection; 1. ambulatory without limitation of activities; 2. ambulatory with limitation of activities; 3. hospitalized without oxygen therapy; 4. hospitalized with supplemental oxygen by mask or nasal prongs; 5. hospitalized. non-invasive ventilation or high-flow oxygen; 6. hospitalized. intubation and mechanical ventilation; 7. hospitalized. ventilation and additional organ support (vasopressors. renal replacement therapy or ECMO); 8. death ,*,*,*,*,*,*,43,25,*,60,Some concerns,unblinded,Other,105,HIC,,N,,,N,N,,,,,,,consistent
293_preprint,293,2,NCT04360824,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3840099,*,Perepu U,SSRN,2021,preprint,5/5/2021,Unblinded,4/26/2020,Multicenter,Public/non profit,National Institutes of Health Clinical and Translational Science Award,Severe/Critical,USA,Treatment,Intermediate dose EX,88,87,13,*,30,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Other,176,HIC,,N,,,,,,,,,,,consistent
293_preprint,293,2,NCT04360824,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3840099,*,Perepu U,SSRN,2021,preprint,5/5/2021,Unblinded,4/26/2020,Multicenter,Public/non profit,National Institutes of Health Clinical and Translational Science Award,Severe/Critical,USA,Control,Standard dose,88,86,18,*,30,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Other,176,HIC,,N,,,,,,,,,,,consistent
293_pub,293,1,NCT04360824,Yes,https://onlinelibrary.wiley.com/doi/10.1111/jth.15450 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3840099,*,Perepu U,J Thromb Haemost,2021,published paper,7/8/2021,Unblinded,4/26/2020,Multicenter,Public/non profit,National Institutes of Health Clinical and Translational Science Award,Severe/Critical,USA,Treatment,Intermediate dose EX,88,87,13,*,30,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Other,176,HIC,,N,,,,,,,,,,,consistent
293_pub,293,2,NCT04360824,Yes,https://onlinelibrary.wiley.com/doi/10.1111/jth.15450 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3840099,*,Perepu U,J Thromb Haemost,2021,published paper,7/8/2021,Unblinded,4/26/2020,Multicenter,Public/non profit,National Institutes of Health Clinical and Translational Science Award,Severe/Critical,USA,Control,Standard dose,88,86,18,*,30,*,*,*,*,*,*,*,*,*,*,*,Low,unblinded,Other,176,HIC,,N,,,,,,,,,,,consistent
296_preprint,296,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1,RECOVERY-CP,Horby P,medRxiv,2021,preprint,5/18/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Treatment,Colchicine,5610,5610,1173,*,28,Discharged from hospital within 28 days,3901,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11340,HIC,,N,N,,,,Y,,,,,,consistent
296_preprint,296,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1,RECOVERY-CP,Horby P,medRxiv,2021,preprint,5/19/2021,Unblinded,11/28/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Control,Standard care,5730,5730,1190,*,28,Discharged from hospital within 28 days,4032,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11340,HIC,,N,N,,,,Y,,,,,,consistent
296_pub,296,1,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext; https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1,RECOVERY-CP,Horby P,Lancet Respir Med,2021,published paper,10/18/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Treatment,Colchicine,5610,5610,1173,*,28,Discharged alive from hospital within 28 days,3901,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11340,HIC,,N,N,,,,Y,,,,,,consistent
296_pub,296,2,NCT04381936; EudraCT 2020-001113-21; ISRCTN5018967,Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00435-5/fulltext; https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1,RECOVERY-CP,Horby P,Lancet Respir Med,2021,published paper,10/18/2021,Unblinded,11/27/2020,Multicenter,Public/non profit,UK Research and Innovation (Medical Research Council) and National Institute of Health Research ,Mild to critical,UK,Control,Standard care,5730,5730,1190,*,28,Discharged alive from hospital within 28 days,4032,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Other,11340,HIC,,N,N,,,,Y,,,,,,consistent
297_preprint,297,2,NCT04680949; EudraCT 2020-005828-11,Yes,https://www.medrxiv.org/content/10.1101/2021.05.16.21257283v1.full-text,SAVE-MORE,Kyriazopoulou E,medRxiv,2021,preprint,5/18/2021, double blinding,12/23/2020,Multicenter,Mixed,Hellenic Institute for the Study of Sepsis and Swedish Orphan Biovitrum AB (Sobi),Moderate/Severe,"Greece, Italy",Treatment,Anakinra,412,405,13,*,28,Hospital discharge,362,*,28,25,*,28,*,68,*,28,Some concerns,blinded,Industry_Mixed,606,HIC,,N,N,N,N,N,,,,,,,discrepTE
297_preprint,297,2,NCT04680949; EudraCT 2020-005828-11,Yes,https://www.medrxiv.org/content/10.1101/2021.05.16.21257283v1.full-text,SAVE-MORE,Kyriazopoulou E,medRxiv,2021,preprint,5/18/2021, double blinding,12/23/2020,Multicenter,Mixed,Hellenic Institute for the Study of Sepsis and Swedish Orphan Biovitrum AB (Sobi),Moderate/Severe,"Greece, Italy",Control,Placebo,194,189,13,*,28,Hospital discharge,151,*,28,24,*,28,*,41,*,28,Some concerns,blinded,Industry_Mixed,606,HIC,,N,N,N,N,N,,,,,,,discrepTE
297_pub,297,1,NCT04680949; EudraCT 2020-005828-11,Yes,https://www.nature.com/articles/s41591-021-01499-z https://www.medrxiv.org/content/10.1101/2021.05.16.21257283v1.full-text,SAVE-MORE,Kyriazopoulou E,Nat Med,2021,published paper,9/3/2021, double blinding,12/23/2020,Multicenter,Mixed,Hellenic Institute for the Study of Sepsis and Swedish Orphan Biovitrum AB (Sobi),Mild to severe,"Greece, Italy",Treatment,Anakinra,412,405,13,*,28,Hospital discharge,362,*,28,25,388,28,*,65,*,*,Some concerns,blinded,Industry_Mixed,606,HIC,,N,N,N,N,N,,,,,,,discrepTE
297_pub,297,2,NCT04680949; EudraCT 2020-005828-11,Yes,https://www.nature.com/articles/s41591-021-01499-z https://www.medrxiv.org/content/10.1101/2021.05.16.21257283v1.full-text,SAVE-MORE,Kyriazopoulou E,Nat Med,2021,published paper,9/3/2021, double blinding,12/23/2020,Multicenter,Mixed,Hellenic Institute for the Study of Sepsis and Swedish Orphan Biovitrum AB (Sobi),Mild to severe,"Greece, Italy",Control,Placebo,194,189,13,*,28,Hospital discharge,151,*,28,24,180,28,*,41,*,*,Some concerns,blinded,Industry_Mixed,606,HIC,,N,N,N,N,N,,,,,,,discrepTE
298_preprint,298,2,ISRCTN16806663,No,https://www.medrxiv.org/content/10.1101/2021.04.15.21255300v1,*,Moni M,medRxiv,2021,preprint,4/20/2021,unblinded,9/20/2020,Single,Public/non profit,"Collaborating centre, the Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham.",Severe,India,Treatment,iNO,14,14,0,*,28,Improvement of 2 points on the WHO Ordinal Scale ,11,14,*,*,*,*,*,*,*,*,High,unblinded,Other,29,LIC_MIC,,,,,,,,,,,,,consistent
298_preprint,298,2,ISRCTN16806663,No,https://www.medrxiv.org/content/10.1101/2021.04.15.21255300v1,*,Moni M,medRxiv,2021,preprint,4/20/2021,unblinded,9/20/2020,Single,Public/non profit,"Collaborating centre, the Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham.",Severe,India,Control,Standard care,15,11,4,*,28,Improvement of 2 points on the WHO Ordinal Scale ,4,14,*,*,*,*,*,*,*,*,High,unblinded,Other,29,LIC_MIC,,,,,,,,,,,,,consistent
298_pub,298,1,ISRCTN16806663,No,https://www.medrxiv.org/content/10.1101/2021.04.15.21255300v1  https://journals.lww.com/imd/Fulltext/2022/03000/Clinical_Efficacy_of_Inhaled_Nitric_Oxide_in.5.aspx,*,Moni M,IMD,2022,published paper,3/1/2022,Unblinded,9/20/2020,Single,Public/non profit,"Collaborating centre, the Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham.",Severe,India,Treatment,iNO,14,14,0,*,28,Improvement of 2 points on the WHO Ordinal Scale ,11,14,*,*,*,*,*,*,*,*,High,unblinded,Other,29,LIC_MIC,,,,,,,,,,,,,consistent
298_pub,298,2,ISRCTN16806663,No,https://www.medrxiv.org/content/10.1101/2021.04.15.21255300v1  https://journals.lww.com/imd/Fulltext/2022/03000/Clinical_Efficacy_of_Inhaled_Nitric_Oxide_in.5.aspx,*,Moni M,IMD,2022,published paper,3/1/2022,Unblinded,9/20/2020,Single,Public/non profit,"Collaborating centre, the Amrita School of Biotechnology, Amrita Vishwa Vidyapeetham.",Severe,India,Control,Standard care,15,11,4,*,28,Improvement of 2 points on the WHO Ordinal Scale ,4,14,*,*,*,*,*,*,*,*,High,unblinded,Other,29,LIC_MIC,,,,,,,,,,,,,consistent
301_preprint,301,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.full-text,*,Lawler PR,medRxiv,2021,preprint,5/17/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, Cancercare Manitoba Foundation, Victoria General Hospital Foundation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, National Institutes of Health (NIH), European Union, Australian National Health and Medical Research Council, Health Research Council of New Zealand, U.K. NIHR, NIHR Imperial Biomedical Research Centre, Health Research Board of Ireland, UPMC Learning While Doing Program, Breast Cancer Research Foundation, French Ministry of Health, the Minderoo Foundation, Amgen, Eisai, Global Coalition for Adaptive Research, Wellcome Trust.",Mild to severe,"Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA.",Treatment,Therapeutic heparin,1190,1181,*,*,*,*,1085,1171,28,129,*,28,*,*,*,*,Some concerns,unblinded,Industry_Mixed,2245,Mixed,,,N,N,,,,,,,,,consistent
301_preprint,301,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.full-text,*,Lawler PR,medRxiv,2021,preprint,5/17/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, Cancercare Manitoba Foundation, Victoria General Hospital Foundation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, National Institutes of Health (NIH), European Union, Australian National Health and Medical Research Council, Health Research Council of New Zealand, U.K. NIHR, NIHR Imperial Biomedical Research Centre, Health Research Board of Ireland, UPMC Learning While Doing Program, Breast Cancer Research Foundation, French Ministry of Health, the Minderoo Foundation, Amgen, Eisai, Global Coalition for Adaptive Research, Wellcome Trust.",Mild to severe,"Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA.",Control,Prophylactic AC,1055,1050,*,*,*,Survival to hospital discharge,962,1048,28,127,*,28,*,*,*,*,Some concerns,unblinded,Industry_Mixed,2245,Mixed,,,N,N,,,,,,,,,consistent
301_pub,301,1,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.nejm.org/doi/10.1056/NEJMoa2105911  https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.full-text,*,Lawler PR,N Engl J Med,2021,published paper,8/4/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, Cancercare Manitoba Foundation, Victoria General Hospital Foundation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, National Institutes of Health (NIH), European Union, Australian National Health and Medical Research Council, Health Research Council of New Zealand, U.K. NIHR, NIHR Imperial Biomedical Research Centre, Health Research Board of Ireland, UPMC Learning While Doing Program, Breast Cancer Research Foundation, French Ministry of Health, the Minderoo Foundation, Amgen, Eisai, Global Coalition for Adaptive Research, Wellcome Trust.",Mild to severe,"Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA.",Treatment,Therapeutic heparin,1190,1181,*,*,*,Survival to hospital discharge,1085,1171,28,129,*,28,*,*,*,*,Some concerns,unblinded,Industry_Mixed,2245,Mixed,,,N,N,,,,,,,,,consistent
301_pub,301,2,"NCT02735707, NCT04505774, NCT04359277, NCT04372589",Yes,https://www.nejm.org/doi/10.1056/NEJMoa2105911  https://www.medrxiv.org/content/10.1101/2021.05.13.21256846v1.full-text,*,Lawler PR,N Engl J Med,2021,published paper,8/4/2021,Unblinded,4/21/2020,Multicenter,Mixed,"Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, Cancercare Manitoba Foundation, Victoria General Hospital Foundation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, National Institutes of Health (NIH), European Union, Australian National Health and Medical Research Council, Health Research Council of New Zealand, U.K. NIHR, NIHR Imperial Biomedical Research Centre, Health Research Board of Ireland, UPMC Learning While Doing Program, Breast Cancer Research Foundation, French Ministry of Health, the Minderoo Foundation, Amgen, Eisai, Global Coalition for Adaptive Research, Wellcome Trust.",Mild to severe,"Australia, Brazil, Canada, Mexico, Nepal, Netherlands, Spain, UK, USA.",Control,Prophylactic AC,1054,1050,*,*,*,Survival to hospital discharge,962,1048,28,127,*,28,*,*,*,*,Some concerns,unblinded,Industry_Mixed,2245,Mixed,,,N,N,,,,,,,,,consistent
302_preprint,302,2,NCT04530422,No,https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1,*,Elgohary M,medRxiv,2021,preprint,5/21/2021, single blinding,4/15/2020,Single,Not reported/unclear,None,Moderate,Egypt,Treatment,Sofosbuvir+Ledipasvir,125,125,0,*,21,Discharge criteria were resolution of symptoms (Normal body temperature for at least three days and significantly improved respiratory symptoms). Radiological improvement of pneumonic pattern in C.T. chest. and documented virological clearance in two samples least 24 hours apart. Discharge criteria also included no co-morbidities or complications. which require hospitalization and SpO2 >93% without assisted oxygen inhalation.,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,250,LIC_MIC,,,,,,,,,,,,,consistent
302_preprint,302,2,NCT04530422,No,https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1,*,Elgohary M,medRxiv,2021,preprint,5/21/2021, single blinding,4/15/2020,Single,Not reported/unclear,None,Moderate,Egypt,Control,Standard care,125,125,6,*,21,Discharge criteria were resolution of symptoms (Normal body temperature for at least three days and significantly improved respiratory symptoms). Radiological improvement of pneumonic pattern in C.T. chest. and documented virological clearance in two samples least 24 hours apart. Discharge criteria also included no co-morbidities or complications. which require hospitalization and SpO2 >93% without assisted oxygen inhalation.,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,250,LIC_MIC,,,,,,,,,,,,,consistent
302_pub,302,1,NCT04530422,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015168/ https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1,*,Elgohary M,J Med Life,2022,published paper,3/1/2022, single blinding,4/15/2020,Single,Not reported/unclear,None,Moderate,Egypt,Treatment,Sofosbuvir+Ledipasvir,125,125,0,*,21,Discharge criteria were resolution of symptoms (Normal body temperature for at least three days and significantly improved respiratory symptoms). Radiological improvement of pneumonic pattern in C.T. chest. and documented virological clearance in two samples least 24 hours apart. Discharge criteria also included no co-morbidities or complications. which require hospitalization and SpO2 >93% without assisted oxygen inhalation.,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,250,LIC_MIC,,,,,,,,,,,,,consistent
302_pub,302,2,NCT04530422,No,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015168/ https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1,*,Elgohary M,J Med Life,2022,published paper,3/1/2022, single blinding,4/15/2020,Single,Not reported/unclear,None,Moderate,Egypt,Control,Standard care,125,125,6,*,21,Discharge criteria were resolution of symptoms (Normal body temperature for at least three days and significantly improved respiratory symptoms). Radiological improvement of pneumonic pattern in C.T. chest. and documented virological clearance in two samples least 24 hours apart. Discharge criteria also included no co-morbidities or complications. which require hospitalization and SpO2 >93% without assisted oxygen inhalation.,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,250,LIC_MIC,,,,,,,,,,,,,consistent
304_preprint,304,3,NCT04315298,Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S (1),medRxiv,2021,preprint,5/14/2021, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi",Moderate to critical,USA,Treatment,Sarilumab,*,367,*,*,*,Proportion with ���������2-point improvement in clinical status using a 7-point ordinal scale on ,214,*,22,*,*,*,237,174,*,*,Some concerns,blinded,Industry_Mixed,463,HIC,,,,,,,,,,,,,consistent
304_preprint,304,3,NCT04315298,Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S (1),medRxiv,2021,preprint,5/14/2021, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi",Moderate to critical,USA,Control,Placebo,*,90,*,*,*,Proportion with ���������2-point improvement in clinical status using a 7-point ordinal scale on ,48,*,22,*,*,*,51,39,*,*,Some concerns,blinded,Industry_Mixed,463,HIC,,,,,,,,,,,,,consistent
304_pub,304,3,NCT04315298,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac153/6537638 https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S,Clin Infect Dis,2022,published paper,2/26/2022, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi; Biomedical Advanced Research and Development Authority; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Moderate to critical,USA,Treatment,Sarilumab,*,367,*,*,*,Proportion with 1-point improvement in clinical status using a 7-point ordinal scale on day 22,214,*,22,*,*,*,237,174,*,*,Some concerns,blinded,Industry_Mixed,463,HIC,,,,,,,,,,,,,consistent
304_pub,304,3,NCT04315298,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac153/6537638 https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S,Clin Infect Dis,2022,published paper,2/26/2022, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi; Biomedical Advanced Research and Development Authority; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Moderate to critical,USA,Control,Placebo,*,90,*,*,*,Proportion with 1-point improvement in clinical status using a 7-point ordinal scale on day 22,48,*,22,*,*,*,51,39,*,*,Some concerns,blinded,Industry_Mixed,463,HIC,,,,,,,,,,,,,consistent
305_preprint,305,3,NCT04315298,Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S (2),medRxiv,2021,preprint,5/14/2021, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc. and Sanofi",Moderate to critical,USA,Treatment,Sarilumab,*,567,264,*,29,at least a 2-point reduction on a 7 point ordinal scale,571,*,22,*,*,*,620,480,*,28,Some concerns,blinded,Industry_Mixed,1407,HIC,,,,,,,,,,,,,consistent
305_preprint,305,3,NCT04315298,Yes,https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S (2),medRxiv,2021,preprint,5/14/2021, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc. and Sanofi",Moderate to critical,USA,Control,Placebo,*,477,64,*,29,at least a 2-point reduction on a 7 point ordinal scale,160,*,22,*,*,*,159,127,*,28,Some concerns,blinded,Industry_Mixed,1407,HIC,,,,,,,,,,,,,consistent
305_pub,305,3,NCT04315298,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac153/6537638 https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S,Clin Infect Dis,2022,published paper,2/26/2022, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi; Biomedical Advanced Research and Development Authority; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Moderate to critical,USA,Treatment,Sarilumab,*,567,264,*,29,at least a 2-point reduction on a 7 point ordinal scale,571,*,22,*,*,*,620,480,*,28,Some concerns,blinded,Industry_Mixed,1407,HIC,,,,,,,,,,,,,consistent
305_pub,305,3,NCT04315298,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac153/6537638 https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1.full,*,Sivapalasingam S,Clin Infect Dis,2022,published paper,2/26/2022, double blinding,3/18/2020,Multicenter,Private,"Regeneron Pharmaceuticals, Inc.; Sanofi; Biomedical Advanced Research and Development Authority; Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority",Moderate to critical,USA,Control,Placebo,*,477,64,*,29,at least a 2-point reduction on a 7 point ordinal scale,160,*,22,*,*,*,159,127,*,28,Some concerns,blinded,Industry_Mixed,1407,HIC,,,,,,,,,,,,,consistent
312_preprint,312,2,NCT04425629,Yes,https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D,medRxiv,2021,preprint,5/21/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Mild outpatients,"Mexico, USA",Treatment,REGN-COV2,1529,1355,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,3029,Mixed,,N,,,,,,,,,,,consistent
312_preprint,312,2,NCT04425629,Yes,https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D,medRxiv,2021,preprint,5/21/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Mild outpatients,"Mexico, USA",Control,Placebo,1500,1341,3,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,3029,Mixed,,N,,,,,,,,,,,consistent
312_pub,312,1,NCT04425629,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2108163 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D,N Engl J Med,2021,published paper,9/29/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Outpatients,"Mexico, USA",Treatment,REGN-COV2,1529,1355,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,3029,Mixed,,N,,,,,,,,,,,consistent
312_pub,312,2,NCT04425629,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2108163 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D,N Engl J Med,2021,published paper,9/29/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Outpatients,"Mexico, USA",Control,Placebo,1500,1341,3,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,3029,Mixed,,N,,,,,,,,,,,consistent
313_preprint,313,2,NCT04425629,Yes,https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D (2),medRxiv,2021,preprint,5/21/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Mild outpatients,"Mexico, USA",Treatment,REGN-COV2,838,736,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,1678,Mixed,,N,,,,,,,,,,,consistent
313_preprint,313,2,NCT04425629,Yes,https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D (2),medRxiv,2021,preprint,5/21/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Mild outpatients,"Mexico, USA",Control,Placebo,840,748,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,1678,Mixed,,N,,,,,,,,,,,consistent
313_pub,313,1,NCT04425629,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2108163 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D (2),N Engl J Med,2021,published paper,9/29/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Outpatients,"Mexico, USA",Treatment,REGN-COV2,838,736,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,1678,Mixed,,N,,,,,,,,,,,consistent
313_pub,313,2,NCT04425629,Yes,https://www.nejm.org/doi/10.1056/NEJMoa2108163 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2 https://www.medrxiv.org/content/10.1101/2021.05.19.21257469v2,*,Weinreich D (2),N Engl J Med,2021,published paper,9/29/2021, double blinding,9/24/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority",Outpatients,"Mexico, USA",Control,Placebo,840,748,1,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Industry_Mixed,1678,Mixed,,N,,,,,,,,,,,consistent
315_preprint,315,2,NCT04545060,No,https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1,COMET-ICE,Gupta A,medRxiv,2021,preprint,5/28/2021, double blinding,8/27/2020,Multicenter,Private,"Vir Biotechnology, Inc. and GlaxoSmithKline.",Mild outpatients,"USA, Canada, Brazil, and Spain",Treatment,Sotrovimab,291,291,0,*,29,*,*,*,*,0,*,29,73,7,430,56,Low,blinded,Industry_Mixed,583,Mixed,,N,,N,N,N,,,,,,,consistent
315_preprint,315,2,NCT04545060,No,https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1,COMET-ICE,Gupta A,medRxiv,2021,preprint,5/28/2021, double blinding,8/27/2020,Multicenter,Private,"Vir Biotechnology, Inc. and GlaxoSmithKline.",Mild outpatients,"USA, Canada, Brazil, and Spain",Control,Placebo,292,292,1,*,29,*,*,*,*,3,*,29,85,26,438,55,Low,blinded,Industry_Mixed,583,Mixed,,N,,N,N,N,,,,,,,consistent
315_pub,315,1,NCT04545060,No,https://pubmed.ncbi.nlm.nih.gov/34706189/ https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1,COMET-ICE,Gupta A,N Engl J Med,2021,published paper,10/27/2021,quadruple blinding,8/27/2020,Multicenter,Private,"Vir Biotechnology, Inc. and GlaxoSmithKline.",Outpatients,"USA, Canada, Brazil, Spain and Peru",Treatment,Sotrovimab,291,291,0,*,28,*,*,*,*,0,*,28,73,7,430,56,Low,blinded,Industry_Mixed,583,Mixed,,N,,N,N,N,,,,,,,consistent
315_pub,315,2,NCT04545060,No,https://pubmed.ncbi.nlm.nih.gov/34706189/ https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v2,COMET-ICE,Gupta A,N Engl J Med,2021,published paper,10/27/2021,quadruple blinding,8/27/2020,Multicenter,Private,"Vir Biotechnology, Inc. and GlaxoSmithKline.",Outpatients,"USA, Canada, Brazil, Spain and Peru",Control,Placebo,292,292,1,*,28,*,*,*,*,3,*,28,85,26,438,55,Low,blinded,Industry_Mixed,583,Mixed,,N,,N,N,N,,,,,,,consistent
316_preprint,316,2,NCT04381936; ISRCTN50189673,Yes,https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1,RECOVERY-ASA,Horby P,medRxiv,2021,preprint,6/8/2021,Unblinded,11/1/2020,Multicenter,Mixed,UK Research and Innovation; National Institute of Health Research ; the Wellcome Trust; Bill and Melinda Gates Foundation; Commonwealth and development Department.,Mild to critical,"UK, Indonesia, Nepal",Treatment,Aspirin,7351,7351,1222,*,28,Discharged from hospital within 28 days,5496,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,14892,Mixed,,,N,,,,,,,,,,consistent
316_preprint,316,2,NCT04381936; ISRCTN50189673,Yes,https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1,RECOVERY-ASA,Horby P,medRxiv,2021,preprint,6/8/2021,Unblinded,11/1/2020,Multicenter,Mixed,UK Research and Innovation; National Institute of Health Research ; the Wellcome Trust; Bill and Melinda Gates Foundation; Commonwealth and development Department.,Mild to critical,"UK, Indonesia, Nepal",Control,Standard care,7541,7541,1299,*,28,Discharged from hospital within 28 days,5548,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,14892,Mixed,,,N,,,,,,,,,,consistent
316_pub,316,1,NCT04381936; ISRCTN50189673,Yes,https://www.sciencedirect.com/science/article/pii/S0140673621018250?via%3Dihub; https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1,RECOVERY-ASA,Horby P,Lancet,2021,published paper,11/17/2021,Unblinded,11/1/2020,Multicenter,Mixed,UK Research and Innovation; National Institute of Health Research ; the Wellcome Trust; Bill and Melinda Gates Foundation; Commonwealth and development Department.,Mild to critical,"UK, Indonesia, Nepal",Treatment,Aspirin,7351,7351,1222,*,28,Discharged from hospital within 28 days,5496,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,14892,Mixed,,,N,,,,,,,,,,consistent
316_pub,316,2,NCT04381936; ISRCTN50189673,Yes,https://www.sciencedirect.com/science/article/pii/S0140673621018250?via%3Dihub; https://www.medrxiv.org/content/10.1101/2021.06.08.21258132v1,RECOVERY-ASA,Horby P,Lancet,2021,published paper,11/17/2021,Unblinded,11/1/2020,Multicenter,Mixed,UK Research and Innovation; National Institute of Health Research ; the Wellcome Trust; Bill and Melinda Gates Foundation; Commonwealth and development Department.,Mild to critical,"UK, Indonesia, Nepal",Control,Standard care,7541,7541,1299,*,28,Discharged from hospital within 28 days,5548,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,14892,Mixed,,,N,,,,,,,,,,consistent
317_preprint,317,2,"NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967",Yes,https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1,RECOVERY-REGEN,Horby P,medRxiv,2021,preprint,6/16/2021,Unblinded,9/18/2020,Multicenter,Mixed,UK Research and Innovation (Medical Research Council); National Institute of Health Research; Regeneron Pharmaceuticals Inc. (REGEN-COV2 donation),Mild to critical,UK,Treatment,REGN-COV2,4839,4839,944,*,28,Discharged from hospital within 28 days,3375,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,9785,HIC,,,,,,,,,,,,,discrepTE
317_preprint,317,2,"NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967",Yes,https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1,RECOVERY-REGEN,Horby P,medRxiv,2021,preprint,6/16/2021,Unblinded,9/18/2020,Multicenter,Mixed,UK Research and Innovation (Medical Research Council); National Institute of Health Research; Regeneron Pharmaceuticals Inc. (REGEN-COV2 donation),Mild to critical,UK,Control,Standard care,4946,4946,1026,*,28,Discharged from hospital within 28 days,3413,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,9785,HIC,,,,,,,,,,,,,discrepTE
317_pub,317,1,"NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967",Yes,https://www.sciencedirect.com/science/article/pii/S0140673622001635?via%3Dihub#sec1 https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1,RECOVERY-REGEN,Horby P,Lancet,2022,published paper,2/12/2022,Unblinded,9/18/2020,Multicenter,Mixed,UK Research and Innovation (Medical Research Council); National Institute of Health Research; Regeneron Pharmaceuticals Inc. (REGEN-COV2 donation),Mild to critical,UK,Treatment,REGN-COV2,4839,4839,943,*,28,Discharged alive from hospital within 28 days,3389,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,9785,HIC,,,,,,,,,,,,,discrepTE
317_pub,317,1,"NCT04381936, EudraCT 2020-001113-21, ISRCTN5018967",Yes,https://www.sciencedirect.com/science/article/pii/S0140673622001635?via%3Dihub#sec1 https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1,RECOVERY-REGEN,Horby P,Lancet,2022,published paper,2/12/2022,Unblinded,9/18/2020,Multicenter,Mixed,UK Research and Innovation (Medical Research Council); National Institute of Health Research; Regeneron Pharmaceuticals Inc. (REGEN-COV2 donation),Mild to critical,UK,Control,Standard care,4946,4946,1029,*,28,Discharged alive from hospital within 28 days,3420,*,28,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,9785,HIC,,,,,,,,,,,,,discrepTE
320_preprint,320,2,"NCT04315948, EudraCT2020-000936-23",Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3854628,DisCoVeRy (RDV),Ader F,SSRN,2021,preprint,5/27/2021,Unblinded,3/22/2020,Multicenter,Public/non profit,"European Union Commission, French Ministry of Health, DIM One Health ÃŽle-de France, REACTing, Fonds Erasme-COVID-ULB, Belgian Health Care Knowledge Centre (KCE)",Mild to critical,"Austria, Belgium, France, Luxembourg, Portugal",Treatment,Remdesivir,429,414,34,*,28,Hospital discharge (points 1 and 2 on WHO scale),265,*,28,60,*,28,241,135,406,28,Some concerns,unblinded,Other,857,HIC,,,N,N,N,N,Y,,,,,,consistent
320_preprint,320,2,"NCT04315948, EudraCT2020-000936-23",Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3854628,DisCoVeRy (RDV),Ader F,SSRN,2021,preprint,5/27/2021,Unblinded,3/22/2020,Multicenter,Public/non profit,"European Union Commission, French Ministry of Health, DIM One Health ÃŽle-de France, REACTing, Fonds Erasme-COVID-ULB, Belgian Health Care Knowledge Centre (KCE)",Mild to critical,"Austria, Belgium, France, Luxembourg, Portugal",Control,Standard care,428,418,38,*,28,Hospital discharge (points 1 and 2 on WHO scale),241,*,28,79,*,28,236,130,418,28,Some concerns,unblinded,Other,857,HIC,,,N,N,N,N,Y,,,,,,consistent
320_pub,320,1,"NCT04315948, EudraCT2020-000936-23",Yes,https://www.sciencedirect.com/science/article/pii/S1473309921004850?via%3Dihub#cesec120 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3866603,DisCoVeRy (RDV),Ader F,Lancet Infect Dis,2021,published paper,9/14/2021,Unblinded,3/22/2020,Multicenter,Public/non profit,"European Union Commission, French Ministry of Health, DIM One Health ��le-de France, REACTing, Fonds Erasme-COVID-ULB, Belgian Health Care Knowledge Centre (KCE)",Mild to critical,"Austria, Belgium, France, Luxembourg, Portugal",Treatment,Remdesivir,429,414,34,*,28,Hospital discharge (points 1 and 2 on WHO scale),265,*,28,60,*,28,241,135,406,28,Some concerns,unblinded,Other,857,HIC,,,N,N,N,N,Y,,,,,,consistent
320_pub,320,2,"NCT04315948, EudraCT2020-000936-23",Yes,https://www.sciencedirect.com/science/article/pii/S1473309921004850?via%3Dihub#cesec120 https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3866603,DisCoVeRy (RDV),Ader F,Lancet Infect Dis,2021,published paper,9/14/2021,Unblinded,3/22/2020,Multicenter,Public/non profit,"European Union Commission, French Ministry of Health, DIM One Health ��le-de France, REACTing, Fonds Erasme-COVID-ULB, Belgian Health Care Knowledge Centre (KCE)",Mild to critical,"Austria, Belgium, France, Luxembourg, Portugal",Control,Standard care,428,418,38,*,28,Hospital discharge (points 1 and 2 on WHO scale),241,*,28,79,*,28,236,130,418,28,Some concerns,unblinded,Other,857,HIC,,,N,N,N,N,Y,,,,,,consistent
324_preprint,324,2,NCT04452318,Yes,https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v1,*,O'Brien M,medRxiv,2021,preprint,6/14/2021, double blinding,7/13/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd.; COVID-19 Prevention Network (CoVPN) ",Mild outpatients,"Moldova, Romania, USA",Treatment,REGN-COV2,156,155,*,*,28,*,*,*,*,*,*,*,52,0,155,*,Some concerns,blinded,Industry_Mixed,314,Mixed,,,,,,,,,,,,,add_delete
324_preprint,324,2,NCT04452318,Yes,https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v1,*,O'Brien M,medRxiv,2021,preprint,6/14/2021, double blinding,7/13/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd.; COVID-19 Prevention Network (CoVPN) ",Outpatients,"Moldova, Romania, USA",Control,Placebo,158,156,*,*,28,*,*,*,*,*,*,*,75,4,156,*,Some concerns,blinded,Industry_Mixed,314,Mixed,,,,,,,,,,,,,add_delete
324_pub,324,1,NCT04452318,Yes,https://jamanetwork.com/journals/jama/fullarticle/2788256 https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v2 https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v1,*,O'Brien M,JAMA,2022,published paper,1/14/2022, double blinding,7/13/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd.; COVID-19 Prevention Network (CoVPN) ",Outpatients,"Moldova, Romania, USA",Treatment,REGN-COV2,156,155,0,*,28,*,*,*,*,*,*,*,52,0,155,28,Some concerns,blinded,Industry_Mixed,314,Mixed,,,,,,,,,,,,,add_delete
324_pub,324,2,NCT04452318,Yes,https://jamanetwork.com/journals/jama/fullarticle/2788256 https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v2 https://www.medrxiv.org/content/10.1101/2021.06.14.21258569v1,*,O'Brien M,JAMA,2022,published paper,1/14/2022, double blinding,7/13/2020,Multicenter,Mixed,"Regeneron Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd.; COVID-19 Prevention Network (CoVPN) ",Outpatients,"Moldova, Romania, USA",Control,Placebo,158,156,0,*,28,*,*,*,*,*,*,*,75,4,156,28,Some concerns,blinded,Industry_Mixed,314,Mixed,,,,,,,,,,,,,add_delete
327_preprint,327,1,NCT02735707,Yes,https://www.medrxiv.org/content/10.1101/2021.06.11.21258760v1,REMAP-CAP,Estcourt L,medRxiv,2021,preprint,6/13/2021,Unblinded,5/5/2020,Multicenter,Mixed,PREPARE consortium by the European Union; Australian National Health and Medical Research Council; Australian Medical Research Future Fund; New Zealand Health Research Council; Canadian Institutes of Health Research COVID-19 Rapid Research Funding; Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant; NIHR; UK NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; UPMC Learning While Doing Program; Translational Breast Cancer Research Consortium; Pittsburgh Foundation; French Ministry of Health; Minderoo Foundation; Wellcome Trust Innovations Project; Australian government; DHSC; EU SoHo Grants,Severe/Critical,"Australia, Canada, UK, USA",Treatment,Convalescent plasma,1084,1075,401,*,21,*,*,*,*,*,*,*,*,32,1075,*,Low,unblinded,Industry_Mixed,2000,HIC,,N,N,N,N,N,Y,,,,,,consistent
327_preprint,327,2,NCT02735707,Yes,https://www.medrxiv.org/content/10.1101/2021.06.11.21258760v1,REMAP-CAP,Estcourt L,medRxiv,2021,preprint,6/13/2021,Unblinded,5/5/2020,Multicenter,Mixed,PREPARE consortium by the European Union; Australian National Health and Medical Research Council; Australian Medical Research Future Fund; New Zealand Health Research Council; Canadian Institutes of Health Research COVID-19 Rapid Research Funding; Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant; NIHR; UK NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; UPMC Learning While Doing Program; Translational Breast Cancer Research Consortium; Pittsburgh Foundation; French Ministry of Health; Minderoo Foundation; Wellcome Trust Innovations Project; Australian government; DHSC; EU SoHo Grants,Severe/Critical,"Australia, Canada, UK, USA",Control,Standard care,916,904,347,*,21,*,*,*,*,*,*,*,*,12,905,*,Low,unblinded,Industry_Mixed,2000,HIC,,N,N,N,N,N,Y,,,,,,consistent
327_pub,327,1,NCT02735707,Yes,https://jamanetwork.com/journals/jama/fullarticle/2784914; https://www.medrxiv.org/content/10.1101/2021.06.11.21258760v1,REMAP-CAP,Estcourt L,JAMA,2021,published paper,10/4/2021,Unblinded,5/5/2020,Multicenter,Mixed,PREPARE consortium by the European Union; Australian National Health and Medical Research Council; Australian Medical Research Future Fund; New Zealand Health Research Council; Canadian Institutes of Health Research COVID-19 Rapid Research Funding; Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant; NIHR; UK NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; UPMC Learning While Doing Program; Translational Breast Cancer Research Consortium; Pittsburgh Foundation; French Ministry of Health; Minderoo Foundation; Wellcome Trust Innovations Project; Australian government; DHSC; EU SoHo Grants,Severe/Critical,"Australia, Canada, UK, USA",Treatment,Convalescent plasma,1084,1075,401,*,21,*,*,*,*,*,*,*,*,32,1075,*,Low,unblinded,Industry_Mixed,2000,HIC,,N,N,N,N,N,Y,,,,,,consistent
327_pub,327,2,NCT02735707,Yes,https://jamanetwork.com/journals/jama/fullarticle/2784914; https://www.medrxiv.org/content/10.1101/2021.06.11.21258760v1,REMAP-CAP,Estcourt L,JAMA,2021,published paper,10/4/2021,Unblinded,5/5/2020,Multicenter,Mixed,PREPARE consortium by the European Union; Australian National Health and Medical Research Council; Australian Medical Research Future Fund; New Zealand Health Research Council; Canadian Institutes of Health Research COVID-19 Rapid Research Funding; Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant; NIHR; UK NIHR; NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; UPMC Learning While Doing Program; Translational Breast Cancer Research Consortium; Pittsburgh Foundation; French Ministry of Health; Minderoo Foundation; Wellcome Trust Innovations Project; Australian government; DHSC; EU SoHo Grants,Severe/Critical,"Australia, Canada, UK, USA",Control,Standard care,916,904,347,*,21,*,*,*,*,*,*,*,*,12,905,*,Low,unblinded,Industry_Mixed,2000,HIC,,N,N,N,N,N,Y,,,,,,consistent
329_preprint,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,medRxiv,2021,preprint,6/9/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Treatment,Namilumab ,57,55,6,*,28,Discharge,43,*,28,*,*,*,30,10,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
329_preprint,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,medRxiv,2021,preprint,6/9/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Treatment,Infliximab,35,29,4,*,28,Discharge,22,*,28,*,*,*,20,6,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
329_preprint,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,medRxiv,2021,preprint,6/9/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Control,Standard care,54,54,10,*,28,Discharge,33,*,28,*,*,*,29,10,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
329_pub,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext#seccestitle10 https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,Lancet Respir Med,2021,published paper,12/16/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Treatment,Namilumab ,57,55,6,*,28,Discharge,43,*,28,*,*,*,30,10,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
329_pub,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext#seccestitle10 https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,Lancet Respir Med,2021,published paper,12/16/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Treatment,Infliximab,35,29,4,*,28,Discharge,22,*,28,*,*,*,20,6,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
329_pub,329,3,"ISRCTN40580903, EudraCT 2020-001684-85",Yes,https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00460-4/fulltext#seccestitle10 https://www.medrxiv.org/content/10.1101/2021.06.02.21258204v1,CATALYST,Fisher B,Lancet Respir Med,2021,published paper,12/16/2021,Unblinded,6/15/2020,Multicenter,Public/non profit,Medical Research Council,Moderate to critical,UK,Control,Standard care,54,54,10,*,28,Discharge,33,*,28,*,*,*,29,10,*,28,Some concerns,unblinded,Other,146,HIC,,N,N,,N,N,,,,,,,consistent
331_preprint,331,2,NCT04473170,No,https://www.researchsquare.com/article/rs-558653/v1,SENTAD-COVID,Carmenate Y,Research Square ,2021,preprint,6/8/2021,Unblinded,4/4/2020,Multicenter,Private,Abu Dhabi Stem Cells Center ,Mild to critical,United Arab Emirates,Treatment,NHPBSC,71,69,4,*,28,Discharge,59,*,28,*,*,*,50,*,*,28,Some concerns,unblinded,Industry_Mixed,143,HIC,,N,,,,,,,,,,,consistent
331_preprint,331,2,NCT04473170,No,https://www.researchsquare.com/article/rs-558653/v1,SENTAD-COVID,Carmenate Y,Research Square ,2021,preprint,6/8/2021,Unblinded,4/4/2020,Multicenter,Private,Abu Dhabi Stem Cells Center ,Mild to critical,United Arab Emirates,Control,Standard care,72,70,7,*,28,Discharge,57,*,28,*,*,*,51,*,*,28,Some concerns,unblinded,Industry_Mixed,143,HIC,,N,,,,,,,,,,,consistent
331_pub,331,1,NCT04473170,No,https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-021-00101-5#availability-of-data-and-materials https://www.researchsquare.com/article/rs-558653/v1,SENTAD-COVID,Ventura-Carmenate Y,Transl Med Commun,2021,published paper,11/3/2021,Unblinded,4/4/2020,Multicenter,Private,Abu Dhabi Stem Cells Center ,Mild to critical,United Arab Emirates,Treatment,NHPBSC,71,69,4,*,28,Discharge,59,*,28,*,*,*,50,*,*,28,Some concerns,unblinded,Industry_Mixed,143,HIC,,N,,,,,,,,,,,consistent
331_pub,331,2,NCT04473170,No,https://transmedcomms.biomedcentral.com/articles/10.1186/s41231-021-00101-5#availability-of-data-and-materials https://www.researchsquare.com/article/rs-558653/v1,SENTAD-COVID,Ventura-Carmenate Y,Transl Med Commun,2021,published paper,11/3/2021,Unblinded,4/4/2020,Multicenter,Private,Abu Dhabi Stem Cells Center ,Mild to critical,United Arab Emirates,Control,Standard care,72,70,7,*,28,Discharge,57,*,28,*,*,*,51,*,*,28,Some concerns,unblinded,Industry_Mixed,143,HIC,,N,,,,,,,,,,,consistent
335_preprint,335,2,NCT04860284,No,https://www.researchsquare.com/article/rs-506195/v1,*,Byakika-Kibwika P,Research Square ,2021,preprint,6/4/2021,Unblinded,9/18/2020,Single,Public/non profit,Government of Uganda through the Makerere University Research and Innovation Fund,Outpatients,Uganda,Treatment,Hydroxychloroquine,55,55,*,*,*,*,*,*,*,*,*,*,33,0,55,10,Some concerns,unblinded,Other,105,LIC_MIC,,,,,,,,,,,,,consistent
335_preprint,335,2,NCT04860284,No,https://www.researchsquare.com/article/rs-506195/v1,*,Byakika-Kibwika P,Research Square ,2021,preprint,6/4/2021,Unblinded,9/18/2020,Single,Public/non profit,Government of Uganda through the Makerere University Research and Innovation Fund,Outpatients,Uganda,Control,Standard care,50,50,*,*,*,*,*,*,*,*,*,*,27,0,50,10,Some concerns,unblinded,Other,105,LIC_MIC,,,,,,,,,,,,,consistent
335_pub,335,1,NCT04860284,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06897-9 https://www.researchsquare.com/article/rs-506195/v1,HONEST ,Byakika-Kibwika P,BMC Infect Dis,2021,published paper,12/6/2021,Unblinded,9/18/2020,Single,Public/non profit,Government of Uganda through the Makerere University Research and Innovation Fund,Outpatients,Uganda,Treatment,Hydroxychloroquine,55,55,*,*,*,*,*,*,*,*,*,*,33,0,55,10,Some concerns,unblinded,Other,105,LIC_MIC,,,,,,,,,,,,,consistent
335_pub,335,2,NCT04860284,No,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06897-9 https://www.researchsquare.com/article/rs-506195/v1,HONEST ,Byakika-Kibwika P,BMC Infect Dis,2021,published paper,12/6/2021,Unblinded,9/18/2020,Single,Public/non profit,Government of Uganda through the Makerere University Research and Innovation Fund,Outpatients,Uganda,Control,Standard care,50,50,*,*,*,*,*,*,*,*,*,*,27,0,50,10,Some concerns,unblinded,Other,105,LIC_MIC,,,,,,,,,,,,,consistent
336_preprint,336,3,CTRI/2020/06/025575,Yes,https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Singh B,medRxiv,2021,preprint,6/8/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Treatment,HCQ+RBV,23,20,3,20,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
336_preprint,336,3,CTRI/2020/06/025575,Yes,https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Singh B,medRxiv,2021,preprint,6/8/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Treatment,LPV/r+RBV,24,22,5,22,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
336_preprint,336,3,CTRI/2020/06/025575,Yes,https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Singh B,medRxiv,2021,preprint,6/8/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Control,Standard care,24,21,6,21,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
336_pub,336,3,CTRI/2020/06/025575,Yes,https://www.dovepress.com/antiviral-combination-clinically-better-than-standard-therapy-in-sever-peer-reviewed-fulltext-article-CPAA; https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Panda PK,Clin Pharmacol,2021,published paper,9/29/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Treatment,HCQ+RBV,23,20,3,20,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
336_pub,336,3,CTRI/2020/06/025575,Yes,https://www.dovepress.com/antiviral-combination-clinically-better-than-standard-therapy-in-sever-peer-reviewed-fulltext-article-CPAA; https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Panda PK,Clin Pharmacol,2021,published paper,9/29/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Treatment,LPV/r+RBV,24,22,5,22,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
336_pub,336,3,CTRI/2020/06/025575,Yes,https://www.dovepress.com/antiviral-combination-clinically-better-than-standard-therapy-in-sever-peer-reviewed-fulltext-article-CPAA; https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Panda PK,Clin Pharmacol,2021,published paper,9/29/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Severe/Critical,India,Control,Standard care,24,21,6,21,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,71,LIC_MIC,,N,,,,,,,,,,,consistent
337_preprint,337,2,CTRI/2020/06/025575,Yes,https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Singh B(2),medRxiv,2021,preprint,6/8/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Mild/Moderate,India,Treatment,HCQ+RBV,20,17,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,40,LIC_MIC,,N,,,,,,,,,,,consistent
337_preprint,337,2,CTRI/2020/06/025575,Yes,https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Singh B(2),medRxiv,2021,preprint,6/8/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Mild/Moderate,India,Control,Standard care,20,16,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,40,LIC_MIC,,N,,,,,,,,,,,consistent
337_pub,337,1,CTRI/2020/06/025575,Yes,https://www.dovepress.com/antiviral-combination-clinically-better-than-standard-therapy-in-sever-peer-reviewed-fulltext-article-CPAA; https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Panda PK(2),Clin Pharmacol,2021,published paper,9/29/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Mild/Moderate,India,Treatment,HCQ+RBV,20,17,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,40,LIC_MIC,,N,,,,,,,,,,,consistent
337_pub,337,2,CTRI/2020/06/025575,Yes,https://www.dovepress.com/antiviral-combination-clinically-better-than-standard-therapy-in-sever-peer-reviewed-fulltext-article-CPAA; https://www.medrxiv.org/content/10.1101/2021.06.06.21258091v1,*,Panda PK(2),Clin Pharmacol,2021,published paper,9/29/2021,Unblinded,6/15/2020,Single,No specific funding,Non-funded,Mild/Moderate,India,Control,Standard care,20,16,0,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,40,LIC_MIC,,N,,,,,,,,,,,consistent
342_preprint,342,2,NCT04753619,No,https://www.medrxiv.org/content/10.1101/2021.06.10.21258709v1,*,Abdulamir A,medRxiv,2021,preprint,6/17/2021,Unblinded,1/1/2021,Multicenter,No specific funding,Funding Statement: none,Mild to severe,Iraq,Treatment,Niclosamide,75,75,3,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,150,LIC_MIC,,N,,,,,,,,,,,consistent
342_preprint,342,2,NCT04753619,No,https://www.medrxiv.org/content/10.1101/2021.06.10.21258709v1,*,Abdulamir A,medRxiv,2021,preprint,6/17/2021,Unblinded,1/1/2021,Multicenter,No specific funding,Funding Statement: none,Mild to severe,Iraq,Control,Standard care,75,75,3,*,*,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,150,LIC_MIC,,N,,,,,,,,,,,consistent
342_pub,342,1,NCT04753619,No,https://www.sciencedirect.com/science/article/pii/S2049080121007299?via%3Dihub https://www.medrxiv.org/content/10.1101/2021.06.10.21258709v1,*,Abdulamir A,Ann Med Surg,2021,published paper,9/4/2021,Unblinded,1/1/2021,Multicenter,No specific funding,None,Mild to severe,Iraq,Treatment,Niclosamide,75,75,3,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,150,LIC_MIC,,N,,,,,,,,,,,consistent
342_pub,342,2,NCT04753619,No,https://www.sciencedirect.com/science/article/pii/S2049080121007299?via%3Dihub https://www.medrxiv.org/content/10.1101/2021.06.10.21258709v1,*,Abdulamir A,Ann Med Surg,2021,published paper,9/4/2021,Unblinded,1/1/2021,Multicenter,No specific funding,None,Mild to severe,Iraq,Control,Standard care,75,75,3,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,150,LIC_MIC,,N,,,,,,,,,,,consistent
364_preprint,364,2,RBR-5vpyh4,Yes,https://www.medrxiv.org/content/10.1101/2021.07.21.21260963v1,BISHOP ,Resende GG,medRxiv,2021,preprint,7/23/2021,Unblinded,9/1/2020,Single,Mixed,Novartis Brazil; National Council for Scientific and Technological Development (CNPq),Unclear severity,Brazil,Treatment,Secukinumab,25,25,1,*,28,WHO scale ���������1 (on both the 8- and 10-point scale this indicated asymptomatic. with or without viral RNA dete,*,*,*,*,*,*,*,5,25,28,Some concerns,unblinded,Industry_Mixed,50,LIC_MIC,,,,,,,,,,,,,consistent
364_preprint,364,2,RBR-5vpyh4,Yes,https://www.medrxiv.org/content/10.1101/2021.07.21.21260963v1,BISHOP ,Resende GG,medRxiv,2021,preprint,7/23/2021,Unblinded,9/1/2020,Single,Mixed,Novartis Brazil; National Council for Scientific and Technological Development (CNPq),Unclear severity,Brazil,Control,Standard care,25,23,1,*,28,WHO scale ���������1 (on both the 8- and 10-point scale this indicated asymptomatic. with or without viral RNA dete,*,*,*,*,*,*,*,6,23,28,Some concerns,unblinded,Industry_Mixed,50,LIC_MIC,,,,,,,,,,,,,consistent
364_pub,364,1,RBR-5vpyh4,Yes,https://www.tandfonline.com/doi/full/10.1080/23744235.2022.2066171?scroll=top&needAccess=true https://www.medrxiv.org/content/10.1101/2021.07.21.21260963v1,BISHOP ,Resende GG,Infect Dis,2022,published paper,4/29/2022,Unblinded,9/1/2020,Single,Mixed,Novartis Brazil; National Council for Scientific and Technological Development (CNPq),Unclear severity,Brazil,Treatment,Secukinumab,25,25,1,*,28,WHO scale ���������1 (on both the 8- and 10-point scale this indicated asymptomatic. with or without viral RNA dete,*,*,*,*,*,*,*,5,25,28,Some concerns,unblinded,Industry_Mixed,50,LIC_MIC,,,,,,,,,,,,,consistent
364_pub,364,2,RBR-5vpyh4,Yes,https://www.tandfonline.com/doi/full/10.1080/23744235.2022.2066171?scroll=top&needAccess=true https://www.medrxiv.org/content/10.1101/2021.07.21.21260963v1,BISHOP ,Resende GG,Infect Dis,2022,published paper,4/29/2022,Unblinded,9/1/2020,Single,Mixed,Novartis Brazil; National Council for Scientific and Technological Development (CNPq),Unclear severity,Brazil,Control,Standard care,25,23,1,*,28,WHO scale ���������1 (on both the 8- and 10-point scale this indicated asymptomatic. with or without viral RNA dete,*,*,*,*,*,*,*,6,23,28,Some concerns,unblinded,Industry_Mixed,50,LIC_MIC,,,,,,,,,,,,,consistent
367_preprint,367,4,NCT04359095,Yes,https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,medRxiv,2021,preprint,7/10/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,Tenofovir/Emtricitabine,163,160,22,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_preprint,367,4,NCT04359095,Yes,https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,medRxiv,2021,preprint,7/10/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,CLC+ROSU,161,153,22,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_preprint,367,4,NCT04359095,Yes,https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,medRxiv,2021,preprint,7/10/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,EMT/TNF+CLC+ROSU,163,159,17,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_preprint,367,4,NCT04359095,Yes,https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,medRxiv,2021,preprint,7/10/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Control,Standard care,162,161,28,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_pub,367,4,NCT04359095,Yes,https://bit.ly/3vtVCzK https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,eClinicalMedicine,2021,published paper,12/20/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,Tenofovir/Emtricitabine,163,160,22,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_pub,367,4,NCT04359095,Yes,https://bit.ly/3vtVCzK https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,eClinicalMedicine,2021,published paper,12/20/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,CLC+ROSU,161,153,22,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_pub,367,4,NCT04359095,Yes,https://bit.ly/3vtVCzK https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,eClinicalMedicine,2021,published paper,12/20/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Treatment,EMT/TNF+CLC+ROSU,163,159,17,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
367_pub,367,4,NCT04359095,Yes,https://bit.ly/3vtVCzK https://www.medrxiv.org/content/10.1101/2021.07.06.21260085v1,*,Gaitan-Duarte H,eClinicalMedicine,2021,published paper,12/20/2021,Unblinded,8/24/2020,Multicenter,Public/non profit,"Colombian Ministry of Science and Technology, Universidad Nacional de Colombia, and Pontificia Universidad Javeriana",Mild to critical,Colombia,Control,Standard care,162,161,28,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,649,LIC_MIC,,N,,,,,,,,,,,consistent
369_preprint,369,2,NCT04362085; NCT04444700,Yes,https://www.medrxiv.org/content/10.1101/2021.07.08.21259351v3,RAPID,Sholzberg M,medRxiv,2021,preprint,7/8/2021,Unblinded,5/29/2020,Multicenter,Public/non profit,"Task 54, Department of National Defence; St. Michael���s Hospital Foundation; St. Joseph���s Health Centre Foundation; 2020 TD Community Health Solutions Fund ��� COVID-19 Research Grant; Michael Garron Hospital; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund; INVENT Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding; SEAMO COVID-19 Innovation Fund; National Institute of General Medical Sciences, NIH; University of Vermont Medical Center Fund Grant; King Saud University",Moderate/Severe,"Brazil, Canada, Ireland, Saudi Arabia, UAE, USA",Treatment,Therapeutic heparin,228,228,4,*,28,*,*,*,*,23,*,28,*,*,*,*,Some concerns,unblinded,Other,465,Mixed,,N,,,,,,,,,,,consistent
369_preprint,369,2,NCT04362085; NCT04444700,Yes,https://www.medrxiv.org/content/10.1101/2021.07.08.21259351v3,RAPID,Sholzberg M,medRxiv,2021,preprint,7/8/2021,Unblinded,5/29/2020,Multicenter,Public/non profit,"Task 54, Department of National Defence; St. Michael���s Hospital Foundation; St. Joseph���s Health Centre Foundation; 2020 TD Community Health Solutions Fund ��� COVID-19 Research Grant; Michael Garron Hospital; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund; INVENT Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding; SEAMO COVID-19 Innovation Fund; National Institute of General Medical Sciences, NIH; University of Vermont Medical Center Fund Grant; King Saud University",Moderate/Severe,"Brazil, Canada, Ireland, Saudi Arabia, UAE, USA",Control,Prophylactic Heparin,237,237,18,*,28,*,*,*,*,38,*,28,*,*,*,*,Some concerns,unblinded,Other,465,Mixed,,N,,,,,,,,,,,consistent
369_pub,369,1,NCT04362085; NCT04444700,Yes,https://www.bmj.com/content/375/bmj.n2400 https://www.medrxiv.org/content/10.1101/2021.07.08.21259351v3,RAPID,Sholzberg M,BMJ,2021,published paper,10/14/2021,Unblinded,5/29/2020,Multicenter,Public/non profit,"Task 54, Department of National Defence; St. Michael���s Hospital Foundation; St. Joseph���s Health Centre Foundation; 2020 TD Community Health Solutions Fund ��� COVID-19 Research Grant; Michael Garron Hospital; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund; INVENT Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding; SEAMO COVID-19 Innovation Fund; National Institute of General Medical Sciences, NIH; University of Vermont Medical Center Fund Grant; King Saud University",Moderate/Severe,"Brazil, Canada, Ireland, Saudi Arabia, UAE, USA",Treatment,Therapeutic heparin,228,228,4,*,28,*,*,*,*,23,*,28,*,*,*,*,Some concerns,unblinded,Other,465,Mixed,,N,,,,,,,,,,,consistent
369_pub,369,2,NCT04362085; NCT04444700,Yes,https://www.bmj.com/content/375/bmj.n2400 https://www.medrxiv.org/content/10.1101/2021.07.08.21259351v3,RAPID,Sholzberg M,BMJ,2021,published paper,10/14/2021,Unblinded,5/29/2020,Multicenter,Public/non profit,"Task 54, Department of National Defence; St. Michael���s Hospital Foundation; St. Joseph���s Health Centre Foundation; 2020 TD Community Health Solutions Fund ��� COVID-19 Research Grant; Michael Garron Hospital; The Ottawa Hospital Foundation COVID-19 Emergency Response Fund; INVENT Kickstarter Award; Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding; SEAMO COVID-19 Innovation Fund; National Institute of General Medical Sciences, NIH; University of Vermont Medical Center Fund Grant; King Saud University",Moderate/Severe,"Brazil, Canada, Ireland, Saudi Arabia, UAE, USA",Control,Prophylactic Heparin,237,237,18,*,28,*,*,*,*,38,*,28,*,*,*,*,Some concerns,unblinded,Other,465,Mixed,,N,,,,,,,,,,,consistent
372_preprint,372,2,NCT04509973,Yes,https://www.medrxiv.org/content/10.1101/2021.07.22.21260755v1,COVID STEROID 2,Munch M,medRxiv,2021,preprint,7/24/2021,quadruple blinding,8/27/2020,Multicenter,Mixed,This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet.,Severe/Critical,"Denmark, India, Sweden and Switzerland",Treatment,Dexamethasone 12mg,*,497,133,*,28,*,*,*,*,*,*,*,*,70,497,*,Some concerns,blinded,Industry_Mixed,1000,Mixed,,N,,,,N,N,longer fu,nrando,N,"mort, SAE",N,exclude_diffanalysis
372_preprint,372,2,NCT04509973,Yes,https://www.medrxiv.org/content/10.1101/2021.07.22.21260755v1,COVID STEROID 2,Munch M,medRxiv,2021,preprint,7/24/2021,quadruple blinding,8/27/2020,Multicenter,Mixed,This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet.,Severe/Critical,"Denmark, India, Sweden and Switzerland",Control,Dexamethasone 6mg,*,485,155,*,28,*,*,*,*,*,*,*,*,85,485,*,Some concerns,blinded,Industry_Mixed,1000,Mixed,,N,,,,N,N,longer fu,nrando,N,"mort, SAE",N,exclude_diffanalysis
372_pub,372,1,NCT04509973,Yes,https://pubmed.ncbi.nlm.nih.gov/34673895/ https://www.medrxiv.org/content/10.1101/2021.07.22.21260755v1,COVID STEROID 2,Munch M,JAMA,2021,published paper,10/21/2021,quadruple blinding,8/27/2020,Multicenter,Mixed,This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet.,Severe/Critical,"Denmark, India, Sweden and Switzerland",Treatment,Dexamethasone 12mg,503,491,133,*,28,*,*,*,*,*,*,*,*,70,497,*,Some concerns,blinded,Industry_Mixed,1000,Mixed,,N,,,,N,N,longer fu,nrando,N,"mort, SAE",N,exclude_diffanalysis
372_pub,372,2,NCT04509973,Yes,https://pubmed.ncbi.nlm.nih.gov/34673895/ https://www.medrxiv.org/content/10.1101/2021.07.22.21260755v1,COVID STEROID 2,Munch M,JAMA,2021,published paper,10/21/2021,quadruple blinding,8/27/2020,Multicenter,Mixed,This trial was funded by the Novo Nordisk Foundation and supported by the Research Council at Rigshospitalet.,Severe/Critical,"Denmark, India, Sweden and Switzerland",Control,Dexamethasone 6mg,497,480,155,*,28,*,*,*,*,*,*,*,*,85,485,*,Some concerns,blinded,Industry_Mixed,1000,Mixed,,N,,,,N,N,longer fu,nrando,N,"mort, SAE",N,exclude_diffanalysis
377_preprint,377,2,NCT04476979,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909736,CORIMUNO-TOCIDEX,Hermine O,SSRN,2021,preprint,8/23/2021,Unblinded,7/24/2020,Multicenter,Public/non profit,"Ministry of Health, Programme Hospitalier de Recherche Clinique; Fondation de l���Assistance Publique ��� Ho��pitaux de Paris, Alliance Tous Unis Contre le Virus;  Fe��de��ration pour la Recherche Me��dicale",Moderate,"France, French Guyana",Treatment,TCZ+Dex,226,224,15,*,28,Discharge,186,*,28,27,*,14,147,48,224,28,Some concerns,unblinded,Other,453,HIC,,,,,,,,,,,,,consistent
377_preprint,377,2,NCT04476979,Yes,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909736,CORIMUNO-TOCIDEX,Hermine O,SSRN,2021,preprint,8/23/2021,Unblinded,7/24/2020,Multicenter,Public/non profit,"Ministry of Health, Programme Hospitalier de Recherche Clinique; Fondation de l���Assistance Publique ��� Ho��pitaux de Paris, Alliance Tous Unis Contre le Virus;  Fe��de��ration pour la Recherche Me��dicale",Moderate,"France, French Guyana",Control,Dexamethasone,227,226,19,*,28,Discharge,169,*,28,32,*,14,139,56,226,28,Some concerns,unblinded,Other,453,HIC,,,,,,,,,,,,,consistent
377_pub,377,1,NCT04476979,Yes,https://bit.ly/3JdAXD8  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909736,CORIMUNO-TOCIDEX,Hermine O,EClinicalMedicine,2021,published paper,3/24/2022,Unblinded,7/24/2020,Multicenter,Public/non profit,"Ministry of Health, Programme Hospitalier de Recherche Clinique; Fondation de l���Assistance Publique ��� Ho��pitaux de Paris, Alliance Tous Unis Contre le Virus;  Fe��de��ration pour la Recherche Me��dicale",Moderate,"France, French Guyana",Treatment,TCZ+Dex,226,224,15,*,28,Discharge,186,*,28,27,*,14,147,48,224,28,Some concerns,unblinded,Other,453,HIC,,,,,,,,,,,,,consistent
377_pub,377,2,NCT04476979,Yes,https://bit.ly/3JdAXD8  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3909736,CORIMUNO-TOCIDEX,Hermine O,EClinicalMedicine,2021,published paper,3/24/2022,Unblinded,7/24/2020,Multicenter,Public/non profit,"Ministry of Health, Programme Hospitalier de Recherche Clinique; Fondation de l���Assistance Publique ��� Ho��pitaux de Paris, Alliance Tous Unis Contre le Virus;  Fe��de��ration pour la Recherche Me��dicale",Moderate,"France, French Guyana",Control,Dexamethasone,227,226,19,*,28,Discharge,169,*,28,32,*,14,139,56,226,28,Some concerns,unblinded,Other,453,HIC,,,,,,,,,,,,,consistent
388_preprint,388,2,NCT04727424,No,https://www.medrxiv.org/content/10.1101/2021.08.19.21262323v2,TOGETHER (fluv),Reis G,medRxiv,2021,preprint,8/23/2021,quadruple blinding,1/15/2021,Multicenter,Public/non profit,The trial was supported by FastGrants and The Rainwater Foundation.,Outpatients,Brazil,Treatment,Fluvoxamine,739,739,17,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,1472,LIC_MIC,,,,,,,N,sample size,N,N,N,mort,exclude_diffanalysis
388_preprint,388,2,NCT04727424,No, https://www.medrxiv.org/content/10.1101/2021.08.19.21262323v2,TOGETHER (fluv),Reis G,medRxiv,2021,preprint,8/23/2021,quadruple blinding,1/15/2021,Multicenter,Public/non profit,The trial was supported by FastGrants and The Rainwater Foundation.,Outpatients,Brazil,Control,Placebo,733,733,24,*,28,*,*,*,*,*,*,*,*,*,*,*,Low,blinded,Other,1472,LIC_MIC,,,,,,,N,sample size,N,N,N,mort,exclude_diffanalysis
388_pub,388,1,NCT04727424,No,https://www.sciencedirect.com/science/article/pii/S2214109X21004484?via%3Dihub#cesec120 https://www.medrxiv.org/content/10.1101/2021.08.19.21262323v2,TOGETHER (fluv),Reis G,Lancet Glob,2021,published paper,10/27/2021,quadruple blinding,1/20/2021,Multicenter,Public/non profit,FastGrants; The Rainwater Foundation.,Outpatients,Brazil,Treatment,Fluvoxamine,741,741,17,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,1497,LIC_MIC,,,,,,,N,sample size,N,N,N,mort,exclude_diffanalysis
388_pub,388,2,NCT04727424,No,https://www.sciencedirect.com/science/article/pii/S2214109X21004484?via%3Dihub#cesec120 https://www.medrxiv.org/content/10.1101/2021.08.19.21262323v2,TOGETHER (fluv),Reis G,Lancet Glob,2021,published paper,10/27/2021,quadruple blinding,1/20/2021,Multicenter,Public/non profit,FastGrants; The Rainwater Foundation.,Outpatients,Brazil,Control,Placebo,756,756,25,*,28,*,*,*,*,*,*,*,*,*,*,*,Some concerns,blinded,Other,1497,LIC_MIC,,,,,,,N,sample size,N,N,N,mort,exclude_diffanalysis
418_preprint,418,2,NCT04377711,Yes,https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1,*,Clemency B,medRxiv,2021,preprint,9/12/2021, double blinding,6/11/2020,Multicenter,Private,"Covis Pharma GmbH; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); National Heart, Lung, and Blood Institute of the NIH",Outpatients,USA,Treatment,Ciclesonide,197,197,0,*,30,Complete alleviation of symptoms,*,*,*,*,*,*,22,*,*,60,Some concerns,blinded,Industry_Mixed,400,HIC,,,,,,,,,,,,,consistent
418_preprint,418,2,NCT04377711,Yes,https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1,*,Clemency B,medRxiv,2021,preprint,9/12/2021, double blinding,6/11/2020,Multicenter,Private,"Covis Pharma GmbH; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); National Heart, Lung, and Blood Institute of the NIH",Outpatients,USA,Control,Standard care,203,203,0,*,30,Complete alleviation of symptoms,*,*,*,*,*,*,29,*,*,60,Some concerns,blinded,Industry_Mixed,400,HIC,,,,,,,,,,,,,consistent
418_pub,418,1,NCT04377711,Yes,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786012 https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1,*,Clemency B,JAMA Intern Med,2021,published paper,11/22/2021, double blinding,6/11/2020,Multicenter,Private,"Covis Pharma GmbH; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); National Heart, Lung, and Blood Institute of the NIH",Outpatients,USA,Treatment,Ciclesonide,197,197,0,*,30,Complete alleviation of symptoms,*,*,*,*,*,*,22,*,*,60,Some concerns,blinded,Industry_Mixed,400,HIC,,,,,,,,,,,,,consistent
418_pub,418,2,NCT04377711,Yes,https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2786012 https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1,*,Clemency B,JAMA Intern Med,2021,published paper,11/22/2021, double blinding,6/11/2020,Multicenter,Private,"Covis Pharma GmbH; National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); National Heart, Lung, and Blood Institute of the NIH",Outpatients,USA,Control,Standard care,203,203,0,*,30,Complete alleviation of symptoms,*,*,*,*,*,*,29,*,*,60,Some concerns,blinded,Industry_Mixed,400,HIC,,,,,,,,,,,,,consistent
430_preprint,430,2,NCT04395105,Yes,https://www.medrxiv.org/content/10.1101/2021.09.15.21263597v1.full-text,*,Maskin LP,medrxiv,2021,preprint,9/21/2021,Unblinded,6/17/2020,Multicenter,No specific funding,"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors",Critical,Argentina,Treatment,Dexamethasone High Dose,49,49,20,*,28,hospital discharge,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,,,,,,,,,,,,consistent
430_preprint,430,2,NCT04395105,Yes,https://www.medrxiv.org/content/10.1101/2021.09.15.21263597v1.full-text,*,Maskin LP,medrxiv,2021,preprint,9/21/2021,Unblinded,6/17/2020,Multicenter,No specific funding,"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors",Critical,Argentina,Control,Dexamethasone Low Dose,51,49,19,*,28,hospital discharge,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,,,,,,,,,,,,consistent
430_pub,430,1,NCT04395105,Yes,https://journals.sagepub.com/doi/10.1177/08850666211066799 https://www.medrxiv.org/content/10.1101/2021.09.15.21263597v1.full-text,*,Maskin LP,Intensive Care Med,2021,published paper,12/13/2021,Unblinded,6/17/2020,Multicenter,No specific funding,"The author(s) received no financial support for the research, authorship
and/or publication of this article.",Critical,Argentina,Treatment,Dexamethasone High Dose,49,49,20,*,28,hospital discharge,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,,,,,,,,,,,,consistent
430_pub,430,2,NCT04395105,Yes,https://journals.sagepub.com/doi/10.1177/08850666211066799 https://www.medrxiv.org/content/10.1101/2021.09.15.21263597v1.full-text,*,Maskin LP,Intensive Care Med,2021,published paper,12/13/2021,Unblinded,6/17/2020,Multicenter,No specific funding,"The author(s) received no financial support for the research, authorship
and/or publication of this article.",Critical,Argentina,Control,Dexamethasone Low Dose,51,49,19,*,28,hospital discharge,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Other,100,LIC_MIC,,,,,,,,,,,,,consistent
427_preprint,427,3,NCT04405570,Yes,https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1,*,Fischer W,medRxiv,2021,preprint,6/17/2021, double blinding,6/19/2020,Multicenter,Mixed,"Ridgeback Biotherapeutics, Wayne and Wendy Holman, Merck, Drug Innovations at Emory (DRIVE) LLC, US government",Outpatients,USA,Treatment,Molnupiravir,*,55,0,*,31,*,*,*,*,*,*,*,11,1,*,28,High,blinded,Industry_Mixed,204,HIC,,,,,,,,,,,,,consistent
427_preprint,427,4,NCT04405570,Yes,https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1,*,Fischer W,medRxiv,2021,preprint,6/17/2021, double blinding,6/19/2020,Multicenter,Mixed,"Ridgeback Biotherapeutics, Wayne and Wendy Holman, Merck, Drug Innovations at Emory (DRIVE) LLC, US government",Outpatients,USA,Control,Placebo,*,62,1,*,31,*,*,*,*,*,*,*,18,1,*,28,High,blinded,Industry_Mixed,204,HIC,,,,,,,,,,,,,consistent
427_pub,427,3,NCT04405570,Yes,https://www.science.org/doi/10.1126/scitranslmed.abl7430 https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1,*,Fischer W,Sci Transl Med,2021,published paper,12/23/2021, double blinding,6/19/2020,Multicenter,Mixed,"Ridgeback Biotherapeutics, Wayne and Wendy Holman, Merck, Drug Innovations at Emory (DRIVE) LLC, US government",Outpatients,USA,Treatment,Molnupiravir,*,55,0,*,31,*,*,*,*,*,*,*,11,1,*,28,High,blinded,Industry_Mixed,204,HIC,,,,,,,,,,,,,consistent
427_pub,427,4,NCT04405570,Yes,https://www.science.org/doi/10.1126/scitranslmed.abl7430 https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1,*,Fischer W,Sci Transl Med,2021,published paper,12/23/2021, double blinding,6/19/2020,Multicenter,Mixed,"Ridgeback Biotherapeutics, Wayne and Wendy Holman, Merck, Drug Innovations at Emory (DRIVE) LLC, US government",Outpatients,USA,Control,Placebo,*,62,1,*,31,*,*,*,*,*,*,*,18,1,*,28,High,blinded,Industry_Mixed,204,HIC,,,,,,,,,,,,,consistent
432_preprint,432,1,NCT04421027,Yes,https://www.medrxiv.org/content/10.1101/2021.10.11.21263897v1.full-text,*,Ely EW,medRxiv,2021,preprint,10/12/2021, double blinding,12/23/2020,Multicenter,Private,Eli Lilly and Company,Critical,"Argentina, Brazil, Mexico, USA",Treatment,Baricitinib,51,51,20,*,28,"Improvement of 1 point on the ordinal scale or discharge.
1. Not hospitalized. no limitations on activities; 2. Not hospitalized. limitation on activities and/or requiring home oxygen; 3. Hospitalized. not requiring supplemental oxygen â€“ no longer requires ongoing medical care (This would include those kept in hospital for quarantine/infection control. awaiting bed in rehabilitation facility or homecare. etc); 4. Hospitalized. not requiring supplemental oxygen â€“ requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized. requiring supplemental oxygen; 6. Hospitalized. on non-invasive ventilation or high-flow oxygen devices; 7. Hospitalized. on invasive mechanical ventilation or ECMO; 8. Death.",23,28,*,26,49,28,44,25,50,28,Some concerns,blinded,Industry_Mixed,101,Mixed,,,,,,,,,,,,,consistent
432_preprint,432,2,NCT04421027,Yes,https://www.medrxiv.org/content/10.1101/2021.10.11.21263897v1.full-text,*,Ely EW,medRxiv,2021,preprint,10/12/2021, double blinding,12/23/2020,Multicenter,Private,Eli Lilly and Company,Critical,"Argentina, Brazil, Mexico, USA",Control,Placebo,50,50,29,*,28,"Improvement of 1 point on the ordinal scale or discharge.
1. Not hospitalized. no limitations on activities; 2. Not hospitalized. limitation on activities and/or requiring home oxygen; 3. Hospitalized. not requiring supplemental oxygen â€“ no longer requires ongoing medical care (This would include those kept in hospital for quarantine/infection control. awaiting bed in rehabilitation facility or homecare. etc); 4. Hospitalized. not requiring supplemental oxygen â€“ requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized. requiring supplemental oxygen; 6. Hospitalized. on non-invasive ventilation or high-flow oxygen devices; 7. Hospitalized. on invasive mechanical ventilation or ECMO; 8. Death.",15,28,*,35,48,28,47,35,49,28,Some concerns,blinded,Industry_Mixed,101,Mixed,,,,,,,,,,,,,consistent
432_pub,432,1,NCT04421027,Yes,https://bit.ly/3pPr2gh https://www.medrxiv.org/content/10.1101/2021.10.11.21263897v1.full-text,COV-BARRIER,Ely EW,Lancet Respir Med,2022,published paper,2/3/2022, double blinding,12/23/2020,Multicenter,Private,Eli Lilly and Company,Critical,"Argentina, Brazil, Mexico, USA",Treatment,Baricitinib,51,51,20,*,28,"Improvement of 1 point on the ordinal scale or discharge.
1. Not hospitalized. no limitations on activities; 2. Not hospitalized. limitation on activities and/or requiring home oxygen; 3. Hospitalized. not requiring supplemental oxygen ��� no longer requires ongoing medical care (This would include those kept in hospital for quarantine/infection control. awaiting bed in rehabilitation facility or homecare. etc); 4. Hospitalized. not requiring supplemental oxygen ��� requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized. requiring supplemental oxygen; 6. Hospitalized. on non-invasive ventilation or high-flow oxygen devices; 7. Hospitalized. on invasive mechanical ventilation or ECMO; 8. Death.",23,28,*,26,49,28,44,25,50,28,Low,blinded,Industry_Mixed,101,Mixed,,,,,,,,,,,,,consistent
432_pub,432,2,NCT04421027,Yes,https://bit.ly/3pPr2gh https://www.medrxiv.org/content/10.1101/2021.10.11.21263897v1.full-text,COV-BARRIER,Ely EW,Lancet Respir Med,2022,published paper,2/3/2022, double blinding,12/23/2020,Multicenter,Private,Eli Lilly and Company,Critical,"Argentina, Brazil, Mexico, USA",Control,Placebo,50,50,29,*,28,"Improvement of 1 point on the ordinal scale or discharge.
1. Not hospitalized. no limitations on activities; 2. Not hospitalized. limitation on activities and/or requiring home oxygen; 3. Hospitalized. not requiring supplemental oxygen ��� no longer requires ongoing medical care (This would include those kept in hospital for quarantine/infection control. awaiting bed in rehabilitation facility or homecare. etc); 4. Hospitalized. not requiring supplemental oxygen ��� requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized. requiring supplemental oxygen; 6. Hospitalized. on non-invasive ventilation or high-flow oxygen devices; 7. Hospitalized. on invasive mechanical ventilation or ECMO; 8. Death.",15,28,*,35,48,28,47,35,49,28,Low,blinded,Industry_Mixed,101,Mixed,,,,,,,,,,,,,consistent
438_preprint,438,1,NCT04473053; ISRCTN14212905; EudraCT 2020-002230-3,Yes,https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1,*,Quinn TM,medRxiv,2021,preprint,10/7/2021,Unblinded,9/1/2020,Multicenter,Mixed,"LifeArc and Oxford
University COVID-19 Research Response Fund. Nichi-Iko (Japan) supplied Futhan (intravenous Nafamostat) for the trial.",Moderate/Severe,UK,Treatment,Nafamostat,23,21,3,*,25,Discharge,18,*,33,*,*,*,16,0,*,25,Some concerns,unblinded,Industry_Mixed,44,HIC,,,,,,,,,,,,,discrepTE
438_preprint,438,2,NCT04473053; ISRCTN14212905; EudraCT 2020-002230-3,Yes,https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1,*,Quinn TM,medRxiv,2021,preprint,10/7/2021,Unblinded,9/1/2020,Multicenter,Mixed,"LifeArc and Oxford
University COVID-19 Research Response Fund. Nichi-Iko (Japan) supplied Futhan (intravenous Nafamostat) for the trial.",Moderate/Severe,UK,Control,Standard care,21,21,3,*,25,Discharge,17,*,33,*,*,*,12,0,*,25,Some concerns,unblinded,Industry_Mixed,44,HIC,,,,,,,,,,,,,discrepTE
438_pub,438,1,NCT04473053; ISRCTN14212905; EudraCT 2020-002230-3,Yes,https://bit.ly/3vKJ86w https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1,DEFINE,Quinn TM,EBioMedicine,2022,published paper,2/11/2022,Unblinded,9/1/2020,Multicenter,Mixed,"LifeArc and Oxford
University COVID-19 Research Response Fund. Nichi-Iko (Japan) supplied Futhan (intravenous Nafamostat) for the trial.",Moderate/Severe,UK,Treatment,Nafamostat,23,21,3,*,25,Discharge,18,*,33,*,*,*,18,0,*,25,Some concerns,unblinded,Industry_Mixed,44,HIC,,,,,,,,,,,,,discrepTE
438_pub,438,2,NCT04473053; ISRCTN14212905; EudraCT 2020-002230-3,Yes,https://bit.ly/3vKJ86w https://www.medrxiv.org/content/10.1101/2021.10.06.21264648v1,DEFINE,Quinn TM,EBioMedicine,2022,published paper,2/11/2022,Unblinded,9/1/2020,Multicenter,Mixed,"LifeArc and Oxford
University COVID-19 Research Response Fund. Nichi-Iko (Japan) supplied Futhan (intravenous Nafamostat) for the trial.",Moderate/Severe,UK,Control,Standard care,21,21,3,*,25,Discharge,17,*,33,*,*,*,12,0,*,25,Some concerns,unblinded,Industry_Mixed,44,HIC,,,,,,,,,,,,,discrepTE
448_preprint,448,1,CTRI/2020/09/027903,*,https://www.medrxiv.org/content/10.1101/2021.07.26.21261119v1,*,Parikh D,medRxiv,2021,preprint,7/27/2021,Unblinded,*,Multicenter,Private,"Intas Pharmaceuticals Ltd., India",Moderate/Severe,India,Treatment,C-IVIG,30,30,1,*,28,improvement of two categories from enrolment status by day 14 on an 8-point ordinal scale of clinical status,*,*,*,*,*,*,3,1,30,28,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,,,,,,,,,,,consistent
448_preprint,448,2,CTRI/2020/09/027903,*,https://www.medrxiv.org/content/10.1101/2021.07.26.21261119v1,*,Parikh D,medRxiv,2021,preprint,7/27/2021,Unblinded,*,Multicenter,Private,"Intas Pharmaceuticals Ltd., India",Moderate/Severe,India,Control,Standard care,30,29,1,*,28,improvement of two categories from enrolment status by day 14 on an 8-point ordinal scale of clinical status,*,*,*,*,*,*,2,1,30,28,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,,,,,,,,,,,consistent
448_pub,448,1,CTRI/2020/09/027903,*,https://articles.theindianpractitioner.com/index.php/tip/article/view/1272 https://www.medrxiv.org/content/10.1101/2021.07.26.21261119v1,*,Parikh D,Indian Pract,2021,published paper,12/2/2021,Unblinded,*,Multicenter,Private,"Intas Pharmaceuticals Ltd., India",Moderate/Severe,India,Treatment,C-IVIG,30,30,1,*,28,improvement of two categories from enrolment status by day 14 on an 8-point ordinal scale of clinical status,*,*,*,*,*,*,3,1,30,28,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,,,,,,,,,,,consistent
448_pub,448,2,CTRI/2020/09/027903,*,https://articles.theindianpractitioner.com/index.php/tip/article/view/1272 https://www.medrxiv.org/content/10.1101/2021.07.26.21261119v1,*,Parikh D,Indian Pract,2021,published paper,12/2/2021,Unblinded,*,Multicenter,Private,"Intas Pharmaceuticals Ltd., India",Moderate/Severe,India,Control,Standard care,30,29,1,*,28,improvement of two categories from enrolment status by day 14 on an 8-point ordinal scale of clinical status,*,*,*,*,*,*,2,1,30,28,Some concerns,unblinded,Industry_Mixed,60,LIC_MIC,,,,,,,,,,,,,consistent
464_preprint,464,2,NCT04345614,Yes,https://www.researchsquare.com/article/rs-1239555/v1  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3976177,CARDEA,Bruen C,Research Square,2022,preprint,1/11/2022,double blinding,9/8/2020,Multicenter,Private,"CalciMedica, Inc. (La Jolla, CA, USA)",Moderate/Severe,USA,Treatment,Auxora,143,143,10,130,30,???category 6 (Hospitalized. not requiring supplemental oxygen or ongoing medical care). category 7 (Discharged. requiring supplemental oxygen). or category 8 (Discharged. not requiring supplemental oxygen) using an 8-point ordinal scale???.,*,*,*,*,*,*,*,34,141,60,Some concerns,blinded,Industry_Mixed,284,HIC,,,,,,,,,,,,,add_delete
464_preprint,464,2,NCT04345614,Yes,https://www.researchsquare.com/article/rs-1239555/v1  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3976177,CARDEA,Bruen C,Research Square,2022,preprint,1/11/2022,double blinding,9/8/2020,Multicenter,Private,"CalciMedica, Inc. (La Jolla, CA, USA)",Moderate/Severe,USA,Control,Placebo,141,141,23,131,30,???category 6 (Hospitalized. not requiring supplemental oxygen or ongoing medical care). category 7 (Discharged. requiring supplemental oxygen). or category 8 (Discharged. not requiring supplemental oxygen) using an 8-point ordinal scale???.,*,*,*,*,*,*,*,49,140,60,Some concerns,blinded,Industry_Mixed,284,HIC,,,,,,,,,,,,,add_delete
464_pub,464,1,NCT04345614,Yes,https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-03964-8#Abs1 https://www.researchsquare.com/article/rs-1239555/v1  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3976177,CARDEA,Bruen C,Crit Care,2022,published paper,4/8/2022, double blinding,9/8/2020,Multicenter,Private,"CalciMedica, Inc. (La Jolla, CA, USA)",Moderate/Severe,USA,Treatment,Auxora,143,130,10,*,30,discharged from the hospital,*,*,*,21,124,30,91,34,141,60,Some concerns,blinded,Industry_Mixed,284,HIC,,,,,,,,,,,,,add_delete
464_pub,464,2,NCT04345614,Yes,https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-03964-8#Abs1 https://www.researchsquare.com/article/rs-1239555/v1  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3976177,CARDEA,Bruen C,Crit Care,2022,published paper,4/8/2022, double blinding,9/8/2020,Multicenter,Private,"CalciMedica, Inc. (La Jolla, CA, USA)",Moderate/Severe,USA,Control,Placebo,141,131,23,*,30,discharged from the hospital,*,*,*,31,129,30,86,49,140,60,Some concerns,blinded,Industry_Mixed,284,HIC,,,,,,,,,,,,,add_delete
480_preprint,480,2,NCT04373460,Yes,https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1,*,Sullivan D,medRxiv,2021,preprint,12/21/2021,double blinding,6/3/2020,Multicenter,Mixed,"U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA); Bloomberg Philanthropies; State of Maryland; the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases; NIH National Center for Advancing Translational Sciences; Division of Intramural Research NIAID NIH; Mental Wellness Foundation; Moriah Fund; Octapharma; HealthNetwork Foundation; the Shear Family Foundation.",Outpatients,USA,Treatment,Convalescent plasma,610,592,0,*,28,*,*,*,*,0,*,28,34,*,*,28,Low,blinded,Industry_Mixed,1225,HIC,,,,,,,,,,,,,add_delete_discrepTE
480_preprint,480,2,NCT04373460,Yes,https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1,*,Sullivan D,medRxiv,2021,preprint,12/21/2021,double blinding,6/3/2020,Multicenter,Mixed,"U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA); Bloomberg Philanthropies; State of Maryland; the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases; NIH National Center for Advancing Translational Sciences; Division of Intramural Research NIAID NIH; Mental Wellness Foundation; Moriah Fund; Octapharma; HealthNetwork Foundation; the Shear Family Foundation.",Outpatients,USA,Control,Placebo,615,589,3,*,28,*,*,*,*,3,*,28,53,*,*,28,Low,blinded,Industry_Mixed,1225,HIC,,,,,,,,,,,,,add_delete_discrepTE
480_pub,480,1,NCT04373460,Yes,https://www.nejm.org/doi/full/10.1056/NEJMoa2119657?s=09#.YkaZJpwqxNE.twitter https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1,*,Sullivan D,N Engl J Med,2022,published paper,3/30/2022, double blinding,6/3/2020,Multicenter,Mixed,"U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA); Bloomberg Philanthropies; State of Maryland; the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases; NIH National Center for Advancing Translational Sciences; Division of Intramural Research NIAID NIH; Mental Wellness Foundation; Moriah Fund; Octapharma; HealthNetwork Foundation; the Shear Family Foundation.",Outpatients,USA,Treatment,Convalescent plasma,610,592,0,*,28,*,*,*,*,0,*,28,34,7,*,28,Low,blinded,Industry_Mixed,1225,HIC,,,,,,,,,,,,,add_delete_discrepTE
480_pub,480,2,NCT04373460,Yes,https://www.nejm.org/doi/full/10.1056/NEJMoa2119657?s=09#.YkaZJpwqxNE.twitter https://www.medrxiv.org/content/10.1101/2021.12.10.21267485v1,*,Sullivan D,N Engl J Med,2022,published paper,3/30/2022, double blinding,6/3/2020,Multicenter,Mixed,"U.S. Department of Defenses (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA); Bloomberg Philanthropies; State of Maryland; the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases; NIH National Center for Advancing Translational Sciences; Division of Intramural Research NIAID NIH; Mental Wellness Foundation; Moriah Fund; Octapharma; HealthNetwork Foundation; the Shear Family Foundation.",Outpatients,USA,Control,Placebo,615,589,3,*,28,*,*,*,*,3,*,28,55,9,*,28,Low,blinded,Industry_Mixed,1225,HIC,,,,,,,,,,,,,add_delete_discrepTE
497_preprint,497,2,NCT04366960,Yes,https://www.medrxiv.org/content/10.1101/2021.11.17.21266488v1,,Morici N,medRxiv,2021,preprint,11/21/2021,Unblinded,4/30/2020,Multicenter,Private,Italfarmaco,Mild to severe,Italy,Treatment,ENX 40 mg b.i.d.,93,91,5,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,186,HIC,,,,,,,,,,,,,consistent
497_preprint,497,2,NCT04366960,Yes,https://www.medrxiv.org/content/10.1101/2021.11.17.21266488v1,,Morici N,medRxiv,2021,preprint,11/21/2021,Unblinded,4/30/2020,Multicenter,Private,Italfarmaco,Mild to severe,Italy,Control,ENX 40 mg o.d,93,92,1,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,186,HIC,,,,,,,,,,,,,consistent
497_pub,497,1,NCT04366960,Yes,https://onlinelibrary.wiley.com/doi/10.1111/eci.13735 https://www.medrxiv.org/content/10.1101/2021.11.17.21266488v1,X-COVID 19,Morici N,Eur J Clin Invest,2021,published paper,12/26/2021,Unblinded,4/30/2020,Multicenter,Private,Italfarmaco,Mild to severe,Italy,Treatment,ENX 40 mg b.i.d.,93,91,5,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,186,HIC,,,,,,,,,,,,,consistent
497_pub,497,2,NCT04366960,Yes,https://onlinelibrary.wiley.com/doi/10.1111/eci.13735 https://www.medrxiv.org/content/10.1101/2021.11.17.21266488v1,X-COVID 19,Morici N,Eur J Clin Invest,2021,published paper,12/26/2021,Unblinded,4/30/2020,Multicenter,Private,Italfarmaco,Mild to severe,Italy,Control,ENX 40 mg o.d,93,92,1,*,30,*,*,*,*,*,*,*,*,*,*,*,Some concerns,unblinded,Industry_Mixed,186,HIC,,,,,,,,,,,,,consistent
498_preprint,498,2,NCT04346628,Yes,https://www.medrxiv.org/content/10.1101/2021.11.22.21266690v1.full-text,,Holubar M,medRxiv,2021,preprint,11/24/2021, double blinding,7/8/2020,Single,Public/non profit,Anonymous donors to Stanford University,Outpatients,USA,Treatment,Favipiravir,75,75,*,*,*,*,*,*,*,*,*,*,19,0,75,28,Some concerns,blinded,Other,149,HIC,,,,,,,,,,,,,consistent
498_preprint,498,2,NCT04346628,Yes,https://www.medrxiv.org/content/10.1101/2021.11.22.21266690v1.full-text,,Holubar M,medRxiv,2021,preprint,11/24/2021, double blinding,7/8/2020,Single,Public/non profit,Anonymous donors to Stanford University,Outpatients,USA,Control,Placebo,74,74,*,*,*,*,*,*,*,*,*,*,10,1,74,28,Some concerns,blinded,Other,149,HIC,,,,,,,,,,,,,consistent
498_pub,498,1,NCT04346628,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac312/6572081 https://www.medrxiv.org/content/10.1101/2021.11.22.21266690v1.full-text,*,Holubar M,Clin Infect Dis,2022,published paper,4/21/2022, double blinding,7/8/2020,Single,Public/non profit,Anonymous donors to Stanford University,Outpatients,USA,Treatment,Favipiravir,75,75,*,*,*,Cessation of symptoms,*,*,*,*,*,*,19,0,75,28,Some concerns,blinded,Other,149,HIC,,,,,,,,,,,,,consistent
498_pub,498,2,NCT04346628,Yes,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac312/6572081 https://www.medrxiv.org/content/10.1101/2021.11.22.21266690v1.full-text,*,Holubar M,Clin Infect Dis,2022,published paper,4/21/2022, double blinding,7/8/2020,Single,Public/non profit,Anonymous donors to Stanford University,Outpatients,USA,Control,Placebo,74,74,*,*,*,Cessation of symptoms,*,*,*,*,*,*,10,1,74,28,Some concerns,blinded,Other,149,HIC,,,,,,,,,,,,,consistent
